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SUMMARY 
 
Acne is a common, chronic disorder that affects many adolescents.  The most 
effective acne medication is systemic isotretinoin.  It provides a permanent cure for 
many patients, but has various side effects.  A South African Acne Treatment 
Guideline was introduced in 2005.  Adherence to this guideline could lead to safer, 
more effective acne management.   
 
The primary aim of this study was to investigate the appropriateness of medications 
prescribed in the treatment of acne in South Africa, and to evaluate the safety and 
efficacy of systemic isotretinoin utilised by patients in the Nelson Mandela Metropole 
(NMM).   
 
A drug utilisation study (including 18 803 South African acne patients’ chronic 
prescription data between 2000 and 2005) and a patient questionnaire survey 
(including information from 57 patients in the NMM who used systemic isotretinoin) 
were conducted.  Basic descriptive and interferential statistics were calculated.   
 
The drug utilisation study revealed that systemic antibiotics were the acne treatment 
prescribed to most (43.3%) patients, followed by 42.1% of patients on systemic 
isotretinoin, 33.2% on hormonal therapy and 18.9% on topical therapy.  Topical 
retinoids were underused.   
 
The questionnaire survey indicated a lack of compliance by prescribers with guideline 
recommendations regarding the prescription (and accompanying counselling and 
monitoring) of isotretinoin.  Incorrect cumulative doses were frequently prescribed, and 
a lack of proper implementation of pregnancy prevention measures was evident.  The 
majority of isotretinoin patients reported a high efficacy of isotretinoin in clearing their 
acne.   
 
 xiii
In conclusion, there was a lack of compliance with acne treatment guidelines and the 
implementation of pregnancy prevention measures for females on isotretinoin.  
Important recommendations from the study included implementing a national 
compulsory South African Pregnancy Prevention Program for females on isotretinoin, 
the use of clinic monitoring cards for isotretinoin patients, and that only dermatologists 
should prescribe isotretinoin.  An example of a flowchart, that could aid prescribers in 
determining the need of isotretinoin therapy, was developed.   
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INTRODUCTION 
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1.1 BACKGROUND TO THE STUDY 
 
Acne vulgaris (also known as common acne) is a multifactorial disease that has an 
abnormal pilosebaceous unit as the final common end point (Puissegur-Lupo, 1985: 
76).  This chronic disorder (Fulton, 2002: 95) is common and affects almost every 
adolescent at some point in time (Tan, 2003: 307).  Acne has shown to have negative 
effects on the social functioning and emotions of patients, and can be associated with 
anxiety, depression and even unemployment (Acne Guideline 2005 update, 2005: 
884; Ng, Tam, Celi, Tate & Schweitzer, 2002: 262).   
 
Acne vulgaris is responsible for more appointments with dermatologists than any other 
skin condition (Pray & Pray, 2003: 17).  The time period in which acne occurs most 
frequently is adolescent years.  The reported incidence of acne amongst adolescents 
in Western societies is 79% to 95% (Pray & Pray, 2003: 17).  The word “acne” is 
derived from the Greek word “acme”, which means “prime of life” (Buxton, 1991: 38), 
thereby indicating that acne is known to be most commonly found in adolescents.  
Most acne cases tend to resolve with the passing of time (Acne Management 
Guideline, 1999: 1024), but facial acne may prevail in up to 54% of people older than 
25 years of age (Pray & Pray, 2003: 17).  In the middle age years, acne prevails in 
three percent of males and in 12% of females (Pray & Pray, 2003: 17).  Even though 
acne occurs most frequently during adolescence, various forms of this disease can 
affect people of all ages (Pal, 1997: 15).  Acne can occur in females over the age of 
30 years (Acne Management Guideline, 1999: 1024), usually due to hormonal causes.  
Infantile acne can occur in infants at the age of approximately three months.   It may 
last up to the age of five years (Acne Management Guideline, 1999: 1024), although it 
usually resolves spontaneously within a few months (Buxton, 1991: 39).   
  
Females usually experience acne eruptions from a slightly earlier age than males.  
Pray and Pray (2003: 17) stated that the average starting age of acne in females is 
12.1 years, while the average starting age of acne in males is 12.8 years.  The age 
range in which the incidence and severity of acne peaks is between 14 to 17 years for 
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females and between 16 to 19 years for males (Acne Management Guideline, 1999: 
1024).   
 
The scientific understanding of the pathogenesis of acne has increased considerably 
over the past three decades (Shalita, 2001: 43).  Therefore, there has been a shift in 
the clinical focus of acne treatment; away from the resolution of advanced lesions (the 
previous primary focus), towards the inhibition of the multiple pathogenic processes 
underlying the earliest acne stages (the new primary focus).  (Shalita, 2001: 43.) 
 
Treatment agents currently available for acne include topical agents (for example 
azelaic acid, benzoyl peroxide, topical retinoids, and topical antibiotics) and systemic 
agents (for example systemic antibiotics, hormonal therapy and systemic isotretinoin).  
Other available treatments include, for example, topical salicylic acid, topical sulfur, 
topical sodium salicylate, corticosteroids, zinc, gluconate and vitamin A (Oprica, 
Emtestam & Nord, 2002: 244).   
 
During acne management, the treatment goals should be healing the existing acne 
lesions, preventing scarring and formation of new lesions and minimising 
psychological distress that may accompany acne (Mossman, 2006).  The Essential 
Drugs Programme of South Africa (1998: 150) states that the management objectives 
for acne vulgaris are the elimination of pathogens and the improvement of the skin 
condition, while Goodman (2006: 613) reported that educating patients and dispelling 
existing myths regarding acne are also important factors in effective acne 
management.   
 
Systemic isotretinoin seldom fails to clear acne completely and it presents a 
permanent cure for a high percentage of patients.  The cure rates for patients treated 
with systemic isotretinoin vary from 38% to 66%, depending on the definition of a cure 
(which may be diverse for different patients and health care providers).  Overall, 
systemic isotretinoin is known to be the most effective agent in the treatment of acne.  
(Acne Guideline 2005 update, 2005: 889.)   
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Even though it is so effective, systemic isotretinoin can cause a wide range of side 
effects.  Some of these side effects are serious, but most of them are more 
unpleasant than it is serious.  Therefore, many patients experience the time on 
isotretinoin therapy as unpleasant, although they endure the side effects because of 
the benefits that becomes evident rapidly after therapy initiation.  (Acne Guideline 
2005 update, 2005: 889.)  Side effects of isotretinoin include teratogenicity, increased 
triglycerides and cholesterol levels, increased liver enzyme levels, mucocutaneous 
side effects (including dryness of lips, skin and eyes and vaginitis) and nose or rectal 
bleeding. Photosensitivity, decreased night vision, blurred vision, benign intracranial 
hypertension (that can present initially as headaches), myalgia, arthralgia, backache, 
depression, suicidal thoughts, an increase or a decrease in appetite, weight gain or 
weight loss, gastrointestinal side effects (including diarrhoea, constipation, irritable 
bowel syndrome, nausea and vomiting), skeletal abnormalities, fragility of nails and 
thinning or loss of hair are other side effects that may also occur.  (Acnetane® 
Package Insert, 2004; Daily Drug Use, 2001: 231; Oratane® Package Insert, 2003; 
Roaccutane® Package Insert, 2003; South African Medicines Formulary, 2003: 199 – 
200.)   
 
Although no one can argue the effectiveness of isotretinoin in acne treatment, the side 
effects (especially the more dangerous side effects like the teratogenicity and the 
possible negative psychological impact) have triggered a continual debate amongst 
the medical society and general public worldwide regarding the use of isotretinoin.  
There are some internet sites for people who strongly disagree with the use of 
isotretinoin, while there are other people and dermatologists who promote the use of 
isotretinoin.  Some dermatologists even avoid prescribing isotretinoin to any woman of 
childbearing age completely.  (Roehr, 2004: 1, 19.)   
 
The existence of this wide range of side effects causes a definite need for prescribers 
to use discretion when prescribing isotretinoin.  Systemic isotretinoin is the drug of 
choice for severe acne, but the popularity of the prescription and use of isotretinoin for 
less severe cases, where other more conservative treatments may have been 
successful, has increased.  Patients often pressurise their doctors into prescribing 
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isotretinoin.  Nevertheless, prescribers should adhere to the recommended indications 
for the use of this agent.  (Acne Guideline 2005 update, 2005: 889.)   
 
The most recent South African Acne Treatment Guideline was published in 2005 in 
the South African Medical Journal (Acne Guideline 2005 update, 2005: 883 – 892).  It 
was based on a consensus document of the Global Alliance to Improve Outcomes in 
Acne (GAIOA).  The GAIOA was created in 2001 as a worldwide effort to assemble a 
group of recognised experts in the field of acne treatment.  The aims of the group 
were to assess the current state of knowledge regarding acne treatment, to 
systematically work through all the relevant literature available, to have meetings in 
which the evidence collected would be discussed, and to prepare a set of 
recommendations for acne management to be distributed to all partaking countries 
where the general implementation of these guidelines would be encouraged.  The 
recommendations and information derived from these meetings were discussed with 
South African dermatologists in their own series of meetings.  The dermatologists 
gave input on special circumstances applicable to the South African situation and 
these contributions were then incorporated into the guidelines.  The recommendations 
are thus decidedly representative of the current universal approach to acne treatment, 
and they also reflect the thoughts of the dermatologists in South Africa.  (Acne 
Guideline 2005 update, 2005: 883.)   
 
This guideline is available to aid health care professionals in prescribing acne 
medication optimally, in providing necessary counselling, in conducting required 
monitoring procedures and in the overall care of acne patients, especially pertaining to 
isotretinoin.  The extent to which this guideline and additional recommendations 
regarding acne treatment derived from literature are followed by health care 
professionals is questionable.  See Appendix H for a summary of the 2005 South 
African Acne Treatment guideline. 
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1.2 OBJECTIVES OF THE STUDY 
 
The primary aim of this study was to investigate the appropriateness of medications 
prescribed in the treatment of acne in a South African population, and to evaluate the 
safety and efficacy of systemic isotretinoin utilised by an acne patient population in the 
Nelson Mandela Metropole (NMM).   
  
The more specific objectives, by which the primary aim was to be achieved, were the 
following: 
 
• Investigation of medications prescribed for the treatment of acne in a selected 
sample of South African patients.   
 
• Investigation of the appropriateness of these acne medications when compared to 
relevant literature recommendations.     
 
• Evaluation of the appropriateness of systemic isotretinoin prescription (in a 
selected sample of patients in the NMM) when compared to the standard Acne 
Treatment Guideline of South Africa (Acne Guideline 2005 update, 2005: 883 – 
892).  This would be done by specifically investigating:   
 
• the acne treatments utilised by patients prior to initiating systemic 
isotretinoin therapy;  
 
• the grade of acne experienced by patients to whom systemic 
isotretinoin was prescribed prior to initiating isotretinoin therapy;  
 
• the cumulative dosage of systemic isotretinoin that was prescribed 
per patient; 
 
• the quality and appropriateness of counselling received by patients 
prior to and during therapy with systemic isotretinoin; and 
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• the appropriateness and presence of patient monitoring procedures 
prior to and during therapy with systemic isotretinoin.   
 
• Investigation of the presence and severity of side effects experienced by patients 
on systemic isotretinoin therapy.   
 
• Evaluation of overall patient satisfaction regarding the outcomes of systemic 
isotretinoin treatment and the tolerability of side effects experienced during 
systemic isotretinoin treatment.   
 
1.3 CHAPTER LAYOUT 
 
Chapter Two serves as a literature review of acne and the treatment of acne.  Special 
emphasis is placed on literature regarding systemic isotretinoin in the management of 
acne.  The third chapter outlines the employed methodology for the drug utilisation 
review as well as the questionnaire survey.  The processes involved in conducting the 
literature review and the processes involved in obtaining, analysing and interpreting 
the data are explained.  Limitations of the study and ethical considerations are also 
stipulated in this chapter.   
 
Chapter Four gives a report and discussion of the results that were obtained from the 
drug utilisation review while Chapter Five gives a report and discussion of the results 
obtained from the patient questionnaire survey.  Chapter Six is a concluding chapter, 
in which a summary of the study findings is given and conclusions are drawn.  
Recommendations are also presented at the end of Chapter Six.   
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CHAPTER 2 
OVERVIEW AND MANAGEMENT OF ACNE 
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2.1 OVERVIEW OF ACNE  
 
2.1.1 INTRODUCTION 
 
This section serves to give a broad overview of acne as a disease state.  The 
definition, prevalence, pathogenesis and clinical diagnosis of acne are outlined.  The 
different acne types, grading systems of acne, factors influencing acne and impact of 
acne are also discussed.  It was important to outline the background of the latest 
South African Acne Treatment Guideline (Acne Guideline 2005 update, 2005:  883 – 
892) before specific acne treatments were discussed.  Thus, a discussion regarding 
the South African Acne Treatment Guideline released is also present in this chapter.   
 
2.1.2 DEFINITION OF ACNE 
 
Acne is an inflammatory disease of the skin which can often specifically be referred to 
as acne vulgaris, or common acne (Dorland’s Pocket Medical Dictionary, 2004).  In 
more scientific terms, acne can be defined as a multifactorial, chronic (Fulton, 2002: 
95), common disorder of the pilosebaceous unit (Mossman, 2006).  The Essential 
Drugs Programme of South Africa (1998: 150) defines acne vulgaris as a skin 
condition of sebum gland hypertrophy leading to a blocking and/or infection with 
Propionibacterium acnes (P. acnes).   
 
Characteristics of acne include the formation of comedones (black heads and/or white 
heads), erythematous papules and/or pustules, nodules and/or cysts and, in some 
cases, scarring and/or hyperpigmentation.  It may not always be possible to determine 
how long each patient will suffer from acne, but the condition usually persists for many 
years.  (Acne Management Guideline, 1999: 1024.)    
 
2.1.3 PREVALENCE OF ACNE 
 
Acne is a widespread skin condition, and it affects the majority of people to a certain 
degree at some point during their adolescent years (Acne Guideline 2005 update, 
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2005: 883; Tan, 2003: 307).  Adolescents, for the purpose of this study, are defined as 
people aged between 13 to 18 years.  Black heads (closed-ended comedones) are 
the mildest form of acne, and they are so common that it could be said that most 
people have had at least the mildest form of acne at some time during their lives 
(Acne Management Guideline, 1999: 1024).  Acne can also be referred to as acne 
vulgaris (or common acne).  Pray and Pray (2003: 17) reported that more people have 
appointments with dermatologists for acne relief than for any other skin condition in 
the United States of America (USA).  Pal (1997: 15) stated that, in the USA, one in 
every six appointments with dermatologists was for acne-related diseases in 1990, 
most of which were for acne vulgaris.  When considering general practitioners, Koh-
Knox, Scot and Popovich (1997: 35) stated that, of the doctors’ appointments for 
patients aged 15 to 19 years during 1991 (in the USA); four percent were for acne 
therapy.  In the USA, about 17 million people of all age groups and ethnic 
backgrounds are affected by acne vulgaris (Mossman, 2006).   
 
Adolescent years are the dominant time period for the occurrence of acne.  The word 
“acne” is derived from the Greek term “acme”, meaning “prime of life” (Buxton, 1991: 
38).  It could therefore be said that acne has always been known to occur more 
frequently in younger people.  When specifically considering adolescent acne, Pray 
and Pray (2003: 17) stated that the reported incidence of acne in adolescents in 
Western societies is 79% to 95%.   
 
When considering the difference in the occurrence rates of acne between genders, it 
was stated by Pray and Pray (2003: 17) that this skin condition generally develops 
earlier in females than in males.  They also stated that the average starting age of 
acne in females is 12.1 years while the average starting age of acne in males is 12.8 
years.  Acne peaks in incidence and severity at different ages for females and males.  
For females, it peaks at an average of 14 to 17 years, while it peaks at an average of 
16 to 19 years for males (Acne Management Guideline, 1999: 1024).  Therefore, it 
can be seen that, although acne usually develops earlier in females than in males, it 
also resolves earlier in females.  A study of office based practices conducted by Stern 
in 1996 reported that the average age of patients seeking guidance with regards to 
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acne was 24 years and that the majority of these patients were females (Koh-Knox, et 
al., 1997: 35; Stern, 1996).   
 
When considering the prevalence of different severities of acne among different age 
groups and genders, Pal (1997: 15) stated that severe acne (where nodules and/or 
cysts are present), affects more males (35%) than females (23%) in the 18 to 28 year 
age group.  From the ages 29 to 49 years, however, more females than males are 
affected by severe acne.  Milder forms of acne (comedonal acne) occur mostly in 
females.  (Pal, 1997: 15.) 
 
Although adolescent years are the most common time for the occurrence of acne, it is 
important to note that various forms of acne exist that may affect people of all ages.  
Although most cases of acne will resolve with the passing of time (Acne Management 
Guideline 1999: 1024), facial acne can prevail in 40% to 54% of patients older than 25 
years (Pray & Pray, 2003: 17).  Pray and Pray (2003: 17) also stated that three 
percent of males and 12% of females in their middle years still have acne.   
 
Females older than 30 years of age can present with acne that is usually due to 
hormonal causes (Acne Management Guideline, 1999: 1024).  Another well 
recognised type of acne occurs in infants at the age of approximately three months 
and may last up to the age of five years (Acne Management Guideline, 1999: 1024), 
although it usually clears up spontaneously after a short while (Buxton, 1991: 38).  
This acne type is known as infantile (or neonatal) acne and is more commonly found 
in boys than in girls (Buxton, 1991: 38).  Buxton (1991: 38) stated that infantile acne 
may be associated with an increased possibility of developing severe acne in 
adolescent years.    
 
When considering the prevalence of acne amongst different races, it was found that 
acne can occur in Caucasians, African-Americans, Hispanics, and Asians (Pray & 
Pray, 2003: 17).  Caucasian patients are more likely to experience moderate and 
severe acne than patients with darker skins, although black skin is prone to worse 
scarring (Rutter, 2004: 175).  
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2.1.4 PATHOGENESIS OF ACNE 
 
The pilosebaceous unit is the primary disease site of acne.  It consists of a hair follicle, 
sebaceous glands, and a piloerector muscle apparatus.  The inside of each hair 
follicle is lined with an outer epidermal skin layer that grows and sheds just as the 
outer epidermis of the skin does.  (Pray & Pray, 2003: 20.)  When acne occurs, a plug 
is formed (by the hair, sebum, and keratinocytes that line the pilosebaceous unit) that 
blocks the flow of sebum to the skin surface.  These plugs form an optimal growth 
environment for P. acnes, which is a natural constituent of cutaneous flora.  These 
bacteria then proliferate in the plugged follicles, which leads to inflammation.  
(Mossman, 2006.)   
 
The primary lesion in acne is known as the microcomedo (Acne Management 
Guideline, 1999: 1026).  Feldman, Careccia, Barham and Hancox (2004: 2123) stated 
that acne vulgaris may be defined as any disorder of the skin whose initial pathology 
is the microscopic microcomedo.  This microcomedo may develop into an inflamed or 
a non-inflamed lesion.  (Acne Management Guideline, 1999: 1026.)  The 
microcomedo is invisible to the naked eye, but histological analysis indicates a dilated 
sebaceous gland and hyperkeratosis of the sebaceous ducts.  About 30% of facial 
follicles will be in this state at any given time in patients who are prone to developing 
acne.  (Acne Guideline 2005 update, 2005: 884.)   
 
After viewing the short summary of the pathogenesis of acne in the previous 
paragraphs, it is important to give detailed attention to the five main pathogenic factors 
involved in the development of acne.  These pathogenic factors represent specific 
targets for acne treatment.  Therefore, it is important for health care professionals to 
know and understand these factors and to take them into account when treating acne 
patients.  Combination treatments where different factors are targeted simultaneously 
achieve better results than combination treatments aimed at the same factors.  (Acne 
Guideline 2005 update, 2005: 884.)  According to the Acne Guideline 2005 update 
(2005:  884), there are five pathogenic factors involved in acne development, namely: 
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• production of androgens in the body; 
• excessive sebum production; 
• abnormal desquamation (sloughing) of the follicular epithelium in the sebaceous 
gland duct; 
• proliferation of P. acnes; and  
• inflammatory and immunological responses.   
 
These five pathogenic factors are discussed separately in more detail in the following 
paragraphs.   
 
2.1.4.1    Androgen and excessive sebum production 
 
According to the Acne Management Guideline (1999: 1026), active sebaceous glands 
are a prerequisite for the development of acne.  Sebaceous glands secrete an oily 
substance called sebum, which is a mixture of fats, cholesterol, proteins, inorganic 
salts and pheromones.  The functions of sebum are to coat the surface of hair and to 
help keep them from drying and becoming brittle.  Sebum also prevents excessive 
evaporation of water from the skin, keeps the skin soft and pliable and inhibits the 
growth of certain bacteria.  (Tortora & Grabowski, 2000:  148.)  Acne patients of both 
genders excrete on average more sebum than non-acne patients.  The level of 
secretion draws a parallel to the severity of acne.  (Acne Management Guideline, 
1999: 1026.)     
 
Excessive sebum excretion is usually due to an excessive androgen production or an 
increased availability of free androgen (which is due to a deficiency of sex-hormone-
binding globulin).  (Acne Management Guideline, 1999: 1026.)    It must therefore be 
noted that acne is androgen-dependent.  Androgens can be defined as any 
substance, for example, testosterone, that promotes masculinisation (Dorland’s 
Pocket Medical Dictionary, 2004: 41).  Up until recently the production of androgens in 
the body has not been listed as a separate pathogenic factor in the development of 
acne.  It was included after the GAIOA reviewed and reached consensus on the 
current state of knowledge in the field of acne and acne treatment in 2002 and 2003.  
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(Acne Guideline 2005 update, 2005: 883.)  Testosterone is converted to 
dihydrotestosterone in the sebaceous glands by the enzyme 5-alpha-reductase.  
Dihydrotestosterone is the main hormone responsible for an increase in sebum 
production.  (Acne Guideline 2005 update, 2005: 884; Cunliffe, Holland, Clark & 
Stables, 2000: 1085.)  This mechanism affects both genders.  It should, however also 
be noted that hormone studies in most females with acne are found to be normal.  
(Acne Management Guideline, 1999: 1026.)   
 
2.1.4.2    Abnormal desquamation of follicular epithelium 
 
Keratinisation is a process whereby new keratin cells form in the basal layer of skin 
(Koh-Knox et al., 1997: 35).  Keratinocytes are the epidermal cells that synthesise 
keratin (Dorland’s Pocket Medical Dictionary, 2004: 466).  Hyperkeratinisation occurs 
when the keratinocytes increase in activity and keratin mechanically blocks the 
outward flow of sebum in the pilosebaceous unit (Koh-Knox et al., 1997: 35).   
 
2.1.4.3    Proliferation of P. acnes and resultant inflammatory and immune 
responses  
 
P. acnes is a Gram-positive, pleomorphic, anaerobic rod (Acne Guideline 2005 
update, 2005: 884) that flourishes in the lipid-rich sebum (Koh-Knox et al.,1997: 35).  
There is a strong relationship between the number of these bacteria and the amount 
of sebum production according to the Acne Guideline 2005 update (2005: 884), but 
according to the Acne Management Guideline (1999: 1026), the number of bacteria 
are not related to the sebum excretion rate, implying that the actual number of 
organisms does not correlate with the severity of the condition.   
 
This bacterium induces immune responses that might lead to inflammation.  These 
responses include the formation of extracellular enzymes, the production of 
interleukin-1-alpha, the generation of heat-shock proteins and a mitogenic effect on T-
cells.  The inflammatory process is further amplified by a positive chemotactic effect 
on neutrophils due to the breakdown of sebum into free fatty acids by bacterial lipase.  
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(Acne Guideline 2005 update, 2005: 884.)  There is an increase in P. acnes 
resistance which correlates with antibiotic therapy failure (Acne Management 
Guideline, 1999: 1026).   
  
Acne can present as non-inflammatory or inflammatory lesions, or both (Koh-Knox et 
al., 1997: 36).  Non-inflammatory acne consists of comedones (Mossman, 2006), 
while inflammatory acne consists of papules, pustules, macules, nodules, draining 
sinuses and/or cysts.  An explanation of comedones (non-inflammatory lesions) and 
the different inflammatory lesions is given in this section.   
 
• A comedo is the basic lesion of acne.  If the comedo stays beneath the skin, it 
produces a white bump called a white head or a closed-ended comedo.  If a 
comedo reaches the surface of the skin, it is called an open-ended comedo or a 
black head.  (Anonymous, 2000: 50; Mossman, 2006.) 
 
• A papule is a small (5 mm or smaller), solid lesion slightly elevated above the skin 
surface (Anonymous, 2000: 50; Mossman, 2006).   
 
• A pustule is a dome-shaped, fragile lesion containing pus.  Pus is a combination 
of white blood cells, dead skin cells, and bacteria.  These pustules can heal 
without scar formation or it can progress to cyst formation.  (Anonymous, 2000: 50; 
Mossman, 2006.) 
 
• A macule is a temporary flat, red spot left by a healed acne lesion.  Macules may 
persist for days or weeks.  (Anonymous, 2000: 50; Mossman, 2006.) 
 
• A nodule is a solid, dome-shaped, or irregularly shaped lesion that can be painful.  
It extends into the deeper skin layers and may cause tissue destruction and may 
result in scarring.  (Anonymous, 2000: 50; Mossman, 2006.) 
 
• Draining sinuses are combinations of nodules and scars, and they form 
interconnecting tunnels surrounded by inflammation (Orrey, 1997: 6).   
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• Cysts are sac-like lesions containing liquid or semi-liquid pus.  Cysts are larger 
than pustules, extend deeper into the skin and can be very painful.  It often results 
in scarring and is resistant to most treatment.  (Anonymous, 2000: 50; Mossman, 
2006.)  
 
2.1.5 CLINICAL DIAGNOSIS OF ACNE 
 
As described in Section 2.1.4, acne can present with a variety of skin lesions as 
described in Section 2.1.4.  Other skin conditions may present with similar-looking 
lesions.  Comedones are practically diagnostic of acne vulgaris and it is difficult to 
make a diagnosis of acne in their absence (Acne Guideline 2005 update, 2005: 885).  
Therefore, the health care provider should always ascertain whether or not 
comedones are present.    
 
Although the face is the area of the body that is most frequently involved in acne, 
other body areas that contain sebaceous glands can also be involved.  These areas 
include the trunk (most often the back), the upper arms, the thighs and the buttocks.  
(Acne Guideline 2005 update, 2005: 885; Heyl & Swart, 1990: 149.) Other areas of 
acne may include the anogenital area (Buxton, 1991: 38) and the occipital area (Heyl 
& Swart, 1990: 149).   
 
2.1.6 TYPES OF ACNE 
 
This section gives a brief overview of the most significant different types of acne.  An 
acne type is usually derived from the cause of the acne, the severity or the 
appearance of the acne, or the affected patient age group.   
 
• Acne conglobata is a severe, extensive form of acne that is more common in 
males and in tropical climates.  It affects the trunk, the face and the limbs.  
(Buxton, 1991: 39.)  It occurs when extensive, deep inflammatory lesions coalesce 
to form painful cysts which communicate with each other below the surface of the 
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skin (Heyl & Swart, 1990: 150).  There are two subtypes of acne conglobata as 
outlined below.   
 
? Pyoderma faciale is a variant of acne conglobata, in which erythematous and 
necrotic lesions are present.  This condition is more prevalent in adult females.  
(Buxton, 1991: 39.) 
 
? Acne fulminans is another type of acne conglobata in which there is 
associated systemic illness with malaise, joint pains and fever.  It appears to be 
due to hypersensitivity to P. acnes.   (Buxton, 1991: 39.) 
 
• Acne cosmetica can be found in females around their early thirties, after many 
years of using mineral oil-based cosmetic preparations.  Actors can also suffer from 
this condition.  (Heyl & Swart, 1990: 150.)  
 
• Acne detergicans is an aggravation of existing acne lesions by washing the skin 
with comedogenic soaps and rough cloths too frequently (Dorland’s Pocket Medical 
Dictionary, 2004: 9).   
 
• Acne excoriée is acne that has been manipulated, leaving erosions and scars 
(Habif, Campbell, Quitadamo & Zug, 2001: 72). 
 
• Acne halogen is an acne eruption due to the intake of the simple salts of bromine 
and iodine present in cold remedies, sedatives, analgesics and vitamins (Dorland’s 
Pocket Medical Dictionary, 2004: 9).   
 
• Acne indurata is a progression of papular acne, where deep-seated and 
destructive lesions that may produce severe scarring are present (Dorland’s Pocket 
Medical Dictionary, 2004: 9).   
 
• Acne keloidalis is a type of scarring acne seen on the neck in males (Buxton, 
1991: 38). 
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• Acne mechanica is an aggravation of existing acne by mechanical factors such as 
stretching or rubbing, as by chin straps, clothing, backpacks, casts and seats 
(Dorland’s Pocket Medical Dictionary, 2004: 9).   
 
• Acne necrotica miliaris is a rare, itchy, chronic form of folliculitis of the scalp.  It 
occurs primarily in adults, with the formation of tiny superficial pustules which are 
destroyed by scratching (Habif, et al., 2001: 72; Dorland’s Pocket Medical 
Dictionary, 2004: 9).   
 
• Acne papulosa is acne vulgaris with the formation of papules (Dorland’s Pocket 
Medical Dictionary, 2004: 9).   
 
• Acne tropicalis is a severe form of acne that may occur in hot, humid climates, 
with nodular, cystic and pustular lesions mainly on the back, buttocks and thighs.  
Conglobate abscesses frequently form on the back.  (Dorland’s Pocket Medical 
Dictionary, 2004: 9.)   
 
• Acne varioliformis is a rare condition with reddish-brown, papulopustular 
umbilicated lesions, usually on the brow and scalp.  It is probably a deep variant of 
necrotica miliaris (Dorland’s Pocket Medical Dictionary, 2004: 9).  
 
• Acne vulgaris is the most common type of acne, in which more males than 
females are affected and a familial tendency is of note.  It affects mainly 
comedogenic areas and occurs most frequently during adolescent years.  (Buxton, 
1991: 40.) 
 
• Comedonal acne is the predominant presence of open- and closed-ended 
comedones (Woodard, 2002).   
 
• Cystic acne is characterised by multiple cysts, nodules, and pitted scarring 
(Woodard, 2002).   
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• Gram-negative folliculitis occurs with a proliferation of Klebsiella, Proteus 
mirabilis, Pseudomonas aeruginosa, Serratia marcescens or Escherichia coli (E. 
coli).  It may be the result of long-term antibacterial treatment in acne patients.  It is 
caused by bacterial interference and the replacement of gram-positive flora of the 
facial skin and mucous membranes of the nose by gram-negative bacteria.  (Böni 
& Nehrhoff, 2003: 273.)  Patients with gram-negative folliculitis may notice a 
sudden change in their acne, with the appearance of pustules or large 
inflammatory cysts (Arndt, 1979: 7).   
 
• Infantile acne, or neonatal acne, occurs in infants and children up to the age of 
five years and usually clears spontaneously (Buxton, 1991: 40).  It usually presents 
on the face (Buxton, 1991: 38), and is a relatively uncommon disorder (Cunliffe, 
Baron & Coulson, 2001: 463).  Apart from rare causes, such as adrenal 
hyperplasia or virilising tumours, the release of adrenal androgens due to 
transplacental stimulation of the adrenal gland is thought to be the primary cause 
of infantile acne.  This, however, does not explain why the lesions may persist for 
such a long time after birth.  (Buxton, 1991: 38.)    
 
• Occupational acne, or chloracne, occurs as a result of long term contact with oils 
or tar.  There are prominent comedones present on the face and neck of a patient 
with this acne type.  (Buxton, 1991: 40.) 
 
• Pomade acne can be found in patients who groom their scalps and facial hair with 
greasy lubricants.  It is marked by closed ended comedones on the forehead, 
temples, cheeks and chin (Dorland’s Pocket Medical Dictionary, 2004: 9).   
 
• Premenstrual acne is acne of a cyclic nature that appears shortly before (and 
rarely after) the onset of menses (Dorland’s Pocket Medical Dictionary, 2004: 9).   
   
• Steroidal acne occurs in the form of comedonal and pustular acne on the chest 
two to five weeks after a steroid has been taken (Habif, et al., 2001: 72). 
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2.1.7 GRADING OF ACNE 
 
Acne must be graded according to severity in order to make an appropriate decision 
regarding a treatment plan for each patient.  Grading of acne has been shown to be 
problematic and highly subjective.  (Acne Guideline 2005 update, 2005: 885.)  There 
are a wide variety of grading systems available in attempts to categorise acne into 
different grades of severity.  Some of these systems calculate severity by considering 
the number of different skin lesions present, while other systems focus more on the 
type of lesion present regardless of the number of lesions.  Some of the more 
complicated grading systems may depend largely on diagrams and photos, where the 
patient’s appearance is compared to a standard set of photos or pictures in order to 
grade the severity of the acne condition.     
 
Most dermatology literature simply grades the severity of acne into mild, moderate or 
severe (Rutter, 2004: 175).  This usually entails the following (Acne Management 
Guideline, 1999: 1027): 
 
• Mild – mostly comedones with a few inflammatory lesions; 
• Moderate – predominantly inflammatory lesions with some comedones; and 
• Severe – nodulocystic acne or moderate acne causing scarring.   
 
This method demands that acne severity should be upgraded to severe if (Acne 
Management Guideline, 1999: 1027): 
 
• it is refractory to appropriate recommendations; 
• the patient is unable to tolerate other recommended treatment; and/or 
• the acne is extensive.   
 
Another method explained in the U.S. Pharmacist (Pray & Pray, 2003: 20 - 22) relies 
on the type, number, and location of lesions and the presence of scarring.  It is a 
method that can be used by the pharmacist as a resource in determining whether the 
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patient can self-treat or whether the patient requires a referral to a prescriber.  Acne is 
divided into four types in this method (Pray & Pray, 2003: 20 - 22): 
 
• Type 1:  The patient has only comedones, with fewer than 10 lesions on the face, 
no lesions on the trunk, and no visible scarring;  
• Type 2:  The patient has papules, 10 to 25 lesions on the face and trunk, and mild 
scarring;    
• Type 3:  The patient has pustules, more than 25 lesions, and moderate scarring; 
and   
• Type 4:  The patient has extensive scarring and nodules or cysts.   
 
According to the GAIOA (Acne Guideline 2005 update, 2005: 885), the most 
uncomplicated way of grading acne is to base the grade on the predominant lesion 
type present on the skin, regardless of how many lesions there are.  The reasoning 
behind this thinking is that one comedo on the face will respond equally well to 
treatment as a thousand comedones, therefore the number of lesions should be 
regarded as less important than the type of lesions when grading acne.  The type of 
lesion will thus determine the therapy implemented.  The individual’s acne will always 
be graded according to the most severe lesion present.   
 
There are four stages of acne according to the GAIOA (Acne Guideline 2005 update, 
2005: 885): 
 
• Grade 1:  Comedones only;  
• Grade 2:  Inflammatory papules present in addition to the comedones;  
• Grade 3:  Pustules present in addition to any of the above; and 
• Grade 4:  Nodules, cysts, conglobate lesions or ulcers present in addition to any 
of the above.   
 
The extent of involvement does not influence the grade of acne, but it should also be 
taken into consideration in the treatment decisions.  Scarring should also be taken into 
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account and would place a patient in a more severe category than one without 
scarring.  (Acne Guideline 2005 update, 2005: 885.)  For the purpose of this study, the 
grading system of the GAIOA will be used, seeing that it is most applicable to the 
South African situation, it was developed by the GAIOA after an extensive literature 
review and practical evaluation of previous grading systems, and it is the most current 
grading system available in South Africa.   
 
2.1.8 FACTORS INFLUENCING ACNE 
 
There are various factors that can influence the development and severity of acne.  
Many lies, or myths, regarding the causative factors of acne exist among the public, 
and a lack of education regarding acne has exacerbated the spreading and beliefs of 
these myths through many ages.  This section serves to give more clarity regarding 
the true factors that may influence acne, although there are still many unsolved myths.   
 
2.1.8.1  Genetic factors 
 
It is an accepted fact that the development of acne can be influenced by genetic 
factors (Acne Management Guideline, 1999: 1026).  There is evidence to suggest a 
genetic predisposition to acne particularly if a parent, or both parents, suffered from 
inflammatory acne (Bello, 2002: 71).  According to Fulton (2002: 96), acne is inherited 
as an autosomal dominant gene.  He stated that if both parents in a family were 
affected by acne, three out of four children may present with this disease.   
 
2.1.8.2  Diet 
 
There is an existing myth that certain foods, particularly fried foods, chocolate and 
cola drinks, can worsen acne.  However, there is no evidence to suggest that these 
foods affect acne in any way (Acne Management Guideline, 1999: 1026; Hall-Smith & 
Cairns, 1981: 80; Pray & Pray, 2003: 20).  Magin, Adams, Heading, Pond and Smith 
(2006: 344) reported that questionnaire-based survey studies citing prevalence of the 
beliefs in various populations regarding causative factors in acne were conducted in 
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the USA (Rasmussen & Smith, 1983), New Zealand (1998), Brittain (Smithard, 
Glazebrook & Williams, 2001) Germany (Niemeier, Kupfer, Demmelbauer-Ebner, 
Stangier, Effendy & Gieler, 1998), Nigeria (Orafidiya, Agbani, Oyedele, Babalola & 
Onayemi, 2002), Saudi Arabia (Al-Hoqail, 2003: 765 - 768) and Sweden (Berg, 1989).  
These studies reported a high prevalence of lay belief in the causal or therapeutic 
roles of diet, cleanliness and sunlight in acne.   
 
As reported by Fulton (2002: 98), doctors at the University of Pennsylvania conducted 
a study in 1969 in which 50 teenagers were each fed a pound of chocolate per day to 
monitor and evaluate the severity of acne in these patients.  Acne improved in two of 
these 50 patients, acne worsened in two patients, while there was no significant 
change in acne severity in the rest of the patients.  (Fulton, 2002: 98.)  There has 
been some recent reassessment of the effect that diet may have on acne, but no 
convincing evidence either for or against the efficacy of diet (as well as face washing 
and sunlight exposure) in acne (Magin, et al., 2006: 344).   
 
Excessive iodides are excreted through the sebaceous gland and may cause flare-ups 
of acne, and thus, excessive iodides may cause increased acne severity.  Iodide can 
be found in dietary supplements that contain elemental iodide and in seaweed.  Some 
drinking water may also contain high iodide concentrations.  The normal dietary intake 
from fish or mainland water is not enough to aggravate acne in most individuals.  
(Fulton, 2002: 98.) 
 
Adebamowo, Spiegelman, Berkey, Danby, Rockett, Colditz, Willett & Holmes (2006) 
quoted a research study by Robinson, in which it was reported that among 1 925 
patients who kept a food diary in 1949, the majority implicated milk in acne flares.  
Adebamowo and his fellow researchers conducted their own prospective study of girls 
in the USA aged nine to 15 years in 1996, in which they found that greater 
consumption of milk was associated with higher prevalence of acne.  They did not find 
an association with diary fat.  This finding was consistent with the result of another 
study conducted by these researchers, where female nurses in the USA reported on 
their high school diet and prevalence of physician-diagnosed severe teenage acne.  
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(Adebamowo, et al., 2006.) Thus, one could conclude that there might be a positive 
association between milk consumption and acne in female adolescents.   
 
2.1.8.3  Cosmetics 
 
According to the Acne Management Guideline (1999: 1026), no correlation between 
the use of cosmetics and acne has been proven in studies in the United Kingdom 
(UK).  Nevertheless, water-based or oil-free products are preferred in patients with 
acne.  Pomade acne or acne cosmetica is recognised in people using cosmetics 
containing mineral oils.  (Acne Management Guideline, 1999: 1026.)   
 
2.1.8.4  Premenstrual flare and the menstrual cycle 
 
Acne flare-ups can occur in approximately 70% of females two to seven days before 
menstruation (Acne Management Guideline, 1999: 1026).  These flare-ups might be 
caused by fluid retention that can lead to an increase in hydration and subsequent 
swelling of the pilosebaceous duct (Buxton, 1991: 38; Hall-Smith & Cairns, 1981: 80).  
Fulton (2002: 100) stated that the stratum corneum can swell to 300% its usual size 
due to heat and humidity.  In addition, the pilosebaceous duct orifice is significantly 
smaller between days 15 to 20 of the menstrual cycle (thus approximately 13 to eight 
days before menstruation), which may cause an increase in duct obstruction and 
resistance to sebum flow (Arndt, 1979: 6).   
 
2.1.8.5  Sweating 
 
Sweating may worsen acne in some patients (Acne Management Guideline, 1999: 
1026).  This worsening is probably caused by the same mechanism as described for 
the premenstrual acne flare-up (Buxton, 1991: 38).   
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2.1.8.6  Ultraviolet radiation 
 
A majority of dermatologists and patients accept that natural sunlight (ultraviolet 
radiation) may improve acne (Acne Management Guideline, 1999: 1026).  An 
improvement in acne over summer seasons (and a worsening in winter seasons) is 
reported by many people.  As reported by Pray and Pray (2003: 17 - 18), researchers 
surveyed 452 acne patients about seasonal symptom variations to explore this 
hypothesis.  Although about half of the patients did confirm that their acne varied 
according to seasons, 56% of these patients stated that their acne actually worsened 
in the summer months, while only 11% claimed to experience a worsened acne 
condition during winter months.  It should be mentioned that factors like heat, humidity 
and sweating (that may worsen acne) are more prevalent in summer months and 
might be responsible for the exacerbation of acne during summer time.  (Pray & Pray, 
2003: 17 - 18.)  Thus, this study did not oppose the acceptance of the positive effect 
that natural sunlight might have on acne.   
 
2.1.8.7  Stress 
 
Most patients and doctors believe that stress can aggravate acne.  Stress can cause 
an alteration in the hypothalamic-pituitary axis, which can lead to hormonal and 
immune system changes.  These changes may affect acne development.  (Acne 
Management Guideline, 1999: 1026.)  As explained in Section 2.1.8.10, during times 
of stress the body secretes cortisol, which increases sebum production.  This process 
can therefore lead to an increased possibility of acne development.  (Mossman, 
2006.)   
 
2.1.8.8  Occupation 
 
In occupations such as mining and catering, where there is a possibility of excessive 
hydration, the ductal orifice size may change and result in worsening of acne.  When 
people are exposed to halogenated aromatic compounds, folliculitis may be induced 
and a condition known as chloracne may arise.  It is characterised by the presence of 
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comedones of various sizes without inflammation.  These comedones may be present 
on unusual sites like the arms or thighs, where oil products soak through clothing.  
(Acne Management Guideline, 1999: 1026.)  Other substances that may cause acne-
like eruptions are grease, tar and creosote.  This type of acne is known as industrial 
acne, and is more of an irritation folliculitis than it is true acne.  (Heyl & Swart, 1990: 
150.)   
 
2.1.8.9  Environmental factors 
 
A study (Cordain, Lindeberg, Hurtado, Hill, Eaton & Brand-Miller, 2002: 1585 – 1586) 
was conducted in two groups of non-Westerners, in which 1200 Kitavan Islanders of 
Papua New Guinea (300 were aged 15 to 25 years) and 115 Aché hunter-gatherers of 
Paraguay (15 were aged 15 to 25 years) were included.  The researchers failed to find 
a single case of acne, even in the mildest form.  It was thought that environmental 
factors, rather than genetic factors, were responsible and urged further work to identify 
these factors.  (Cordain, et al., 2002: 1585 – 1586; Pray & Pray, 2003: 17.)   
 
2.1.8.10  Medication-induced acne 
 
Androgenic hormones increase the size of sebaceous glands and the amount of 
sebum in both male and female adolescents.  Oestrogens have the opposite effect in 
pre-adolescent males.  Oral contraceptives that contain more than 50ųg 
ethinylestradiol can make acne worse and the combined type oral contraceptives may 
lower sex-hormone-binding globulin concentrations, which can lead to increased free 
testosterone.  (Buxton, 1991: 38.)   
 
Oral steroids can cause a papular eruption which is dose dependent and clears up 
after discontinuation of the drug.  Corticosteroids mimic cortisol, a natural steroid 
produced in the body during times of stress that stimulates sebum production 
(Mossman, 2006).  Corticosteroids are not directly comedogenic, but can sensitise the 
follicular epithelium to the comedogenic effects of sebum (Arndt, 1979: 7).  Anti-
convulsants are known to exacerbate existing acne (Heyl & Swart, 1990: 150).  Table 
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2.1, adopted from the Acne Management Guideline (1999: 1027), depicts these, and 
other, medications that may cause acne.   
 
Table 2.1:  Medications reported to be associated with acne or acne-like 
eruptions 
MEDICATION TYPES SPECIFIC EXAMPLES 
Hormones and steroids 
 
Gonadotrophins 
Androgens 
Anabolic steroids 
Oral and topical steroids 
Halogens 
 
Bromides 
Iodides 
Halothane 
Anti-convulsants 
 
Diphenylhydantoin 
Phenobarbitone 
Troxidone 
Phenytoin sodium (Mossman, 2006.) 
Valproic acid (Mossman, 2006.) 
Carbamazepine (Mossman, 2006.) 
Anti-tuberculosis medication 
 
Isoniazid 
Rifampicin 
Miscellaneous 
 
Chloral hydrate 
Cyanocobalamin 
Disulfiram 
Lithium 
Psoralens (with Ultra Violet A (UVA)) 
Quinine 
Sulphur 
Thiouracil 
Thiourea 
Iodine (Mossman, 2006.) 
Azathioprine (Rutter, 2004: 176) 
Psoralen and Ultra Violet A 
(PUVA) 
 
0.5% of patients receiving PUVA develop acne or perioral 
dermatitis 
Table adopted from the Acne Management Guideline (1999: 1027) 
 
2.1.8.11  Hygiene  
 
There is a common misunderstanding that poor hygiene may lead to acne (Pal, 1997: 
15).  Dirt does not contribute to the formation of acne lesions (Mossman, 2006).    
Excessive cleansing of the skin should be discouraged (Bello, 2002: 71), as 
unwarranted exposure to water and medications can cause overdrying of the skin and 
rebound sebum secretion (Woodard, 2002).  Proper hygiene includes washing the 
face twice a day with mild soap and water (Essential Drugs Programme of South 
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Africa, 1998: 150).  Fulton (2002: 97) stated that even if people washed their faces 20 
times per day, they would not be able to remove the impacted pores of acne easily.  
An important fact that the health care provider must be aware of and communicate to 
the acne patient is that the dark colour of black heads is not due to dirt or unhygienic 
practice, but it is due to melanin (Buxton, 1991: 38) and oxidised lipids (Arndt, 1979: 
4).   
 
2.1.8.12  Mechanical pressure 
 
Pressure or friction on the skin from tight clothing, athletic equipment or even 
backpacks can worsen acne (Mossman, 2006).   
 
2.1.8.13  Scrubbing, squeezing and picking of lesions 
 
Inflammation could be triggered by hard scrubbing of the face and should be 
discouraged (Mossman, 2006), particularly excessive scrubbing with exfoliants (Bello, 
2002: 71).  Surface bacteria can be forced into pilosebaceous units by squeezing or 
picking blemishes.  Thus, these activities are discouraged as they can contribute to 
the formation of comedones.  (Mossman, 2006.) 
 
2.1.8.14  Sexual activity 
 
An existing myth is that acne could be aggravated by sexual activity (Fulton, 2002: 
98).  However, there is no evidence that sexual activity triggers or worsens acne 
(Bello, 2002: 71).   
 
2.1.9 PSYCHOLOGICAL, PHYSICAL AND ECONOMIC IMPACT OF ACNE 
 
Severe acne can cause permanent physical damage and frequently equally severe 
psychological damage (Isotretinoin (Roaccutane) usage – a South African consensus 
guideline, 1997: 1410).  It can also have an economic impact on a person or on a 
 29
community.  This section will give a more detailed explanation of each of these three 
factors.   
 
2.1.9.1   Psychological impact of acne 
 
The impact of acne on the quality of the lives of patients is highly significant (Acne 
Guideline 2005 update, 2005: 883).  In many cases, the onset of acne is 
approximately at the same time as the onset of puberty, and therefore the self-image 
of the patient may be affected negatively by this condition (Pray & Pray, 2003: 20).   
 
Due to the fact that the acne patient is unable to predict the duration or the severity of 
the condition, or the likelihood of a positive treatment outcome, even mild cases of 
acne can cause a great degree of stress, frustration, embarrassment, depression and 
anger (Pray & Pray, 2003: 20).  Tan, Vasey & Fung (2000) conducted a study in which 
they reported that 49% of acne patients believed that acne could be cured and that 
the duration of treatment would be less than six months (Tan, et al., 2000; Woodard, 
2002).   
 
Clinically, it is difficult to determine the impact of acne on a person’s life (Acne 
Guideline 2005 update, 2005: 883).  Acne patients may be denied the “sick-role” given 
to other patients with minor conditions (like headache), because acne is often seen as 
a negligible condition with little consequence (Pray & Pray, 2003: 20).   
 
In a survey (Kellett & Gawkrodger, 1999) of 111 people aged 16 to 39 years who were 
referred to dermatologists for acne, results showed that acne patients had levels of 
social, emotional, and psychological impairments as significant as those reported by 
patients with chronically disabling diseases such as asthma, epilepsy, diabetes, back 
pain or arthritis (Kellett & Gawkrodger, 1999; Woodard, 2002).  Acne can even be 
linked to unemployment (Acne Guideline 2005 update, 2005: 883; Ng, et al., 2002: 
262) and social phobias (Pal, 1997: 15).  Tan JKL (2004: 1) reported that previous 
studies on the psychosocial impact of acne have documented dissatisfaction with 
appearance, embarrassment, self-consciousness, and lack of self-confidence in acne 
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patients.  Social interaction with the opposite gender, interaction with strangers and 
public appearances may also be affected negatively in acne patients (Tan JKL, 2004: 
1).   A study conducted by Cooper (2003: 98) revealed that 70% of patients with acne 
expressed feelings of embarrassment, 63% anxiety and 27% frank depression.  Over 
half of these patients had received distressing comments from peers and 57% 
reported an effect on their social life.   
 
Another study that was conducted in 1986 was reported by Docrat (1997: 20) and Tan 
JKL (2004: 2).  In this study, unemployment was evaluated in 625 patients aged 18 to 
30 years in England.  The results of the study revealed that there was a significantly 
higher unemployment level amongst acne patients of both genders compared to 
patients without acne.  Approximately 16.5% of males with acne were unemployed 
whilst 9.2% of males without acne were unemployed.  As for the females, 14.3% of 
women with acne were unemployed compared to 8.7% of women without acne.  The 
results confirmed widely held perceptions amongst acne sufferers.  It should be noted, 
however, that social status, intelligence and academic background were not included 
in the analysis.   
 
Woodard (2002) reported on a study conducted in 2000 that indicated that 75% of 
patients waited approximately one year before seeking professional help for acne.  A 
study was conducted by Smith in 2000 among 103 college students ranging from 18 
to 21 years in Houston, wherein the nature of adolescent health concerns (with 
specific focus on acne and its impact on social functioning) was explored.  Results 
indicated that acne was a constant health concern among the participants and that the 
participants’ knowledge of acne was associated with many misconceptions regarding 
the causative factors and treatment of acne.  (Smith, 2000.) 
 
All health care professionals share the task of treating and counselling acne patients 
to minimise the negative effects of acne.  Pharmacists have an important role in 
educating patients with acne about the condition, in optimising acne treatment 
regimens and in dispelling myths about acne.  The quality of the lives of acne patients 
could be improved with pharmacist counselling (Bello, 2002: 71).  Studies have 
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demonstrated that effective treatment of acne was accompanied by improvement in 
self-esteem, obsessive-compulsiveness, shame, embarrassment, body image, social 
assertiveness, and self-confidence (Tan JKL, 2004: 2).   
 
2.1.9.2   Physical impact of acne 
 
The most important physical complications of acne are post-inflammatory 
pigmentation and scar formation, which can be pock-like, keloidal or both (Heyl & 
Swart, 1990: 150).  The redness and pigmentation after acne has resolved can take 
months to fade (Habif, et al., 2001: 72).  Acne can have several other complications, 
with or without treatment.  Complications may also arise due to the side effects of the 
agents used in the treatment of acne.  These complications can include gram-negative 
folliculitis, localised cellulitis, acne keloidalis, acne conglobata (the most severe type 
of acne) and hyperpigmentation.  (Woodard, 2002.)   
 
2.1.9.3   Economic impact of acne 
 
In 1997, the health care funders of pharmaceutical products for dermatological 
conditions in South Africa ranked acne within the top eight disease states that are 
most expensive to treat.  Acne was ranked just below conditions such as 
hypertension, hypercholesterolaemia, depression and peptic ulcer disease.  
Dermatological products made up six to seven percent of the reimbursed 
pharmaceutical benefits bill in 1997.  Approximately 55% of the money reimbursed for 
dermatologicals was due to acne.  (Wessels, Anderson & Kropman, 1999: 780.)  
Thus, acne has a significant financial implication in South Africa.   
 
2.2 MANAGEMENT OF ACNE 
 
2.2.1 INTRODUCTION 
 
According to Shalita (2001: 43), the scientific understanding of the pathogenesis of 
acne has increased considerably over the past three decades.  Therefore, there has 
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been a shift in the clinical focus of acne treatment; away from the resolution of 
advanced lesions (the previous primary focus), towards the inhibition of the multiple 
pathogenic processes underlying the earliest acne stages (the new primary focus).  
(Shalita, 2001: 43.)   
 
Treatment agents currently available for acne include topical agents (for example 
azelaic acid, benzoyl peroxide, topical retinoids, and topical antibiotics) and systemic 
agents (for example systemic antibiotics, hormonal therapy and systemic isotretinoin).  
Other available treatments include, for example, topical salicylic acid, topical sulfur, 
topical sodium salicylate, corticosteroids, zinc, gluconate and vitamin A (Oprica, 
Emtestam & Nord, 2002: 244).  Complementary and alternative natural treatment 
options are also present, for example garlic tincture, lemon oil and tea tree oil.  Tea 
tree oil has been demonstrated to be as effective as benzoyl peroxide in the treatment 
of mild to moderate acne.  (MIMS Complementary Desk Reference, 2006/2007: xxxvi, 
xlii, 109, 133.)  Physical treatment methods include light therapy or laser therapy, 
cryotherapy, cortisone injections and black and/or white head extractions (Acne 
Management Guideline, 1999: 1031).   
 
During acne management, the treatment goals should be healing the existing acne 
lesions, preventing scarring and formation of new lesions and minimising 
psychological distress that may accompany acne (Mossman, 2006).  The Essential 
Drugs Programme of South Africa (1998: 150) states that the management objectives 
for acne vulgaris are the elimination of pathogens and the improvement of the skin 
condition, while Goodman (2006: 613) reported that educating patients and dispelling 
existing myths regarding acne are also important factors in effective acne 
management.   
 
This section serves as an introduction to the most recent South African Acne 
Treatment Guideline.  This section also gives more detail of the management of acne 
with the above-mentioned agents.  Indications and contraindications for the use of the 
different acne treatments, side effects of the agents, and dosage instructions are 
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discussed in this section.  Systemic isotretinoin was excluded from this section, but is 
discussed separately in Section 2.3.   
 
2.2.2    SOUTH AFRICAN ACNE TREATMENT GUIDELINE  
 
The most recent South African Acne Treatment Guideline, compiled by W. Sinclair 
and H.F. Jordaan, was published in 2005 in the South African Medical Journal (Acne 
Guideline 2005 update, 2005: 883 – 892).  It was based primarily on a consensus 
document of the GAIOA.  The GAIOA was created in 2001 as a world-wide effort to 
assemble a group of experts in the field of acne treatment.  The aim was to assess the 
current state of knowledge in this field, to systematically work through all the relevant 
literature available, to have meetings in which collected evidence were to be 
discussed, and to draw up a set of recommendations for acne management (which 
would be distributed to all partaking countries where the general implementation of 
these guidelines would be encouraged).  Two main groups were formed; one in 
America and one in Europe.  Meetings were held separately, but the information was 
shared and there was unification of the ultimate guidelines.  Africa, Australia and 
South America were included with the European group and the South African 
delegates attended most of the meetings.  There were four meetings held in Europe.  
(Acne Guideline 2005 update, 2005: 883.)   
 
The recommendations and information that originated from these meetings were 
published in the Journal of the American Academy of Dermatology in 2003 and were 
brought back to South Africa.  It was discussed with South African dermatologists in a 
series of meetings held during March 2004 and April 2004 at six main centres in the 
country.  Approximately 80% of local dermatologists attended these meetings, 
commented on the recommendations, and contributed on special circumstances 
applicable to South Africa.  All relevant information collected from these meetings was 
incorporated into the guidelines.  The recommendations are therefore representative 
of the current international acne treatment approach, and also reflect the thoughts of 
the South African dermatologists.  The guideline should be applied by dermatologists, 
general medical practitioners, pharmacists, gynaecologists, nurses and beauticians.  It 
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should be met with the necessary authority and should be accepted by all health care 
professionals.  The guideline review discusses the use of the major classes of anti-
acne therapy and the way it should be used.  It also gives guidelines for the 
management of the different grades of acne vulgaris.  (Acne Guideline 2005 update, 
2005: 883.)   
 
2.2.3 TOPICAL ACNE TREATMENT AGENTS 
 
For mild acne, topical therapy alone is usually preferred.  A topical comedolytic agent, 
especially from the retinoid group, can be used in a daily sequence with benzoyl 
peroxide, a topical antibacterial agent.  When combined with systemic antibiotic 
treatment or hormonal therapy, topical therapy can also be useful for moderate to 
severe acne.  (Akhavan & Bershad, 2003: 475.)  Topical medications provide less 
aggressive intervention than systemic therapy, but also have advantages.  It can be 
directly applied to affected skin, which maximises the proportion of drug delivery to the 
pilosebaceous units.  Unnecessary systemic exposure is also limited through the use 
of topical agents and the potential for systemic side effects and drug interactions are 
decreased.  (Akhavan & Bershad, 2003: 476.)  Topical acne medications are available 
in several formulations.  Creams and lotions are usually reserved for dry or sensitive 
skin, whereas gels are prescribed for oil-prone complexions. (Feldman, et al., 2004: 
2124.)  The most important topical agents available for acne treatment are discussed 
in this section.   
 
2.2.3.1  Azelaic acid 
 
Azelaic acid is a dicarboxylic acid derived from Pityrosporum ovale (Presbury & 
Weiss, 2000).  It has been clinically proven that azelaic acid reduces the number of 
non-inflamed lesions and the P.acnes count (Oprica, et al., 2002: 244).  Thus, it has 
mild keratolytic and antibacterial effects (Akhavan & Bershad, 2003: 486).  This topical 
agent is structurally unrelated to any other topical anti-acne agent (Liao, 2003: 45).   
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Azelaic acid is a useful adjunct to more conventional topical treatments, especially 
where local irritation has been a cause of dissatisfaction with standard regimens 
(Akhavan & Bershad, 2003: 486).  Azelaic acid is tolerated better, and poses less 
severe skin irritation, than tretinoin or benzoyl peroxide (Liao, 2003: 45).  Akhavan and 
Bershad (2003: 488) reported that twelve-week placebo controlled studies were 
conducted in 1989 in Stockholm.  These studies indicated that azelaic acid is effective 
in improving mild to moderate acne when applied as a 20% cream twice daily.  In 
South Africa, azelaic acid is available as Skinoren Acne Cream® 20% and Skinoren 
Gel® 15% (MIMS Desk Reference, 2005: 1200).  A visible improvement in acne can 
be expected within four weeks of therapy (Akhavan & Bershad, 2003: 486).  Azelaic 
acid may be particularly effective in the treatment of acne with post-inflammatory 
hyperpigmentation (Feldman et al., 2004: 2127).   
 
Common side effects of azelaic acid include pruritus, burning, stinging and tingling.  
Erythema, dryness, peeling, hypopigmentation and hypertrichosis have also been 
reported.  It has not been linked with systemic side effects.  Safety of azelaic acid in 
patients younger than 12 years, pregnancy and breastfeeding women has not yet 
been established.  There is no known drug interaction with azelaic acid, although it 
might be expected to enhance the irritative potential of concomitant topical therapy.  
(Akhavan & Bershad, 2003: 476, 478, 488.)   
 
2.2.3.2  Benzoyl peroxide 
 
Benzoyl peroxide has a mild keratolytic effect, acting as a comedolytic agent (Acne 
Guideline 2005 update, 2005: 887).  It is also a broad-spectrum antimicrobial (Acne 
Guideline 2005 update, 2005: 887) and its usefulness for treating acne is primarily due 
to its potent bactericidal effect against P.acnes (Akhavan & Bershad, 2003: 482).  The 
presence of free fatty acids (an indication of bacterial function) is greatly reduced by 
benzoyl peroxide (Presbury & Weiss, 2000).  No resistance to benzoyl peroxide has 
yet been reported (Acne Management Guideline, 1999: 1027 – 1028), which gives it 
an advantage over the topical antibiotic agents.    Benzoyl peroxide was found to be at 
least as effective for acne as clindamycin and erythromycin formulations (Feldman et 
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al., 2004: 2126).  The combination of benzoyl peroxide with an allylamine antifungal 
may be more beneficial than benzoyl peroxide alone for acne vulgaris, and further 
testing is warranted.  It may be prudent to avoid antibiotics for milder forms of acne 
and for maintenance therapy to limit development of resistance, for which the 
combination of benzoyl peroxide with an allylamine antifungal might be useful.  
(Burkhart & Burkhart, 2007: 92.)   
 
Fixed-combination products containing benzoyl peroxide and either clindamycin (not 
available in South Africa) or erythromycin are more effective for acne than their 
individual components alone.  Such combinations are not associated with the 
development of antibacterial-resistant bacteria.  (Akhavan & Bershad, 2003: 482; 
Feldman et al., 2004: 2126.)   
 
Benzoyl peroxide can be used as monotherapy in mild acne, in combination with 
topical retinoids in severe comedonal and early inflammatory acne, and as an anti-
resistance agent in combination with systemic antibiotics.  It should be used in 
patients with mild to moderate acne.  (Acne Guideline 2005 update, 2005: 887.)  
Marks (2004: 461) suggested that benzoyl peroxide is the best choice of topical 
treatment for acne in patients older than 35 years.   
 
Benzoyl peroxide is available in different strengths and formulations.  It is available as 
2.5%, five percent or 10% gels and creams, and as lotions, masks and cleansers.  
(Acne Guideline 2005 update, 2005: 887; Akhavan & Bershad, 2003: 482.)  Liao 
(2003: 45) reported two small trials that were conducted in 1986, involving 153 
patients with mild to moderate acne, in which the efficacy of the different 
concentrations of topical benzoyl peroxide were compared.  These trials showed no 
differences in efficacy among the various preparations.  Erythema and scaling 
occurred with almost identical frequency with the 2.5% and five percent 
concentrations, but more often with the 10% concentration.   
 
Benzoyl peroxide should be applied once or twice daily to the entire affected area.  
When a person has a sensitive skin, or when the patient is very young or anxious, a 
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lower strength (5%) benzoyl peroxide should be used.  Higher concentrations (10%) 
should be used for the torso area and the shoulders.   (Acne Guideline 2005 update, 
2005: 887.)   
 
No serious side effects have been reported with topical benzoyl peroxide use.  
Common side effects of benzoyl peroxide include erythema, skin dryness, contact 
dermatitis and peeling.  It can also bleach the skin or hair.  (Oprica, et al., 2002: 244.)  
Patients should avoid other potential sources of skin irritation, such as UV radiation 
and other topical acne medications except those recommended by the doctor. 
Benzoyl peroxide can inactivate tretinoin when both are used simultaneously.  The 
newer retinoids adapalene and tazarotene, however, are stable in the presence of 
benzoyl peroxide.  The safety of benzoyl peroxide has not yet been established in 
patients younger than 12 years, in pregnancy and in breastfeeding women.  However, 
the non-prescription status of benzoyl peroxide makes such use inevitable.  (Akhavan 
& Bershad, 2003: 476, 482.)   
 
2.2.3.3  Topical antibiotics 
 
Antibiotics, especially topical antibiotics, are largely abused in the management of 
acne and many of the problems experienced with the use of antibiotics are due to the 
inappropriate use of topical preparations.  (Acne Guideline 2005 update, 2005: 885.)  
Erythromycin and clindamycin are the antibiotics available in topical formulation for 
acne treatment in South Africa.  These two are equally effective.  The surface free 
fatty acids are reduced by 40% to 50% by these agents, even though the number of P. 
acnes organisms on the surface is not greatly decreased.  A clinically significant 
reduction in comedones (likely to be an indirect effect of antibiotic therapy) has been 
observed.  (Presbury & Weiss, 2000.)  Liao (2003: 46) reported that several large 
randomised controlled trials (for example by Becker, Bergstresser, Whiting, 
Clendenning, Dobson, Jordan, Abell, LeZotta, Pochi, Shupack, Sigafoes, Stoughton & 
Voorhees, 1981) demonstrated that topical clindamycin one percent and topical 
erythromycin two percent applied twice daily were consistently superior to placebo in 
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reducing the number of papules and pustules in patients with moderate to severe 
acne.   
 
• Clindamycin 
 
Topical clindamycin is available as a one percent lotion or solution in South Africa, 
although gels and solutions are also available in other parts of the world.    These are 
typically applied to affected areas once or twice daily.  In an eight-week, multicenter, 
placebo-controlled trial (Becker, et al., 1981), topical clindamycin was found to 
produce statistically significant improvements in acne.  Although not available in South 
Africa, fixed combination clindamycin and benzoyl peroxide was significantly more 
effective in treating moderate acne than either of the two agents applied separately, 
and fixed combination clindamycin and tretinoin has been shown to reduce acne to a 
greater extent and produce more rapid response than either agent used separately.   
 
Erythema and dry skin are the most prevalent side effects reported with topical 
clindamycin products.  Topical use is associated with diarrhoea and is contraindicated 
in patients with a history of regional enteritis, ulcerative colitis or antibacterial-
associated colitis.  There are no clinical reports of side effects in infants whose 
mothers were breastfeeding while using topical clindamycin.  (Akhavan & Bershad, 
2003: 483.)   
 
• Erythromycin 
 
Topical erythromycin is available in South Africa as swabs and as two percent 
solutions.  A fixed combination gel of erythromycin 30 mg and benzoyl peroxide five 
percent are also available in South Africa (Benzamycine®), as well as a fixed 
combination of erythromycin 40 mg and zinc acetate 1.2% in the form of a lotion 
(Zineryt®).  (South African Medicines Formulary, 2003: 198.)  The mechanism by 
which zinc exerts its effects against acne is not fully understood.  It is known, however, 
that zinc salts exert an anti-inflammatory effect by inhibiting chemotaxis in acne 
patients.  It also modulates inflammatory cytokines.  It has been suggested that the 
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combination of erythromycin and zinc exerts a direct bactericidal effect, as indicated 
by a decrease in P. acnes counts when the efficacy of the combination is compared 
with a vehicle only.  This bactericidal effect was also accompanied by a significant 
decrease in the skin’s free fatty acid concentration.  (Tan H, 2004: 81.)  In other parts 
of the world, topical erythromycin is also available as gels and ointments.  It is usually 
applied twice daily following washing and drying of skin (Akhavan & Bershad, 2003: 
484).   
 
Akhavan and Bershad (2003: 484) reported several previous studies conducted where 
erythromycin efficacy was researched.  They reported a study where it was proven 
that both gel and solution forms of two percent erythromycin were superior to placebo 
in controlled trials (Jones & Crumley, 1981) of populations exceeding 150 patients.  
They also reported a study (Eady, Bojar, Jones, Cove, Holland & Cunliffe, 1996), 
where the addition of five percent benzoyl peroxide to three percent erythromycin gel 
had a greater effect than erythromycin alone in patients where resistant strains of 
cutaneous bacteria was present in acne patients.  Another study (Leyden, Hickman & 
Jarratt, 2001) proved that the combination of three percent erythromycin and five 
percent benzoyl peroxide were equal in efficacy to the topical combination of one 
percent clindamycin and five percent benzoyl peroxide.  Both combinations were more 
efficacious than five percent benzoyl peroxide alone for acne.   
 
Occasional burning, peeling, erythema, pruritus and dryness are the side effects most 
frequently associated with topical erythromycin use.  Due to erythromycin’s low 
systemic absorption, no systemic reactions have been reported.  Topical erythromycin 
should only be considered during pregnancy if the potential benefits outweigh the 
risks.  It is not known whether topical erythromycin is excreted in breast milk, and 
caution is advised.  (Akhavan & Bershad, 2003: 484.)   
 
To prevent the development of resistance, topical antibiotics should be combined with 
topical non-antibiotic antimicrobials like benzoyl peroxide.  Anti-resistance agents that 
can be used include benzoyl peroxide, zinc acetate and oral isotretinoin.  (Acne 
Guideline 2005 update, 2005: 886.)  As mentioned previously, erythromycin is 
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frequently combined with benzoyl peroxide.  Although this formulation is relatively 
unstable, it will remain stable for up to three months when refrigerated after fresh 
preparation.  (Acne Management Guideline, 1999: 1029; Presbury & Weiss, 2000.) 
 
2.2.3.4  Topical retinoids 
 
The different topical retinoids available for the treatment of acne include tretinoin, 
adapalene, isotretinoin and tazarotene.  Other common skin disorders, such as 
photoaging and psoriasis, can also be treated by retinoids.  Less familiar retinoids are 
alitretinoin (for the treatment of Kaposi’s sarcoma), and bexarotene (for cutaneous T-
cell lymphoma).  (Akhavan & Bershad, 2003: 477.)  The target of topical retinoids is 
the microcomedo (a non-inflamed lesion), thereby making the environment less 
favourable for the development of inflamed lesions (Oprica, et al., 2002: 244).  Topical 
retinoids have significant anti-inflammatory effects, which are not only useful in 
treating inflammatory acne, but also play a role in treating the inflammatory 
microcomedo.  They can therefore be used with success in inflammatory acne right 
from the start of treatment.  They are also useful in maintenance therapy where long-
term use can prevent formation of new lesions and suppress the development of 
inflammatory microcomedones.  Topical retinoids also effectively promote normal 
desquamation of follicular epithelium and enhance penetration of other medications.   
(Acne Guideline 2005 update, 2005: 887; Feldman et al., 2004: 2125; Chivot, 2005: 
14; Shalita, 2001: 44.)  They are the strongest available comedolytic agents (Chivot, 
2005: 16), and also reduce the size of the sebaceous gland and decrease sebum 
production (Akhavan & Bershad, 2003: 477; Shalita, 2001: 44).   
 
In an analysis of the USA National Practice Data by Balkrishnan, Fleischer, Paruthi 
and Feldman (2003: 176), it was found that topical retinoids were underutilised in the 
management of acne relative to many published treatment guidelines and clinical 
evidence summaries.  The researchers found that although the prescription of topical 
retinoids was growing amongst dermatologists, there was greater underutilisation by 
non-dermatologists.  The key factor to the underutilisation might have been the 
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tendency of the prescribers to reserve topical retinoids for patients with comedonal 
acne and not for patients with inflammatory acne.  (Balkrishnan, et al., 2003: 176.)   
 
All retinoids used to treat acne have similar efficacy (Acne Guideline 2005 update, 
2005: 887).  Their most significant limitations are local skin irritation, gradual clinical 
improvement, and acne exacerbation (“retinoid flare”), which occurs during the first 
month of treatment and may persist for several weeks.  (Chivot, 2005: 16.)  Mild, 
retinoid-associated irritation may adversely affect patient compliance, and is the main 
reason for discontinuation of treatment.  Of the four preparations, adapalene causes 
the least irritation upon application.  (Czernielewski, Michel, Bouclier, Baker & Hensby, 
2001: 5, 11.)  Marks (2004: 461) found that, although older skin seems more resistant 
to the irritant effects of benzoyl peroxide than more youthful skin, older skin seems to 
be more sensitive to topical retinoids.   
 
Topical retinoids should be applied to the whole affected area and not only to visible 
lesions, because their main action, in addition to the therapeutic effect on visible 
lesions, is preventative.  It should be the primary form of treatment for most forms of 
acne vulgaris and it should be used early in acne development for the best results.  An 
antimicrobial agent may be added when inflammatory lesions are present.  (Acne 
Guideline 2005 update, 2005: 887.) 
 
• Tretinoin 
 
Tretinoin was the first retinoid to be used (Chivot, 2005: 14) and is a naturally 
occurring form of vitamin A.  Typical formulations of topical tretinoin for use in acne 
include 0.025%, 0.05% and 0.1% creams and gels.  It can also be formulated in 
vehicles designed to reduce the rate of drug release, increase drug retention in the 
stratum corneum and inhibit deeper penetration.  (Akhavan & Bershad, 2003: 447.)  In 
South Africa, topical tretinoin preparations include 0.05% creams and gels and a 
0.025% gel (South African Medicines Formulary, 2003: 199).   
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It has been the treatment of choice for comedones.  (Acne Management Guideline, 
1999: 1029.)  It should be applied once daily, at bedtime (Akhavan & Bershad, 2003: 
477), as it is inactivated by UV light (Feldman et al., 2004: 2126).  Tretinoin is one of 
the most effective therapies currently available for treatment of acne.  The initial 
response to medication may be seen at two to three weeks, but improvement is 
usually gradual.  (Akhavan & Bershad, 2003: 477.)  Feldman and his associates 
(2004: 2125) stated that visible improvement can be observed after eight to 12 weeks 
of treatment.  Most patients need two to four months to achieve notable success.  
Long-term adherence until spontaneous remission is necessary, because topical 
therapy controls rather than cures acne.  (Akhavan & Bershad, 2003: 477.)   
 
Tretinoin may be irritant and not always well tolerated.  It may cause an increased 
sensitivity to sunlight, although it does not increase the risk of skin cancer.  (Acne 
Management Guideline, 1999: 1029.)  Tretinoin should be avoided in pregnancy and 
should not be used in patients younger than 12 years (Akhavan & Bershad, 2003: 
478, 479; Feldman et al., 2004: 2126).   
 
• Isotretinoin 
 
Topical isotretinoin is available for acne treatment and tolerated relatively well (Acne 
Management Guideline, 1999: 1029).  Isotretinoin is a natural isomer of vitamin A 
found in the body in small amounts (Akhavan & Bershad, 2003: 479).  A gel 
formulation containing 0.05% isotretinoin is available in South Africa that can be 
applied twice daily (South African Medicines Formulary, 2003: 199).   
 
In a double-blind study conducted in 1987 of 268 patients, as reported by Akhavan 
and Bersham (2003: 479 – 480), topical isotretinoin 0.05% gel was reported effective 
in the treatment of mild to moderate acne when applied twice daily for 14 weeks.  
Inflammatory and non-inflammatory lesions were reduced.  Side effects are similar to 
those of topical tretinoin.  Topical isotretinoin has not been implicated in causing 
systemic toxicity, but should be avoided in pregnancy.  It should be used with extreme 
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caution in women of childbearing potential.  It is also contraindicated in lactation.  
(Akhavan & Bersham, 2003: 479 – 480.)   
 
• Adapalene 
 
Adapalene is a naphthoic acid derivative with retinoid-like activity (Liao, 2003: 45).  It 
is available as a 0.1% gel in South Africa (South African Medicines Formulary, 2003: 
199) and should be applied thinly every night to acne-prone skin.  In a study of 268 
patients with facial acne vulgaris receiving either adapalene 0.1% gel or tretinoin 
0.025% gel for 12 weeks, adapalene appeared to be as effective as tretinoin.  
(Akhavan & Bershad, 2003: 480 – 481; Feldman et al., 2004: 2126.)  Cunliffe (2000: 
S14) found that adapalene can be co-prescribed with virtually any other oral or topical 
therapy, with the exception of oral isotretinoin.   
 
Large, multicenter clinical trials in the USA and Europe (Cunliffe, Caputo, Dreno, 
Förström, Heenen, Orfanos, Privat, Robledo Aguilar, Meynadier, Alirezai, Jablonska, 
Shalita, Weiss, Chalker, Ellis, Greenspan, Katz, Kantor, Millikan, Swinehart, Swinyer, 
Whitmore, Czernielewski & Verschoore, 1997) indicated a greater reduction of 
inflammatory, non-inflammatory and total acne lesions in patients treated with 
adapalene compared with the patients treated with tretinoin.  In both studies, patients 
who used adapalene experienced less burning, scaling, erythema and dryness than 
those on tretinoin.  (Akhavan & Bershad, 2003: 480 – 481.)  This can therefore 
indicate that adapalene is both safer and more effective than tretinoin.   
 
Another study (Ioannides, Rigopoulos & Katsambas, 2002: 525 – 527) in which the 
effectiveness and safety of adapalene 0.1% gel and isotretinoin 0.05% gel were 
compared, it was found that adapalene produced greater reductions in non-
inflammatory and inflammatory lesion counts than isotretinoin gel during the 12-week 
period of once-daily application.  However, the differences in reduction between 
treatments were insignificant at the end of the study.  Adapalene gel was significantly 
better tolerated than isotretinoin gel during the whole treatment period.  The 
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researchers stated that adapalene may begin a new era of treatment with low-irritant 
retinoids.  (Ioannides, et al., 2002: 525 – 527.)   
 
With adapalene, the side effects common to all topical retinoids are pronounced in the 
first month of therapy and decrease thereafter.  Exposure to sunlight and other 
irritating topical agents should be avoided.  The use of adapalene is generally avoided 
during pregnancy and lactation.  (Akhavan & Bershad, 2003: 480 – 481.)  
 
• Tazarotene 
 
Tazarotene was first introduced to the world in 1997 (Akhavan & Bershad, 2003: 481).  
It is available in South Africa as Zorak® in a 0.05% or 0.1% gel formulation (South 
African Medicines Formulary, 2003: 183).  Only the 0.1% formulation is approved for 
acne treatment.  Tazarotene is also used for treatment of plaque psoriasis and 
photoaging.  It should be applied nightly.  (Akhavan & Bershad, 2003: 481.)  Akhavan 
and Bershad (2003, 481 - 482) reported that in a multicenter, double-blind, 
randomised study of 375 patients with acne conducted in 2001, 0.1% tazarotene gel 
was found to be effective for acne and reasonably well tolerated by most patients.  In 
another study conducted in 2002, as reported by Akhavan and Bershad (2003: 481 - 
482) where 0.1% tazarotene gel was compared to 0.025% tretinoin gel, tazarotene 
was found to be the more effective agent in reducing non-inflammatory lesions and 
equally as effective as tretinoin in treating inflammatory lesions.  Its use currently is 
more as an alternative to tretinoin and adapalene in refractory cases (Akhavan & 
Bershad, 2003: 481).  Tazarotene is the most irritating of the topical retinoids 
(Feldman et al., 2004: 2126), with local skin irritation reported in about half of patients 
applying it for only two to 10 minutes daily.  Due to the risk of sunburn, UV protection 
is recommended with the use of tazarotene.  Safety in patients younger than 12 years 
has not been established.  The use of tazarotene is prohibited during pregnancy and 
in sexually active patients without reliable contraception.  (Akhavan & Bershad, 2003: 
481 – 482.)   
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2.2.3.5  Other topical anti-acne agents 
 
Agents that are discussed in this section include salicylic acid, sulfur and sodium 
sulfacetamide.  These agents are generally not considered first-line therapies, but 
they may be used in patients who cannot tolerate other topical agents (Feldman et al., 
2004: 2127).   
 
• Salicylic acid 
 
Salicylic acid is a topical keratolytic agent (Akhavan & Bershad, 2003: 485).  It has 
mild anti-inflammatory and comedolytic effects (Liao, 2003: 44).  It is a component of a 
wide variety of over-the-counter acne remedies.  It is commonly found in acne 
cleansers and is approved for use in paediatric acne.  (Akhavan & Bershad, 2003: 
485.)  It can be used as initial therapy for mild acne or as an adjunctive agent in a 
broader therapeutic regimen.  A two percent solution has been demonstrated to 
significantly improve acne.  (Liao, 2003: 44.)  At concentrations of two percent or 
higher, salicylic acid can cause a degree of local skin peeling and discomfort.  If it is 
used for prolonged periods over large areas of the body, side effects resulting from 
systemic exposure may occur, for example salicylate toxicity, toxic inner ear damage 
and hypersensitivity.  Salicylic acid should be avoided in pregnancy due to its known 
induction of malformations in rat embryos.  Salicylates should also be avoided for at 
least six weeks after recovery from chickenpox or receiving the varicella vaccine, as 
concurrent use may induce Reye’s syndrome.  (Akhavan & Bershad, 2003: 485.)   
 
• Sulfur 
 
Sulfur is a mild keratolytic and bacteriostatic agent.  Topical sulfur is available as 
lotions, creams, soaps and ointments.  It has been used for many years in the 
treatment of acne in concentrations ranging from one percent to 10%.  It is more 
effective in combination with other active ingredients, for example benzoyl peroxide or 
sodium sulfacetamide.  It may also be combined with resorcinol or salicylic acid.  It 
may be applied to acne-prone areas three times per day for several days, decreasing 
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the frequency of application as symptoms improve.  The main side effects of sulfur 
administration to the skin are dryness and bad odour of the skin.  The use of sulfur in 
pregnancy should be reserved for cases where the benefits outweigh the potential 
harm to the fetus.  (Akhavan & Bershad, 2003: 485 – 486.)  Lotions containing two to 
six percent sulfur may be useful in treating acne in elderly patients (Marks, 2004: 461).   
 
• Sodium sulfacetamide 
 
Sodium sulfacetamide is a bacteriostatic antibacterial.  It may be combined in the 
concentration of 10% with five percent sulfur, and is found in this combination in 
topical acne suspensions, lotions and creams.  This combination is synergistic in 
nature.  Side effects are local itching, erythema and discomfort.  This topical agent is 
contraindicated in any patients sensitive to sulfonamides.  Sodium sulfacetamide 
should best be avoided in pregnancy.  (Akhavan & Bershad, 2003: 486.) 
 
2.2.4 SYSTEMIC ACNE TREATMENT AGENTS 
 
2.2.4.1  Hormonal regimens 
 
Oral contraceptives may be useful for treatment of all types of acne in females and 
adolescent girls.  Sebum production is controlled by androgens, and oral 
contraceptives are known to decrease androgen levels by increasing sex-hormone-
binding globulin levels, thus reducing the availability of free testosterone.  Two to four 
months of therapy may be required before improvement becomes apparent, and 
relapses are common if medication is discontinued.  (Johnson & Nunley, 2000: 1826.)   
 
Hormone therapy is indicated in the Acne Guideline 2005 update (Acne Guideline 
2005 update, 2005: 888 – 889) for early use in females with moderate to severe acne 
who also show signs of androgen overactivity.  These signs include seborrhoea, 
hirsutism and androgenic alopecia.  It may also be prescribed to females with normal 
serum androgens, if these females present with persistent inflammatory papules or 
nodules on the lower face.  Hormone therapy is useful in combination treatment, in 
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women with late-onset acne and in females with prominent premenstrual acne flares.  
Hormone therapy in combination with a topical retinoid is an acceptable treatment 
option, and can bring about a much quicker response than hormonal treatment alone.  
(Acne Guideline 2005 update, 2005: 888 – 889.)   
 
Adult females who present with acne in addition to hirsutism, alopecia or menstrual 
disturbances should be examined for the possibility of ovarian or adrenal 
hyperandrogenism or polycystic ovarian syndrome.  Although not labeled by the Food 
and Drug Administration (FDA) for treatment of acne, spironolactone (with anti-
androgenic properties), at doses of 100 mg to 200 mg daily, has been shown to be 
effective in treating acne vulgaris in most females and adolescent girls.  (Johnson & 
Nunley, 2000: 1826 – 1827.)  Improvement of acne with the use of spironolactone has 
been reported to be between 35% and 100% (Woodard, 2002).  Side effects of 
spironolactone include menstrual irregularities, breast tenderness and fatigue.  
Hyperkalaemia may also present.  (Johnson & Nunley, 2000: 1826 – 1827.)  The use 
of spironolactone is also mentioned as a possible treatment option in the South 
African 2005 Acne Treatment Guideline (Acne Guideline 2005 update, 2005: 889).   
 
All oral contraceptive formulations, especially those with third-generation progestins, 
may improve acne (Acne Guideline 2005 update, 2005: 889; Seibert, Barbouche, 
Fagan, Myint, Wetterneck & Wittemyer, 2003: 57).  Norgestimate and desogestrel are 
members of a less androgenic new generation of progestins.  They may be more 
effective for acne than older types of progestins.  (Woodard, 2002.)  Drospirenone is 
also an acceptable hormonal therapy option in South Africa (Acne Guideline 2005 
update, 2005: 889).  Predominantly progestogenic pills containing levonorgestrel and 
norethisterone may aggravate acne as they have androgenic side effects (Weiss, 
1997: 15).  It should be noted that acne may worsen in five percent of oral 
contraceptive users (Seibert, et al., 2003: 57).   
 
For more severe forms of acne, anti-androgens must be used (Acne Guideline 2005 
update, 2005: 889).  The anti-androgen cyproterone acetate (2 mg) combined with 
ethinylestradiol 35 mcg is the most effective available combined oral contraceptive for 
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acne treatment in females (Acne Guideline 2005 update, 2005: 889; Acne 
Management Guideline, 1999: 1031).  Cyproterone acetate may be taken at a dosage 
of 2 mg added to ethinylestradiol (as in the combination as explained above), or in a 
dosage of 10 mg taken for 15 days per cycle, added to a separate oral contraceptive 
for more severe cases (Acne Guideline 2005 update, 2005: 889).  When cyproterone 
acetate is taken on its own, it may cause an irregular menstrual cycle.  Thus, the 
combination with oestrogen (as mentioned above) or with an oral contraceptive may 
prove to be optimal.  The combination of 2 mg cyproterone acetate and 35 mcg 
ethinylestradiol is equally effective as a birth control measure as other contraceptive 
medications, although the effect on acne may take three to four cycles before 
becoming apparent.  (Acne Management Guideline, 1999: 1031.)  Sebum production 
may decrease by up to 40% by the third month of oral contraceptive use (Woodard, 
2002).   
 
Side effects of the combination of an oestrogen with cyproterone acetate may include 
weight gain, melasma, migraine and depression.  The weight gain may be up to five 
percent of the patient’s normal weight, but is usually lost again after three months of 
treatment.  (Acne Management Guideline, 1999: 1031.)  Many females and health 
care providers believe that oral contraceptives are associated with substantial risks, 
especially in females older than 35 years of age.  This may be why only four percent 
of women in this age category use combined oral contraceptives.  (Seibert, et al., 
2003: 54.)  It is estimated that women older than 40 years make more than 700 000 
visits per year to doctors for acne (Seibert, et al., 2003: 54 – 57).   
 
Side effects that may arise from oral contraceptive use include increased risk of 
venous thromboembolism, myocardial infarction, ischaemic stroke and symptomatic 
gallstone disease.  These risks are higher in females aged over 35 years of age and in 
females who smoke.  In a European study of the WHO, females who used oral 
contraceptives containing less than 50 mcg oestrogen, including those who were older 
than 35 years of age, showed no increased risk for ischaemic stroke as long as their 
blood pressure was checked before they began taking oral contraceptives.  However, 
in females who smoked more than 10 cigarettes per day, the risk for stroke increased 
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seven times.  The increase was almost 10 times in females who reported a history of 
hypertension.  The risk of breast cancer remains controversial.  (Seibert, et al., 2003: 
54 – 57.)   
 
The use of cyproterone acetate in topical forms has also been studied.  Iraji, Momeni, 
Haji and Siadat (2006: 26) reported a study conducted by Gruber, Sator, Joura, 
Kokoschka, Heinze and Huber (1998:  459 - 463), where 40 patients were evaluated 
for the efficacy of cyproterone acetate in the liposomal form.  All patients were female 
and received liposomal cyproterone acetate, placebo or oral cyproterone acetate.  
Treatment lasted for three months.  It was concluded that topical cyproterone acetate 
was equally effective as oral cyproterone acetate and was at least 40% more effective 
than placebo for the treatment of acne vulgaris.  The serum level of topical 
cyproterone acetate was 10% of the serum level of systemic cyproterone acetate.  
The preparation of cyproterone acetate in the liposome form is expensive and 
complicated.  (Gruber, et al., 1998: 463.)  Iraji and associates (2006: 26) then 
conducted a study using an alcoholic formulation of cyproterone acetate.  Once again, 
effectiveness of the topical cyproterone acetate was 40% to 50% more effective than 
placebo.  Cyproterone acetate in topical formulation is not yet available, but the use in 
treatment of mild to moderate acne in female patients, and as an adjuvant in treatment 
of moderate to severe acne is currently recommended and investigated.  (Iraji, et 
al.,2006: 26.)   
 
2.2.4.2  Systemic antibiotics 
 
Antibiotic therapy is the most frequently used type of therapy in the treatment of acne.  
Systemic antibiotics are more effective than topical antibiotics.  (Acne Guideline 2005 
update, 2005: 885.)  Systemic antibiotics work by producing antibacterial, anti-
inflammatory and immunomodulatory actions.  These agents can inhibit bacterial 
lipases and reduce the production of free fatty acids.  Effective antibacterial therapy 
can reduce the P.acnes population by 90%.  (Tan, 2003: 308 – 309.)  The therapeutic 
effect of systemic antibiotics takes several weeks to become evident and improvement 
progresses as treatment continues.  According to Tan (2003: 308 – 309), systemic 
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antibiotics are indicated for moderate to severe inflammatory acne, as well as for 
truncal acne.  It is also indicated for patients with acne that has failed to respond to 
topical antibiotic therapy; and those who have a potential for scarring and pigmentary 
changes, as well as for patients who are considered to have a serious condition due to 
psychological or social reasons.  (Tan, 2003: 308 – 309.) 
 
Widespread use of antibiotics has led to the emergence of resistance and therapeutic 
failure (Acne Guideline 2005 update, 2005: 885 – 886; Oprica, et al., 2002: 244).  
Therapeutic failure can also be caused by incorrect use of the medicine, when an 
inadequate dose is prescribed, due to poor compliance and due to folliculitis caused 
by other bacteria.  Resistance to antibiotics has increased over the past 25 years.  
(Acne Guideline 2005 update, 2005: 885.)   
 
Resistant bacteria can be transferred to close contacts as well as to and from doctors, 
with dermatologists being at particular risk.  The edge of a topically treated area will 
always have a zone where the concentration of antibiotic will be suboptimal, 
encouraging the growth of resistant bacteria.  Resistance may be prevented by 
avoiding the unnecessary use of antibiotics.  (They are only indicated for acne Grades 
2 to 4).  Further, antibiotics should be used in combination treatment and never as 
monotherapy.  The minimum duration of treatment should be six weeks and the 
maximum duration should be 12 weeks (three months).  An additional month of 
therapy can be considered if there has been a steady improvement over the previous 
three months even though total clearance has not yet been achieved.  The use of high 
doses is encouraged for the full duration of treatment in order to increase efficiency 
and to reduce the emergence of resistance.  Strict patient compliance is necessary.  
(Acne Guideline 2005 update, 2005: 885 – 886.)   
 
Antibiotics used for acne treatment include oxytetracycline, tetracycline hydrochloride, 
minocycline, doxycycline, lymecycline, erythromycin, sulfamethoxazole combined with 
trimethoprim (known as cotrimoxazole) and trimethoprim.  (Acne Management 
Guideline, 1999: 1031.)  
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• Overview of tetracycline derivatives 
 
The newer tetracycline derivatives (minocycline, lymecycline and doxycycline) should 
be considered as a first choice when treating acne.  The effectiveness of tetracycline 
and oxytetracycline in the treatment of acne cannot compare with that of the more 
modern medicines and they are no longer significantly more cost-effective, giving 
them poor cost-effectiveness ratios.  (Acne Guideline 2005 update, 2005: 885).   
 
All tetracycline derivatives are contraindicated in patients who use retinoids, as the 
concomitant use of these agents may cause an increased risk of increased 
intracranial pressure.  Tetracyclines may also decrease the effectiveness of oral 
contraceptives, and additional contraceptive measures are advisable during a 
treatment course of a tetracycline antibiotic.  (South African Medicines Formulary, 
2003: 273; Johnson & Nunley, 2000: 1825.)   
 
• Tetracycline and Oxytetracycline 
 
Oxytetracycline and tetracycline were the traditional treatments of choice for acne, but 
resistant strains of P. acnes have made them less effective.  A clinical response can 
be expected during the second month of therapy with either of these two agents.  
(Acne Management Guideline, 1999: 1031.)  Tetracycline and oxytetracycline should 
be considered as third choice systemic antibiotics in the treatment of acne.  The 
optimal dose of oxytetracycline is one gram per day (Acne Guideline 2005 update, 
2005: 886) and the optimal dose of tetracycline in acne treatment is 500 mg daily 
(Tan, 2003: 309).   
 
Tetracycline must be taken on an empty stomach, as absorption is affected by the 
presence of food and diary products (Tan, 2003: 309) such as milk and iron 
supplements (Feldman et al., 2004: 2127).  The most common side effect of 
tetracycline is gastrointestinal disturbances.  Diarrhoea, vomiting and dyspepsia are 
common, and oesophagitis and oesophageal ulceration can also occur on rare 
occasions.  Vaginal candidiasis may present in females due to the changes that 
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tetracycline can induce in the mucocutaneous bacterial flora.  Tetracycline may also 
cause skin reactions (including Stevens-Johnson syndrome and acneiform eruptions), 
and can cause hypersensitivity reactions and serum sickness-like reactions.  Benign 
intracranial hypertension is characterised by dizziness, lethargy, headache, nausea, 
vomiting, photophobia, diplopia and papilloedema.  (Tan, 2003: 309.)   
 
Tetracyclines can chelate with calcium orthophosphate and become deposited in teeth 
and bones.  This produces permanent yellow-brownish staining of teeth in children if a 
mother takes it during the last half of pregnancy.  This staining may persist up to eight 
years of age and the use of tetracycline should be avoided until this age.  The South 
African Medicines Formulary (2003: 273) states that tetracyclines should preferably be 
avoided in all patients younger than 12 years of age.   
 
Other birth defects have also been reported with the use of tetracyclines while 
pregnant.  A review of 1 944 cases in which tetracyclines were taken during 
pregnancy identified birth defects in 61 infants that may be related to this medicine.  
There have also been reports of hepatotoxicity of pregnancy with tetracycline.  
(DeSimone & Miller, 2001: 81.)  It should therefore also not be used by breastfeeding 
mothers (South African Medicines Formulary, 2003: 272 – 273).   
 
• Doxycycline 
 
Doxycycline absorption is not affected by the presence of food and it can be taken 
with meals.  It is the most likely of the tetracycline derivatives to cause photosensitivity 
(Acne Guideline 2005 update, 2005: 886; Johnson & Nunley, 2000: 1825), and should 
preferably be avoided in the summer months.  Doxycycline can cause acute 
exanthematous pustulosis, which resolves when medication is stopped.  
Gastrointestinal side effects can also occur with doxycycline use, and a large glass of 
water should be taken with the medication to minimise the occurrence of dyspepsia.  
(Tan, 2003: 309 – 310.)   
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Doxycycline is slightly less expensive than minocycline or lymecycline in South Africa, 
although there is very little difference between the prices of these three medicines.  
Doxycycline or minocycline can be considered as second choice systemic antibiotics 
in the management of acne, while lymecycline is the first choice systemic antibiotic.  
The optimal dose for doxycycline is 100 mg to 200 mg per day.  (Acne Guideline 2005 
update, 2005: 886.)   
 
Doxycycline is contraindicated in children younger than eight years and should 
preferably be avoided in children younger than 12 years.  It should also be avoided in 
pregnancy and lactation.  This is due to the fact that, like tetracycline, doxycycline 
deposits in the growing bone and can cause growth retardation.  It also deposits in 
teeth, causing discolouration and occasionally enamel hypoplasia.  (South African 
Medicines Formulary, 2003: 273 – 274.)   
 
• Minocycline 
 
Minocycline is as effective as doxycycline in reducing inflammatory acne lesions.  In 
patients with acne, it has been shown that isolates of P.acnes which are resistant to 
tetracycline show cross-resistance to doxycycline, but remain sensitive to minocycline.  
Photosensitivity induced by minocycline is infrequent, but the use of minocycline has 
been associated with more potentially serious side effects than the use of doxycycline 
(Tan, 2003: 311).  Minocycline is associated with more central nervous system (CNS) 
side effects than other tetracyclines.  Vertigo, dizziness and ataxia may occur, but are 
reversible when the medicine is stopped.  (Tan, 2003: 311.)  Minocycline may be 
associated with a bluish discoloration of the skin (hyperpigmentation), especially in 
inflamed areas (Johnson & Nunley, 2000: 1826; Tan, 2003: 311).  Serum-sickness-
like reactions, drug-induced lupus and hypersensitivity reactions may present (Liao, 
2003: 48).  The existence of minocycline-related autoimmune diseases and 
minocycline-induced liver dysfunction has been established.  (Tan, 2003: 311.)  It is 
recommended that liver function tests and anti-nuclear antibody (ANA) determinations 
need to be done three monthly if a patient is on minocycline for more than three 
months.  The optimal dose for minocycline is 100 mg to 200 mg per day.  (Acne 
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Guideline 2005 update, 2005: 886).  Minocycline, like tetracycline and doxycycline, is 
contraindicated in patients younger than eight years and should preferably be avoided 
in patients younger than 12 years.  It should also be avoided in pregnancy and 
lactation.  (South African Medicines Formulary, 2003: 274.)   
 
• Lymecycline 
 
Lymecycline seems free of many of the side effects of doxycycline and minocycline 
(including phototoxicity, gastrointestinal disturbance, hyperpigmentation, 
hypersensitivity syndromes, serum sickness-like illness and drug-induced lupus), and 
should be considered as a first-choice antibiotic when treating moderate to severe 
inflammatory acne.  The optimal dose for lymecycline is 300 mg to 600 mg per day.  
(Acne Guideline 2005 update, 2005: 886.)  As with the other tetracycline derivatives, it 
should also be avoided in children, pregnancy and nursing women.  (South African 
Medicines Formulary, 2003: 274.)   
 
• Erythromycin 
 
Erythromycin is as effective as tetracycline derivatives in the treatment of inflammatory 
acne, but has been associated with the emergence of resistant strains (Feldman et al., 
2004: 2127; Oprica, et al., 2002: 244).  It has been proven that the topical use of 
clindamycin may also encourage resistance to erythromycin (Oprica, et al., 2002: 244; 
Tan, 2003: 311).  Besides the issue of resistance, one of the main limitations of 
erythromycin therapy is the gastrointestinal adverse effects that it can cause.  
Abdominal pain, vomiting, flatulence and diarrhoea, sometimes to an intolerable 
degree, can occur.  (Johnson & Nunley, 2000: 1826; Tan, 2003: 311.)  Erythromycin 
can be used to treat acne in children under 12 years old or during pregnancy (Acne 
Guideline 2005 update, 2005: 886; South African Medicines Formulary, 2003: 270 – 
271.)   
 
 
 55
• Sulfamethoxazole combined with trimethoprim (cotrimoxazole) and 
trimethoprim alone 
 
Sulfamethoxazole combined with trimethoprim (cotrimoxazole) can be considered as 
an acne treatment option in selected cases of acne patients (Acne Guideline 2005 
update, 2005: 886).  It is also useful to treat gram-negative folliculitis.  The reason for 
the reservation of cotrimoxazole for selected cases in acne treatment is because of 
the potential of serious side effects.  These side effects include Stevens-Johnson 
syndrome, hypersensitivity reactions (such as toxic epidermal necrolysis) and bone-
marrow suppression.  (Tan, 2003: 310 – 312.)  Cotrimoxazole is contraindicated in the 
third trimester of pregnancy and should not be used in children younger than two 
years old (South African Medicines Formulary, 2003: 279 – 280).   
 
Trimethoprim alone can also be useful in treatment of inflammatory acne.  The most 
prevalent side effect of trimethoprim as sole therapy is a drug eruption that usually 
occurs after three weeks of therapy and resolves rapidly when medication is stopped.  
(Tan, 2003: 312.)  It should not be used by pregnant females or by infants younger 
than two months old (South African Medicines Formulary, 2003: 278).   
 
2.2.4.3  Other systemic anti-acne agents 
 
Other systemic agents that are covered in this section include corticosteroids and 
dapsone.   
 
• Systemic corticosteroids 
 
In some cases, systemic corticosteroids are still prescribed in the treatment of acne, 
although it is not mentioned in the South African 2005 Acne Treatment Guideline 
(Acne Guideline 2005 update, 2005: 883 – 892).  However, Cunliffe (2000: S14) found 
it to be effective in patients unresponsive to other treatments with localised nodules, 
inflammatory cysts or sinus tracts.  Cunliffe (2000: S14) recommended the use of a 
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potent steroid such as dexamethasone cream twice daily for seven days.  Oral 
steroids may also be prescribed for patients whose acne flares while on isotretinoin.   
 
• Dapsone 
 
Dapsone, at a dosage of 50 mg to 150 mg per day, can bring about complete 
clearance of nodular inflammatory acne, thus this acne type can be controlled with 
long-term maintenance dapsone treatment.  Low-dose dapsone is relatively safe, 
provided that the patient has a normal glucose-6-phosphate dehydrogenase level and 
that full blood counts are done regularly to detect resulting anaemia.  (Acne Guideline 
2005 update, 2005: 890.)  
 
2.2.5 PHYSICAL ACNE TREATMENTS 
 
Physical treatments for acne discussed in this section include comedone extraction, 
intralesional cortisone, cryotherapy and photodynamic therapy.  
 
2.2.5.1  Comedone extraction 
 
When removed through application of pressure over individual lesions, the resolution 
of comedones may be hastened.  Opening the lesion with the tip of a scalpel blade 
may make removal easier without causing excessive damage.  (Acne Management 
Guideline, 1999: 1031; Presbury & Weiss, 2000.)   
 
2.2.5.2  Intralesional corticosteroids 
 
Intralesional depot steroid administered into a cyst or an inflammatory nodule will 
bring about noticeable improvement within two days.  Drainage, which may also be 
beneficial, can result from piercing the lesion.  (Acne Management Guideline, 1999: 
1031; Presbury & Weiss, 2000.)   
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2.2.5.3  Cryotherapy 
 
Cysts can be treated by applications of liquid nitrogen, lasting two seconds each, 
every two minutes (Acne Management Guideline, 1999: 1031; Presbury & Weiss, 
2000).   
 
2.2.5.4  Photodynamic therapy 
 
Photodynamic therapy is not a first line therapy due to its side effects and the time and 
cost it requires.  It can nevertheless be an effective alternative to isotretinoin and is 
useful for refractory cases.  It combines well with systemic antibiotics and topical 
medications.  (Melville, 2006)  
 
 A study conducted by Omi, Bjerring, Sato, Kawana, Hankins and Honda (2004: 157 – 
158) in which 28 patients were treated with a continuous-wave machine with a central 
spectrum from 410 to 420 nm and a maximum density of 200 mW per cm2, indicated 
that the total number of acne lesions was significantly reduced after irradiation 
compared with the number before the irradiation.  There were no apparent side effects 
experienced by any of the 28 patients.   
 
2.2.6 SUMMARY OF MANAGEMENT OF THE DIFFERENT GRADES OF ACNE 
 
Table 2.2 represents a summary of the management of the different grades of acne 
according to the Acne Guideline 2005 update (2005: 891).  The grades of acne in this 
table are also according to the Acne Guideline 2005 update (2005: 885) as described 
in Section 2.1.7.   
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Table 2.2:  Management of different grades of acne vulgaris 
GRADE MANAGEMENT GUIDELINES 
Grade 1 
Topical management.  A topical retinoid will suffice in most cases, but addition of benzoyl 
peroxide or azelaic acid may be necessary in resistant cases.   
Grade 2 
In milder cases with superficial inflammatory papules:  same treatment as for grade 1 acne.  
Where papules are more deeply situated:  systemic antibiotics are indicated.   
Grade 3 
Systemic antibiotics are necessary.  These should always be used in combination with a 
topical retinoid and, if the systemic treatment needs to go on for longer than three months, 
a topical anti-resistance agent should be added.   
 
Hormonal treatment can be used in female patients who desire contraception or who have 
other gynaecological indications for this treatment.   
Grade 4 
Systemic isotretinoin is the drug of choice.   
 
Oral contraceptives combined with anti-androgens can sometimes be effective in females.   
 
Systemic antibiotics can bring about excellent improvement, but the improvement is of 
short duration and systemic antibiotics do not represent a long-term solution for this type of 
acne and unacceptably long antibiotic courses are usually necessary.   
Table adopted from Acne Guideline 2005 update (2005: 885).   
 
2.3 SYSTEMIC ISOTRETINOIN IN THE MANAGEMENT OF ACNE 
 
2.3.1 INTRODUCTION 
 
In this section, the focus falls specifically on systemic isotretinoin in the management 
of acne.  The background, mechanism of action, indications, contraindications, side 
effects, counselling required and effectiveness of isotretinoin are discussed.   
 
2.3.2 BACKGROUND TO SYSTEMIC ISOTRETINOIN 
 
Systemic isotretinoin represents by far the most effective agent in the treatment of 
acne (Acne Guideline 2005 update, 2005: 889).  It was approved by the FDA in 1982 
for the treatment of severe recalcitrant nodular acne (Ashworth, 2005: 61) and has 
been marketed in the USA since then (Wysowski, Swann & Vega, 2002: 505).  
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According to Roche’s safety database, more than 5.5 million patients were treated 
with isotretinoin between 1990 and 1996 (Alcalay, Landau & Zucker, 2001: 9).  A cost-
minimisation model in South Africa (Wessels, et al., 1999: 791) has shown that where 
systemic isotretinoin is clinically indicated, the sooner the therapy is initiated the more 
cost-effective the outcome will be.  Wessels and associates (1999: 791) stated that if 
isotretinoin is prescribed for moderate to severe acne, the cost of treatment is 
significantly reduced in the long term when compared with standard chronic systemic 
antibiotic therapy.   
 
Isotretinoin seldom fails to clear acne completely and it presents a permanent cure in 
a high percentage of cases.  The cure rates vary from 38% to 66% depending on the 
definition of a cure.  (Acne Guideline 2005 update, 2005: 889.)  It has shown great 
success in acne treatment, and has been confirmed to be the superior drug in the 
treatment of severe, recalcitrant nodulocystic acne unresponsive to or relapsing after 
conventional therapy (Chivot, 2005: 16).  Shalita (2001: 47) described it as the single 
most effective agent for the treatment of acne.  Systemic isotretinoin is the drug of 
choice for severe acne, but the popularity of the use of isotretinoin for less severe 
cases, where other more conservative treatments might have been successful, has 
increased.  It is often prescribed under pressure from patients.  Nevertheless, 
prescribers should adhere to the prescribed indications of this medication.  (Acne 
Guideline 2005 update, 2005: 889.) 
 
Although no one can argue the effectiveness of isotretinoin in acne treatment, the side 
effects (especially the more dangerous side effects like the teratogenicity and the 
possible negative psychological impact) have triggered a continual debate amongst 
the medical society and general public worldwide regarding the use of isotretinoin.  
There are some internet sites for people who strongly disagree with the use of 
isotretinoin, while there are other people and dermatologists who promote the use of 
isotretinoin.  Some dermatologists even avoid prescribing isotretinoin to any woman of 
childbearing age completely.  (Roehr, 2004: 1, 19.)   
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Isotretinoin may also be used to treat other skin disorders, including keratosis 
follicularis, pityriasis rubra pilaris, lamellar ichthyosis, keratosis palmaris et plantaris, 
rosacea, and leukoplakia (Medline Drug Information: Isotretinoin).   
 
2.3.3 PHARMACOKINETICS AND PHARMACODYNAMICS OF ISOTRETINOIN 
 
Isotretinoin is the only acne agent that exerts its effect by interfering with four major 
pathogenic factors involved in acne formation.  It has a comedolytic effect, it 
significantly decreases the formation of sebum and has great direct and indirect anti-
inflammatory potential.  It also indirectly decreases the amount of P. acnes present on 
the skin.  (Chivot, 2005: 16.)  Sebum production is reduced by at least 90% through 
competitive inhibition of retinol dehydrogenase-4, the enzyme that mediates the skin’s 
production of dihydrotestosterone and androstenedione (Ashworth, 2005: 61).   
 
Isotretinoin is highly lipophilic, and its systemic absorption is enhanced when it is 
administered with a high-fat meal.  Both peak plasma concentration and the total 
exposure of isotretinoin more than doubled following administration with a high-fat 
meal versus fasting conditions.  Patients should be advised in this regard.  Even if it is 
not taken with a fatty meal, it should always be taken with meals.  (Ashworth, 2005: 61 
– 62.)   
 
Isotretinoin is more than 99.9% plasma protein bound, primarily to albumin.  At least 
three metabolites have been identified in human plasma following systemic 
administration.  The metabolites and any conjugates of isotretinoin are excreted in the 
faeces and urine in relatively equal amounts.  Isotretinoin is also found in semen of 
male patients following systemic absorption, but the amount delivered to a female 
partner through intercourse is about one million times less than what she would 
receive from a single 40 mg oral dose and is not thought to be teratogenic. (Ashworth, 
2005: 62.)   
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2.3.4 INDICATIONS OF SYSTEMIC ISOTRETINOIN 
 
Systemic isotretinoin is indicated in (Acne Guideline 2005 update, 2005: 890): 
 
• severe nodulocystic acne and its variants; 
• inflammatory acne with scarring; 
• moderate to severe acne unresponsive to treatment with: 
o three months of combination treatment including systemic tetracyclines; 
and/or 
o four cycles of anti-androgen containing hormonal treatment; 
• acne with severe psychological distress (dysmorphophobic patients);  
• gram-negative folliculitis; and/or 
• frequently relapsing acne where repeated or prolonged courses of systemic 
antibiotics are needed.   
 
The dosage taken in a full course of isotretinoin is very important.  The daily dose 
should not be below 0.5 mg/kg per day and should not exceed 1 mg/kg per day, the 
latter in order to limit side effects.  A cumulative dose is the total dose of isotretinoin 
ingested by a patient over the total period of isotretinoin treatment.  The minimum 
cumulative dose that should be taken is 120 mg/kg, and the maximum cumulative 
dose is 150 mg/kg.  The chances for a permanent cure are greatly reduced if 
treatment is discontinued before the threshold of 120 mg/kg has been reached, even if 
the acne has cleared completely before then.  (Acne Guideline 2005 update, 2005: 
890.)  It has also been shown that younger patients who have had acne for a shorter 
length of time, those with truncal acne and females relapse more frequently (Acne 
Management Guideline, 1999: 1031; Ashworth, 2005: 63).   
 
Patients who develop significant or worsening acne before the age of 15 years are at 
risk of developing severe acne, and can be treated with isotretinoin with the 
anticipation of a degree of relapse at a later stage.  (Acne Management Guideline, 
1999: 1031.)  It has been shown that 39% of patients will have a relapse requiring 
systemic antibiotics, hormonal treatment or repeat isotretinoin.  Relapse usually 
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occurs within three years after the end of the original course.  Many patients will 
respond to the second course.  (Isotretinoin (Roaccutane) usage – a South African 
consensus guideline, 1997: 1411.)  The duration of treatment will be determined by 
the daily dose of isotretinoin taken and the body weight of the patient, and is usually 
between four to six months (Acne Guideline 2005 update, 2005: 890).     
 
A pulse-dose regimen, where 0.5 mg/kg is taken daily on the first seven days of each 
month, may also be indicated.  This regimen is usually free from side effects, except 
for the teratogenic effect.  It has shown to be highly effective for patients who relapse 
after a previous full course of isotretinoin, as well as for older patients with chronic, 
resistant acne.  South African dermatologists felt that this regimen should be included 
in the accepted South African Acne Treatment Guidelines.  (Acne Guideline 2005 
update, 2005: 890.)   
 
In young teenagers with very severe comedonal acne, a special set of circumstances 
exist in which low-dosage continuous isotretinoin may be used.  These patients 
respond very poorly to topical comedolytic agents initially, and a four to six month 
course of 10 to 20 mg of isotretinoin per day can lead to prompt clearance of these 
lesions, whereafter maintenance with topical retinoids should be effective.  (Acne 
Guideline 2005 update, 2005: 890.)   
 
2.3.5 SIDE EFFECTS AND ACCOMPANYING COUNSELLING AND MONITORING 
REQUIREMENTS  
 
Systemic isotretinoin can cause numerous side effects, some of which are serious, 
although most of them are not.  Most patients experience the period on this 
medication as very unpleasant, but they endure the side effects because of the 
benefits that become apparent soon after initiation of therapy.  (Acne Guideline 2005 
update, 2005: 889.)  Most of the side effects are predictable and do not interfere with 
the management of the patient (Acne Management Guideline, 1999: 1032).  The most 
significant side effects are discussed in this section.   
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2.3.5.1    Teratogenicity 
 
Teratogenicity is the most serious side effect of isotretinoin (Acne Guideline 2005 
update, 2005: 889).  Approximately 50% of pregnancies abort spontaneously when 
exposed to isotretinoin.  Of the remaining 50%, about half result in births of infants 
with cardiovascular, craniofacial, or skeletal abnormalities, or a cleft palate.  (Acne 
Management Guideline, 1999: 1032; Sadick, 2002: 90.)   
 
Teratogenicity is preventable if the patient adheres to strict contraception for a month 
before the start of treatment, undergoes a negative pregnancy test thereafter and 
starts medication on the third day of her next menstrual period.  Effective 
contraception has to continue for one month after taking the last capsule in the 
course.  Monthly negative pregnancy tests are recommended in South Africa (Acne 
Guideline 2005 update, 2005: 889) but are compulsory in the USA (Jones, 2007).   
 
In South Africa, females should be aware of the risks and should sign consent forms 
before the use of isotretinoin that indicate their understanding of the teratogenic side 
effect and that they understand that a therapeutic abortion would be compulsory if 
pregnancy should occur during treatment.  (Acne Guideline 2005 update, 2005: 889.)  
In the USA, only females who are not pregnant and have committed to using two 
effective forms of birth control during therapy and for one month following isotretinoin 
discontinuation may take isotretinoin (Ashworth, 2005: 63; Jones, 2007).   
 
The Accutane Pregnancy Prevention Program was instituted in 1988 in the USA with 
the stated objective of ensuring that isotretinoin prescriptions are written for female 
patients with severe recalcitrant nodular acne who are able to comply with the 
necessary contraceptive requirements in order to avoid pregnancy during the 
isotretinoin therapy course (Wysowski, et al., 2002: 505).   
 
A more rigid program to pregnancy prevention and monitoring in the USA was 
instituted in 2005, called the iPLEDGE program.  According to this program, both male 
and female users of systemic isotretinoin would have to enrol into the National 
 64
Registry iPLEDGE by 31 December 2005.  If this is not achieved, patients would not 
be able to receive isotretinoin in the USA.  Also, women of childbearing age must 
provide two negative pregnancy tests before initial isotretinoin prescription and must 
show proof of a negative pregnancy test every month before they receive a repeat 
prescription.  The use of two forms of contraception throughout therapy, and for 30 
days after treatment, is compulsory.  They need to enter these contraception forms 
into the registry.  All patients must sign a document confirming that they are aware of 
the potential side effects of isotretinoin, including depression and suicidal thoughts.  
Prescribers and pharmacists also have to sign up in this registry.  (Layton, Dreno, 
Gollnick & Zouboulis, 2006: 773.)  The recommended primary forms of birth control 
include tubal sterilisation, vasectomy, intrauterine devices and combination hormonal 
therapy.  Secondary forms of contraception include condoms, diaphragms, cervical 
caps and vaginal sponges containing spermicide.  According to the iPLEDGE system, 
the female condom and progesterone-only birth control pills are unacceptable forms of 
birth control during the use of systemic isotretinoin.  (Jones, 2007.)   
 
In 2002, Roche Laboratories released the System to Manage Accutane Related 
Teratogenicity (SMART) program, aimed at preventing pregnant women from 
receiving isotretinoin.  In this program, female patients must have screening and 
confirmation pregnancy tests prior to receiving a prescription for isotretinoin.  Patients 
must also commit to using two forms of birth control for at least one month prior to 
initiation of therapy, during therapy, and one month after discontinuing isotretinoin.  A 
pregnancy test must also be done on a monthly basis while the patient is on 
isotretinoin therapy.  (Liao, 2003: 49 – 50.)     
 
In the UK, a Pregnancy Prevention Program was instituted 2001.  This program 
makes it compulsory for all females of childbearing potential to undergo a pregnancy 
test before initiation of isotretinoin, monthly during isotretinoin use and five weeks after 
therapy cessation.  One, but preferably two complementary methods of effective 
contraception (including a barrier method) should be used before and during 
isotretinoin therapy.  (Layton, et al., 2006: 773 – 774.)   
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In South Africa, the manufacturer of Roaccutane®, Roche Products, released a 
Pregnancy Prevention Program to assist prescribing physicians and patients in 
avoiding foetal exposure to isotretinoin.  The program consists of a patient information 
brochure, a brochure on birth control, a female patient information and consent form, a 
physician’s guide to prescription, and a physician’s checklist for prescribing to 
females.  Roche recommends that the pregnancy prevention information should be 
given to patients both verbally and in writing.  A male patient information and consent 
form is also available.  (Roaccutane® Package Insert, 2003.)  The manufacturer of 
Oratane®, Pharmaplan, also provides a patient information leaflet, a female patient 
information leaflet, a female patient consent form and an information guide for the 
prescriber (Oratane® Package Insert, 2003).  Adcock Ingram, the manufacturer of 
Acnetane®, provides a patient information leaflet, a female patient information leaflet, 
an official consent form and a guideline and checklist for prescribers (Acnetane® 
Package Insert, 2004).   
 
A study was conducted in Quebec (Boucher & Beaulac-Baillargeon, 2006: 339 – 343) 
to assess whether prescribers advised females taking isotretinoin according to 
pregnancy prevention recommendations, whether females understood those 
recommendations and whether females complied with the advice.  There were 45 
females included in the study.  Of these females, 35 declared that pharmacists gave 
them verbal information about teratogenicity and pregnancy prevention when they 
filled their isotretinoin prescriptions.  Pharmacists also gave written information, other 
than the package inserts, to 28 women.  Prescribers discussed teratogenic risks with 
42 of the females, gave written information about contraception to two women, 
advised 27 females to use two contraceptive measures and advised 13 females to 
start with contraception one month prior to initiation of isotretinoin therapy.  The 
prescribers also advised nine females to wait for the next menstrual period before 
starting isotretinoin and 12 patients were advised to continue with two contraceptive 
measures for one month after ceasing isotretinoin therapy.   The doctors prescribed 
pregnancy tests to 20 of the females before isotretinoin initiation, prescribed monthly 
pregnancy testing to six of the females and used the consent form for six of the 
females.  (Boucher & Beaulac-Baillargeon, 2006: 338, 340.)  It was shown through 
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this study that compliance with pregnancy prevention regulations were lacking 
amongst the health care providers.   
 
2.3.5.2  Isotretinoin and depression 
 
Depression has been listed as a side effect of isotretinoin on the medication label 
since its release (Ng & Schweitzer, 2003: 78).  The suspected psychiatric side effects 
of isotretinoin therapy received considerable attention from media as well as medical 
quarters in recent years (Ferahbas, Turan, Esel, Utas, Kutlugun & Kilic, 2004: 153).  
Consensus has not been reached on the issue of depression and suicide resulting 
from isotretinoin use.  It has been shown that there is a lower incidence of suicide in 
patients who are on isotretinoin compared with a similar population not exposed to it.  
Caution is advised in patients with a history of depression.  Mood swings should be 
reported to the prescriber and the medication should be discontinued if any symptoms 
of depression occur during treatment.  (Acne Guideline 2005 update, 2005: 889.)   
 
In a previous study (Jick, Kremers & Vasilakis-Scaramozza, 2000: 1231 – 1236), two 
population-based databases were assessed to determine the relative risks of 
psychiatric disorders amongst isotretinoin users, compared with acne patients treated 
with antibiotics.  There were 7 195 isotretinoin users and 13 700 antibiotic users 
included in a Saskatchewan database, while a database in the UK included 340 
isotretinoin users and 676 antibiotic users.  In both cases, the relative risks of neurotic 
behaviours, psychotic disturbance, depression and suicidal behaviour were no 
different for acne patients who took isotretinoin than for those who did not.  (Jick, et 
al., 2000: 1231 – 1236; Kubetin, 2001.)  Ng and Schweitzer (2003: 79) reported that a 
clinical trial conducted in 1990 found spontaneous depression occurring in one 
percent of 700 patients treated with isotretinoin for cystic acne, psoriasis and other 
dermatological disorders.     
 
The FDA has received 431 reports of depression, suicidal tendency, suicidal attempts 
and suicides in patients treated with isotretinoin between 1982 and 2000 in the USA.  
In these reports, there were 37 suicides and 110 patients hospitalised for depression.  
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A past history of psychiatric illness was reported for 22% of the suicide group and 
44% of the depressed group.  (Ng & Schweitzer, 2003: 79; Wooltorton, 2003: 66.)  
Isotretinoin ranked fourth, fifth and 10th in the FDA’s database with the most reports of 
depression, serious depression and suicide attempts, respectively.  Isotretinoin was 
also the only non-psychotropic medication in the top 10 ranked drugs for suicide 
attempts.  (Ng & Schweitzer, 2003: 79; Wooltorton, 2003: 66.)     
 
According to Hull and D’Arcy (2003: 493 – 494), a Medline search between January 
1966 and May 2003 of the published medical literature found 24 documented cases of 
isotretinoin-associated depression, with three suicides.  There was also 
documentation of three patients who attempted suicide by taking an overdose of 
isotretinoin.  (Hull & D’Arcy, 2003: 493 – 494.)  However, several controlled studies 
have not confirmed the association between isotretinoin treatment and these 
psychiatric disorders (Ferahbas, et al., 2004: 154).    
 
In a recent study (O’Reilly, Shumake, Gonzalez-Lima, Lane & Bailey, 2006: 1925), it 
was found that the chronic administration of isotretinoin to young adult male mice 
increased depression related behaviour.  This report was the first to demonstrate that 
isotretinoin administration enhances depression-related behaviour in mice.  (O’Reilly, 
Shumake, Gonzalez-Lima, Lane & Bailey, 2006: 1925.)  Another study (Bremner, 
Fani, Ashraf, Votaw, Brummer, Cummins, Vaccarino, Goodman, Reed, Siddiq & 
Nemeroff, 2005: 983, 987) was conducted to determine the effect of isotretinoin on 
brain functioning in acne patients.  It was found that a four month treatment trial with 
isotretinoin was associated with a decrease in brain functioning in the orbitofrontal 
cortex, a brain region implicated in depression.  The greatest magnitude of decrease 
was observed in subjects who developed symptoms of headache during the course of 
treatment.     
 
Hull and D’Arcy (2003: 494) stated that there is an increase in the prevalence of 
depression amongst adolescents and young adults.  This, together with the fact that 
acne may have a psychological impact on patients, should be taken into account 
when considering the relationship between isotretinoin and depression.  (Hull & 
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D’Arcy, 2003: 494.)  All patients with a history of, or tendency towards, psychological 
illness should be closely monitored while on isotretinoin therapy, and if psychological 
symptoms present or worsen during isotretinoin treatment, the treatment should be 
discontinued immediately.  (Acne Management Guideline, 1999: 1032.)   
 
2.3.5.3  Skeletal abnormalities 
 
Treatment with high doses of isotretinoin over prolonged time periods for diseases of 
cornification has been associated with skeletal abnormalities, including hyperostosis 
calcification of spinal ligaments and osteoporosis.  It has recently been shown that the 
normal four to five month course of isotretinoin does not cause any skeletal 
abnormalities, but there are no data available on patients who were exposed to long-
term low-dosage use of isotretinoin.  This uncertainty, together with the teratogenic 
effect, is the main reason why long-term low-dosage treatment should be discouraged 
at this stage.  (Acne Guideline 2005 update, 2005: 890.)   
 
2.3.5.4  Benign intracranial hypertension (Pseudotumor Cerebri) 
 
At each doctor’s appointment, the patient should be questioned about headaches, as 
nightly or early-morning headaches could indicate raised intracranial pressure.  
Benign intracranial hypertension is an uncommon side effect of isotretinoin, but it can 
be precipitated by the concomitant use of tetracyclines or systemic corticosteroids 
(Acne Guideline 2005 update, 2005: 890).   
 
Friedman stated in an article (2005: 33) that headache was the most common side 
effect from isotretinoin use in a report from the USA Adverse Effects Reporting 
System (AERS) from 1982 to 1985, accounting for 15 of 104 spontaneously reported 
side effects.  Some of these patients were taking isotretinoin and tetracyclines 
simultaneously, suggesting a synergistic action between these two agents.  Friedman 
(2005: 33) also reported that a physician reporting system identified 181 cases of 
intracranial hypertension associated with isotretinoin.  The mean time from exposure 
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to the onset of symptoms was approximately two months and nine days.  (Friedman, 
2005: 33.)   
 
2.3.5.5  Raised lipid levels 
 
Triglyceride levels may become raised during isotretinoin therapy (Acne Guideline 
2005 update, 2005: 890).  Elevated triglycerides, elevated cholesterol and decreased 
high-density lipoproteins (HDL) occur in approximately 25%, seven percent and 15% 
of patients on isotretinoin, respectively (Ashworth, 2005: 65) and rapidly return to pre-
treatment levels after therapy is stopped (Acne Management Guideline, 1999: 1031).   
 
Blood tests to determine baseline triglycerides need to be done before treatment 
starts and should be repeated after one month of treatment.  If the baseline and one 
month values are both normal, further lipid testing is unnecessary.  (Acne Guideline 
2005 update, 2005: 890.)  In a study conducted by Sadick (2002: 91), there was a 
total of 166 patients out of 473 participants on isotretinoin who had alterations in blood 
chemistry.  There were 77 patients with elevated serum cholesterol levels and 41 
patients with increased triglyceride levels.  It was interesting to note that elevated 
cholesterol occurred more frequently than elevated triglycerides in the patient 
population.  (Sadick, 2002: 91.)  A sudden elevation of triglycerides may, in theory, 
precipitate acute pancreatitis, although this is unlikely (Isotretinoin (Roaccutane) 
usage – a South African consensus guideline, 1997: 1412).   
 
2.3.5.6  Liver enzyme changes 
 
Liver enzyme levels may become raised during isotretinoin treatment (Acne Guideline 
2005 update, 2005: 890).  Approximately 15% of patients on isotretinoin may show 
elevations in liver enzyme levels (Ashworth, 2005: 65).  Blood tests to determine 
baseline liver enzyme values need to be done before treatment starts and should be 
repeated after one month of treatment.  Should the baseline and one month values 
both be normal, further liver enzyme testing is unnecessary.  (Acne Guideline 2005 
update, 2005: 890.)   
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2.3.5.7  Other side effects 
 
Dry, peeling and itchy skin can occur in more than 80% of isotretinoin users.  Applying 
aqueous cream or other emollients after bathing may help to alleviate this side effect.  
(Isotretinoin (Roaccutane) usage – a South African consensus guideline, 1997: 1412.)  
Cheilitis (dry lips) is found in more than 90% of patients on isotretinoin (Ashworth, 
2005: 65; Isotretinoin (Roaccutane) usage – a South African consensus guideline, 
1997: 1412) and is the most common side effect related to the mucous membranes 
(Sadick, 2002: 90).  It may be treated by frequent application of lip balm (Isotretinoin 
(Roaccutane) usage – a South African consensus guideline, 1997: 1412).   
 
Dry eyes or conjunctivitis may present in approximately 40% of patients on 
isotretinoin, and the use of artifical tears or eye ointment can bring relief (Isotretinoin 
(Roaccutane) usage – a South African consensus guideline, 1997: 1412).  Dry mouth, 
epistaxis, gum bleeding and vaginal dryness are other side effects associated with the 
mucous membranes that may occur (Sadick, 2002: 90).  Nose bleeds can present 
frequently during winter months.  This can be treated by applying vaseline several 
times per day to the insides of the nostrils.  (Isotretinoin (Roaccutane) usage – a 
South African consensus guideline, 1997: 1412.)  Dermatitis may occur in less than 
10% of patients, in which case emollients can be used (Isotretinoin (Roaccutane) 
usage – a South African consensus guideline, 1997: 1412).  Nail fragility, including the 
occurrence of ingrown toe- and fingernails, is another side effect of isotretinoin 
(Önder, Öztaş & Öztaş, 2001: 115 – 116).   
 
Photosensitivity can occur in approximately five percent of patients treated with 
systemic isotretinoin.  Patients may also experience severe night blindness that can 
hamper driving at night.  (Acne Guideline 2005 update, 2005: 889; Isotretinoin 
(Roaccutane) usage – a South African consensus guideline, 1997: 1412.)   
 
Systemic isotretinoin can cause muscle pains (myalgia) and joint pains (arthralgia) 
(Acne Guideline 2005 update, 2005: 889).  These two musculoskeletal side effects are 
not unusual amongst patients taking isotretinoin (it can occur in approximately 16% of 
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patients using isotretinoin) and the symptoms rarely persist once treatment has been 
completed.  Backache and neck stiffness may also occur.  (Isotretinoin (Roaccutane) 
usage – a South African consensus guideline, 1997: 1412; Sadick, 2002: 92.)  
Strenuous exercise should be avoided during isotretinoin therapy (Isotretinoin 
(Roaccutane) usage – a South African consensus guideline, 1997: 1412).  Mild hair 
loss may occur with isotretinoin treatment (Acne Guideline 2005 update, 2005: 889).   
 
Loss of eyebrows and lashes and thinning of hair may also become prevalent with 
isotretinoin use (Ashworth, 2005: 65).  These hair changes should return to normal 
within a year of isotretinoin use (Isotretinoin (Roaccutane) usage – a South African 
consensus guideline, 1997: 1412).   
 
Isotretinoin can cause an initial temporary exacerbation of acne that the patient should 
be aware of (Acne Guideline 2005 update, 2005: 889).  This exacerbation can be 
anticipated in six percent of patients early in the course.  Prednisone in a dose of 0.5 
to 1 mg/kg daily for two to three weeks is recommended for severe flares.  In rare 
cases it may be necessary to stop the isotretinoin, or at least halve the dose.  If 
stopped, it should be reintroduced at 0.5 mg/kg daily and then increased or decreased 
as necessary.  (Acne Management Guideline, 1999: 1031.)   
 
Gastrointestinal side effects include rectal bleeding, nausea, diarrhoea, bloody 
diarrhoea and constipation (Sadick, 2002: 92).  Inflammatory bowel disease (IBD) has 
been reported in patients with no previous history of IBD who used isotretinoin 
(Ashworth, 2005: 65).  Irregular menses can also occur, although this side effect is 
rare (Sadick, 2002: 93).  The occurrence of acute appendicitis in selected cases of 
patients on isotretinoin may indicate a connection between appendicitis and 
isotretinoin use (Azón-Masoliver & Grau, 2000: 233).   
 
Changes in appetite and weight have been shown to occur.  In the study conducted by 
Sadick (2002: 93), four patients of 473 patients reported weight loss and one patient 
reported a decreased appetite.  Poor wound healing is another side effect (Sadick, 
2002: 93).   
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2.3.6 DRUG INTERACTIONS OF SYSTEMIC ISOTRETINOIN 
 
Systemic isotretinoin may impair the effectiveness of progestin-only contraceptives 
(the mini-pill) (Ashworth, 2005: 64).  All forms of hormonal birth control, whether oral, 
topical or intramuscular, may fail with concurrent retinoid therapy.  That is the reason 
why two birth control measures are compulsory in the USA.  (Ashworth, 2005: 63; 
Jones, 2007.)   
 
Concurrent use of isotretinoin and any tetracycline derivative is contraindicated, as the 
chance of benign intracranial hypertension is increased (Ashworth, 2005: 64.)  
Phenytoin and isotretinoin are both highly bound to albumin and concurrent 
administration may reduce phenytoin binding and promote phenytoin toxicity.  
Phenytoin can cause osteomalacia and retinoids may adversely affect skeletal health.  
This is another reason why these agents should not be administered simultaneously.  
(Ashworth, 2005: 64.)   
 
Chronic systemic corticosteroid use can cause osteoporosis; patients should not use 
corticosteroids with isotretinoin, or patients who use these agents simultaneously 
should be closely monitored.  Coadministration of vitamin A supplements may cause 
hypervitaminosis A.  (Ashworth, 2005: 64.)   
 
2.3.7 CONCLUSION 
 
In conclusion, it can be seen that isotretinoin is an acne treatment method with many 
controversies surrounding it.  This is due to the many side effects and drug 
interactions that patients are exposed to during isotretinoin use, although isotretinoin 
is the most effective available acne treatment.  For every patient, the benefit of using 
isotretinoin must outweigh the risks involved.  Isotretinoin should be used only as 
indicated and other treatment modalities should be implemented where isotretinoin 
use is inappropriate.  In South Africa, adherence to the South African Acne Treatment 
Guideline (Acne Guideline 2005 update, 2005: 883 – 892) is very important.  All 
prescribers and other health care workers involved in the skin care of patients are 
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strongly encouraged to follow the recommendations of this guideline.  The compliance 
with the guideline by health care professionals and patients could lead to a cost-
effective, safe and therapeutically effective treatment approach to acne vulgaris in 
South Africa.   
 
In this study, the acne medications prescribed to a representative South African 
sample of acne patients on a chronic basis were investigated and compared to the 
literature recommendations regarding the management of acne.  A specific sample of 
patients from the NMM who were on systemic isotretinoin during the time of the study 
was investigated for the purposes of determining the compliance of prescribers and 
patients to recommendations regarding acne treatment, specifically isotretinoin.  In the 
latter investigation, specific focus was placed on compliance with the latest South 
African Acne Treatment Guideline released in 2005 (Acne Guideline 2005 update, 
2005:  883 – 892).   
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3.1 INTRODUCTION 
 
The primary aim of this study was to investigate the appropriateness of drugs used for 
the treatment of acne vulgaris in a South African population, specifically focusing on 
the NMM, and to evaluate the safety and efficacy of systemic isotretinoin utilised by 
acne patients.  In this chapter, the methodology employed for this study will be 
explained.   
 
3.2 LITERATURE REVIEW 
 
In order to obtain information relevant to the study, a comprehensive literature review 
was conducted.  Information specifically pertaining to acne pathology, acne 
management and systemic isotretinoin was obtained.  This information exploration 
was initiated by a Medline search, whereafter several electronic online databases 
(including EBSCOHOST, Nexus and ScienceDirect) were employed in finding relevant 
literature.  Other sources of information included journal articles, published books and 
dependable internet sites.  The literature search extended from 1990 to 2007.  Where 
applicable, references outside this time frame were consulted.   
 
3.3 DATA FOR DRUG UTILISATION REVIEW 
 
A brief explanation of a drug utilisation study (as well as the reason for conducting 
such a study) is provided in this section.  Background to the company that provided 
data for the drug utilisation review is also included in this section.  In addition, the 
method of data requisition, the layout and format of the data, and the method of data 
verification are explained.   
 
3.3.1 DEFINITION OF AND NEED FOR DRUG UTILISATION RESEARCH 
 
According to the WHO (Introduction to Drug Utilization Research, 2003: 8), drug 
utilisation research is defined as the marketing, distribution, prescription, and use of 
medicines in a society, with special emphasis on the resulting medical, social and 
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economic consequences.  The ultimate goal of drug utilisation research should be to 
assess whether drug therapy is rational or not (Introduction to Drug Utilization 
Research, 2003: 7).  The reasons for the conduction of drug utilisation studies are to 
describe medication usage patterns, to detect early signs of irrational medication use, 
to enable interventions that will improve medication use and to continuously improve 
the quality of medication use (Introduction to Drug Utilization Research, 2003: 9).   
 
There are different types of drug utilisation studies that can be conducted; of which 
quantitative studies of drug consumption (as implemented in this research study) is 
one type.  Quantitative studies of drug consumption can provide overall statistics, 
commonly with a detailed breakdown, or specific data in a given situation.  Sources of 
information for quantitative studies of drug consumption may include sales data 
obtained by privately owned companies, official figures from medical aid funds and 
health services (obtained as part of costing and reimbursement activities) or 
prescription data (also obtained from health services, hospitals or group practices).  
International or national quantitative studies are useful in comparing trends in the use 
of certain medications in different countries or areas, in evaluating the effects of 
regulatory measures and information campaigns and in undertaking benefit-risk 
analyses.  (Capellà, 1993: 68 – 69.)  Other drug utilisation study types, as described in 
detail by Capellà (1993: 66 – 72), include studies of supply, qualitative studies, more 
detailed studies of prescriptions and prescribing, studies of patient compliance and ad 
hoc studies. 
 
In order to investigate the acne medication use of a sample of South African patients, 
the implementation of a drug utilisation study of a quantitative nature was optimal.  
Medication prescription patterns for a large group of acne patients over a long time 
period could be obtained and findings could be compared to literature 
recommendations, irrational medication use could be identified and recommendations 
regarding medication use could be made.  Limitations of this drug utilisation study are 
discussed in Section 3.11.   
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3.3.2 BACKGROUND TO THE PHARMACEUTICAL BENEFIT MANAGEMENT 
COMPANY RESPONSIBLE FOR PROVISION OF DATA FOR THE STUDY  
 
The Pharmaceutical Benefit Management (PBM) Company that provided the data for 
the drug utilisation review will henceforth be referred to as Company A.  Company A 
acts on behalf of various chronic medical aid schemes in South Africa.  Company A 
grants authorisation for the use of medicines on a chronic basis, treating a variety of 
chronic disease states.  It is important to note that Company A is not a medical aid 
scheme in itself, but rather an independent manager of numerous chronic medical aid 
schemes in the private sector.  Company A operates on a pre-certification basis where 
chronic status of the medication is requested via an application form, whereafter 
prescriptions are assessed and authorised by a panel of health care professionals 
prior to a patient’s medication being granted “chronic” status.  On commencement of 
the drug utilisation study (October 2006), there were 191 895 patients served by 
Company A.   
 
3.3.3 DATA REQUISITION 
 
Approval was obtained from Company A to use their data for the purposes of this 
study.  All records pertaining to patients diagnosed with acne between 2000 and 2005 
were requested.  See Appendix B for the letter of request to Company A.  This dataset 
was extracted on 16 October 2006 and is referred to as Population A throughout the 
study.   
 
3.3.4 DATA FORMAT 
 
The dataset (Population A) contained 104 906 records representing 23 585 patients.  
Data were requested in text format.  This enabled the data to be compatible with most 
versions of software packages.  The data were provided in a zipped format on a CD.  
Microsoft Winzip® was used to extract the data and the files were imported into a 
database in Microsoft Office Access® 2003.  See Appendix C for an extract of the 
dataset.   
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3.3.5 DATA LAYOUT 
 
Table 3.1 provides information on the data fields that were provided by Company A.  
The column headed “Data received” indicates the headings assigned to the different 
fields by Company A.  It should be noted that the data requested from the medical aid 
were not identical to the data received.  It should also be noted that Company A might 
possibly have a wider range of information available for every patient than that which 
were requested for the study.    
 
Table 3.1:  Fields included in data received from Company A 
FIELD DATA RECEIVED DESCRIPTION 
1 BenID Unique patient identity code 
2 Gender Gender of patient 
3 BirDte Birth date of patient 
4 Postal Code Postal code of patient 
5 Active Flag Whether patient is still on that medical aid or not 
6 Modified_Date Date when medical aid details had last been modified 
7 Comm Date Date that treatment commenced 
8 Term Date Date that treatment terminated 
9 ICD10 Code ICD-10 Code of diagnosis 
10 Diagnosis Description of the ICD-10 Code diagnosis 
11 Drug Form Medication dosage form 
12 Drug Name Medication trade name 
13 Strength Medication dosage strength 
14 Nappi NAPPI Code of medication 
15 RetPrc Retail price of medication 
16 PacSze Pack size of medication 
17 Directions Directions for use of medication 
18 – 29 Jan to Dec Amount of medication received during each month 
30 ATC_Description Description of the ATC Code (active ingredient) of the medicine 
31 ATC_Code ATC Code of the medicine 
 
3.3.6 DATA VERIFICATION 
 
The possibility of data capturing errors in the database of Company A should always 
be considered.  Therefore, the dataset was verified prior to analysis.   
 
The validity of the age and gender data was investigated.  There was a gender 
captured for every patient in the dataset, and no exclusions based on lack of gender 
capturing were necessary.  There was one patient with a birth date of 30 December 
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1899 at 00h00, four patients with birth dates of 1 January 1900 at 00h00, and one 
patient with a birth date of 1 January 1901 at 00h00.  These birth dates were 
unrealistic, as it was perfectly timed at beginnings and endings of a century (and 
patients would also be very old if these birth dates were true).  The 24 records of 
these patients were excluded from the dataset prior to analysis to maintain credibility.   
 
There were 26 males who, according to the dataset, received hormone therapy for 
acne treatment.  An enquiry in this regard was made to Company A to investigate 
these improbable records.  According to Company A, manual data capturing errors of 
the gender of these 26 males did occur.  For purposes of credibility of the dataset, the 
113 records pertaining to these 26 patients were excluded prior to analysis.   
 
When considering the validity of the diagnoses of the patients, it was found that 663 
patients (contributing to 3 206 records) were included in the dataset even though they 
had not once been diagnosed with any form of acne.  Therefore, these patients and 
their records were also excluded from the analysis.  There were also two records for 
two patients where the diagnoses fields were left blank and these two records were 
also excluded.   
 
There were 11 patients who had been diagnosed with acne, and were prescribed 
medication for the treatment of hypertension, depression and other disorders not 
related to acne.  These were also considered to be data capturing errors and these 11 
patients with their 31 records were also excluded from analysis.   
 
As only patients diagnosed and treated for acne from 1 January 2000 to 31 December 
2005 were to be included in the study, and the dataset contained records from 1 
December 1993 to 7 June 2006, it was necessary to exclude records prior to 2000 
and after 2005.  Thus, 26 432 records pertaining to 3 954 patients were excluded from 
the dataset.   
 
It was decided to exclude all patients with rosacea, also known as acne rosacea, from 
the dataset.  The reason for this exclusion was that acne rosacea is treated separately 
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and differently from acne vulgaris or the other acne forms present in the dataset.  The 
specific treatment of acne rosacea was not the focus of this study and could alter the 
statistics obtained if left in the dataset.  Thus, the 120 patients with their 1 420 records 
were excluded from the dataset prior to analysis.   
 
Altogether, the final patient population consisted of 18 803 patients with 73 689 
records.  Thus, 26.5% of the original dataset were excluded from analysis due to 
preference and not due to data capturing errors, while 3.2% of the original dataset 
were omitted from further analysis due to data capturing errors.   
 
3.4 DATA FOR QUESTIONNAIRE SURVEY 
 
The reason for the implementation of a patient questionnaire survey, as well as the 
methods employed in designing, piloting, distributing and collecting the patient 
questionnaire survey are discussed in this section.   
 
3.4.1 REASON FOR PATIENT QUESTIONNAIRE SURVEY 
 
The drug utilisation review conducted in this study gave a broad overview of acne 
medication prescribed on a chronic basis to a representative sample of South African 
patients and made a valuable contribution to the study.  However, it was also 
necessary to specifically investigate the prescription of systemic isotretinoin, as well 
as the accompanying counselling and monitoring of patients to whom this medication 
is prescribed.  It was also required to obtain personal opinions and experiences of 
patients regarding the use of isotretinoin.  Because of the more personal nature of this 
type of study, it was decided to implement a questionnaire survey in addition to the 
drug utilisation review.  The questionnaire survey could also contribute to the drug 
utilisation review by obtaining information regarding acne medication use of patients, 
in addition to the more personal information as described above.  Due to the fact that 
patients included for the questionnaire survey were on isotretinoin therapy in 2006, 
their medication use (as well as counselling and monitoring received) could more 
optimally be compared to the 2005 South African Acne Treatment Guideline (Acne 
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Guideline 2005, 2005: 883 – 892) than information obtained from the drug utilisation 
review.   
 
A questionnaire survey, rather than personal interviews, was used for this study.  The 
main reason for this choice was that personal interviews could have been more time 
consuming than a questionnaire survey, and in order to include as many participants 
as possible, a questionnaire survey was chosen.  The negative aspects of the 
questionnaire survey are discussed in Section 3.11.   
 
3.4.2 RESEARCH TOOL DESIGN 
 
A research tool was designed in the form of a patient questionnaire.  The 
questionnaire was aimed specifically at patients who were on systemic isotretinoin 
therapy during the time of the distribution of the questionnaire.   
 
The questionnaire was designed with closed- and open-ended questions in order to 
obtain quantitative information.  Sections present in the questionnaire included 
demographic information of the patient, acne and acne treatment, other medical 
conditions and medications, systemic isotretinoin therapy, patient counselling and 
monitoring, side effect profile of the patient, miscellaneous questions and pregnancy.   
 
A cover letter containing information pertaining to the study, directed to the participant 
or the parent or guardian of the participant was included with each questionnaire.  An 
ethical consent form and an ethical assent form were also included with each 
questionnaire.  The consent forms were to be signed by all respondents aged 18 
years or older, or by parents or guardians of respondents younger than 18 years of 
age.  The assent forms were to be signed by respondents younger than 18 years of 
age, in order to give permission to their parents or guardians to sign the consent forms 
on their behalf.  See Appendix D for the cover letter of information, Appendix G for the 
questionnaire, Appendix E for the ethical consent form and Appendix F for the ethical 
assent form.   
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3.4.3 PILOT STUDY 
 
After the initial design of the questionnaire, a pilot study was conducted, by means of 
convenience sampling.  Two community pharmacies in the NMM, one in Port 
Elizabeth and one in Uitenhage, were included.  After obtaining permission from the 
responsible pharmacists of the selected pharmacies, the questionnaires were 
distributed to the two community pharmacies.  The pharmacists were requested to 
distribute the questionnaires to patients currently receiving isotretinoin from the 
pharmacy.  The pharmacists were also asked to explain the procedures required to 
complete the questionnaire as well as the ethical consent and assent forms.  The 
pharmacists were also asked to inform the patients that comments and questions 
regarding the questionnaire would be welcomed.  Altogether, six patients completed 
the questionnaire and ethical forms and returned these forms to their pharmacies.  
The forms were then collected by the researcher.  The pilot study took place from 5 
August 2006 to 5 September 2006.   
 
After thorough investigation of the results of the pilot study, necessary changes to the 
questionnaire, letter of information to the patient and ethical assent and consent forms 
were made.  Changes were small enough to allow for the incorporation of information 
obtained from the six pilot study respondents into the final study findings.   
 
3.4.4 QUESTIONNAIRE DISTRIBUTION 
 
A list of all community pharmacies in the NMM in 2006 was obtained from the South 
African Pharmacy Council.  There were 89 pharmacies on the list, of which 73 (82.0%) 
were situated in Port Elizabeth, 13 (14.6%) in Uitenhage and three (3.4%) in 
Despatch.  It was decided to include a third of the pharmacies (30 pharmacies) in the 
study.  A stratified randomised sampling method was used to choose the 30 
pharmacies that would be asked to participate in the study.  The same percentage 
distribution as described above was used in determining the percentage of 
pharmacies from each of the three areas to be included.  Thus, 25 pharmacies 
situated in Port Elizabeth, four pharmacies situated in Uitenhage and one pharmacy in 
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Despatch were included in the study.  In order to ensure that the correct percentages 
of pharmacies from each area could be chosen, pharmacies were separated into three 
lists according to the three areas.  All three lists were kept alphabetically.  Every third 
pharmacy on each area list (including only the necessary number of pharmacies from 
each area as stipulated previously), was chosen.  A random number (between one 
and three) was selected from a closed container in order to determine the starting 
point (first pharmacy, second pharmacy or third pharmacy on the list) from where 
every third pharmacy from each list would be chosen for participation.  As a result, the 
selection process began from the second pharmacy on every list.  The 30 pharmacies 
were then selected.  The responsible pharmacist of each of these pharmacies was 
telephonically contacted on 18 September 2006 in order to obtain permission for the 
inclusion of the pharmacy and their isotretinoin patients in the study.  An appointment 
was made with each of the responsible pharmacists during the telephone 
conversations.  The purpose of the appointments was to explain the details of the 
procedures to the pharmacists and hand over the questionnaires.   
 
Of the 30 pharmacies originally chosen, 12 could not, or chose not to, participate and 
12 replacement pharmacies were chosen in the same manner as described above.  
After telephone conversations with these 12 pharmacies, three could not, or chose not 
to, participate and another three replacement pharmacies were chosen in the same 
manner as described above.  There was one of these three chosen pharmacies who 
could not participate, and another replacement pharmacy was chosen using the same 
method.  This method had to be continued for four pharmacies, as the first three 
contacted pharmacies could not (or were not willing to) participate.  Eventually, after 
continuing with the same method of selecting pharmacies, a final pharmacy agreed to 
participate in the study.  It should be noted that after every third pharmacy on the list 
was contacted, and 30 pharmacies had not yet agreed to participate, the inclusion of 
every third pharmacy continued by counting from the last pharmacy contacted and 
starting from the top of the list again.   
 
During the meetings with the responsible pharmacist from each pharmacy, they were 
asked to provide an estimate of the number of patients who currently received 
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isotretinoin from the pharmacy.  This allowed for estimation of the number of 
questionnaires to be distributed to every pharmacy.  Envelopes, each containing a 
patient information letter, questionnaire and ethical consent and assent form, were 
personally delivered to each pharmacy in an “out” folder (meaning that the 
pharmacists were still to hand out the envelopes in this folder to the isotretinoin 
patients).  An “in” folder was also supplied to each pharmacy, in which the completed 
and returned forms could be placed and stored in the pharmacy for collection by the 
researcher.  Altogether, 189 questionnaires, patient information letters, consent and 
assent forms were distributed.  The distribution took place from 26 September 2006 to 
28 September 2006.   
 
Pharmacists were asked to hand an envelope to every patient who was receiving 
isotretinoin from the pharmacy when they came to the pharmacy for medication.  
Pharmacists were also asked to explain the procedure of completing the questionnaire 
and ethical forms to the patient, as well as to emphasise the importance of the study 
and the return date of the questionnaire and ethical forms (the initial return date was 
10 November 2006).  Patients had to complete the forms and return them to their 
pharmacies.   
 
3.4.5 QUESTIONNAIRE COLLECTION 
 
The initial time given for data collection was six weeks and three days (26 September 
2006 to 10 November 2006).  The time taken to distribute the questionnaires to all the 
pharmacies (three days) was included within this time frame.  A follow-up telephone 
call was made to each pharmacy three weeks after delivering the envelopes to the 
pharmacies.  This was done to remind pharmacists to give out the questionnaires to 
their patients, to determine the response rate of patients and to answer any questions 
that the pharmacists might have had.  A telephone call to each pharmacy was made 
again two days before the final return date of the questionnaire to remind the 
pharmacists of the final return date.  The questionnaires and ethical forms in the 
envelopes were personally collected from every pharmacy from 10 November 2006 to 
14 November 2006.   
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Due to a lack of response from patients and due to the fact that isotretinoin is a 
monthly repeat medicine (thus, some patients only came to the pharmacy once a 
month), it was decided to extend the data collection time period to 19 December 2006.  
The total time for data collection became 12 weeks.  In this time, each pharmacy 
received three telephone calls as reminders of the study.  The final collection of the 
completed questionnaires took place from 21 December 2006 to 3 January 2007.    
 
A total of 189 questionnaires were handed out to the pharmacies, 51 patients 
completed the questionnaires (a response rate of 27.0%) and, together with the six 
patients who completed the pilot study questionnaires, were included for statistical 
analysis.  A total of 57 patients were therefore included in the analysis.  These 
patients will henceforth be referred to as Population B.   
 
3.5 DATA STANDARDISATION 
 
3.5.1 ICD-10 CODE 
 
ICD-10 stands for the tenth revision of the International Classification of Diseases.  It 
is a system of categories to which morbid entries are assigned according to 
established criteria. It Includes the entire range of conditions in a manageable number 
of categories, grouped into “blocks” to facilitate mortality reporting. It is produced by 
the World Health Organization.  (National Library of Medicine - Medical Subject 
Headings, 2007.)  Different acne types are classified in “block” L70 to L73 and include 
acne (L70.9), acne vulgaris (L70.0), acne conglobata (L70.1), acne keloidalis (L73.0), 
and nodulocystic acne (L70.0).  Acne associated with polycystic ovary syndrome 
(E28.2) was, together with the above-mentioned acne types, included as acceptable 
acne types for analysis.  In the case of patients diagnosed with L70.0, there were two 
possible diagnoses descriptions in the dataset.  Acne vulgaris and nodulocystic acne 
were both, on separate occasions, used to describe L70.0.  This could have been due 
to the fact that there is no ICD-10 code for nodulocystic acne.  Accordingly, for the 
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analysis, the diagnosis description for L70.0 was used in the determination of the acne 
type.   
 
3.5.2 ATC CLASSIFICATION SYSTEM 
 
The ATC system stands for the Anatomical Therapeutic Chemical classification 
system.  It is used to classify medications into different groups according to the system 
or organ on which they act and/or their therapeutic and chemical characteristics.  It is 
controlled by the WHO Collaborating Centre for Drug Statistics Methodology and was 
first published in 1976.  Drugs are classified in groups at five different levels. The 
drugs are divided into fourteen main groups (1st level), with one 
pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th levels are 
chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical 
substance. (World Health Organization Collaborating Centre for Drug Statistics 
Methodology, 2006.)   
3.5.3 AGE GROUPING TECHNIQUE  
Erikson’s Stages of Psychosocial Development (Erikson’s Psychological Stages 
Summary Chart, 2007), as shown in Table 3.2, were studied and taken into 
consideration upon deciding on the age categories used in this study.   
 
Table 3.2:  Erikson’s Stages of Psychosocial Development  
AGE GROUP BRIEF DESCRIPTION 
Birth to 18 months Infancy  
2 to 3 years Early Childhood 
3 to 5 years Preschool 
6 to 11 years School Age 
12 to 18 years Adolescence  
19 to 40 years Young Adulthood  
< 40 to 65 years Middle Adulthood 
65 years to death Maturity 
(Adopted from Erikson’s Psychological Stages Summary Chart, 2007.) 
The following age categories, as indicated in Table 3.3, were used for both patient 
populations included in this study.   
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Table 3.3: Age grouping used for Population A and Population B 
AGE GROUP (IN YEARS) BRIEF DESCRIPTION 
Younger than 13 Pre-adolescent 
13 to 18 Adolescent 
19 to 24 Late adolescent / early twenties 
25 to 34 Late twenties / early thirties 
35 to 49 Middle-aged 
50 to 64 Menopausal / post-menopausal 
65 or older Elderly 
 
The reasoning behind grouping of ages, and this specific age grouping technique, was 
that acne is a type of disease that can occur at every age, but certain types of acne 
are more commonly associated with certain ages.  Also, recommendations in the 
treatment of acne differ considerably for people of different ages, for example infants, 
adolescents and menopausal patients.  This was explained in more detail in Chapter 
2.  By using this grouping technique, important details could be obtained, for example 
the age groups most frequently affected by acne, the acne types that were most 
prevalent in every age group and the most prevalent acne medications prescribed to 
every age group.  Although there was no analysis of specific age groups below 13 
years, it should be noted that for the purpose of this study, the term “children” was 
used to define all patients younger than 13 years.   
 
3.5.4 AGE CALCULATIONS OF POPULATION A 
 
Only birth dates for Population A were supplied in the data set of Company A.  
Therefore, ages of patients had to be calculated.  This was done by determining the 
number of days between the birth date of the patient and 1 January 2003.  This date, 
1 January 2003, was chosen because it represented the exact middle of the time 
period included for analysis in the study (1 January 2000 to 31 December 2005).  The 
ages of the patients therefore did not necessarily represent their exact ages at the 
time of acne diagnosis or of acne medication prescription, but rather the approximate 
ages according to the method described above.   
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3.6 DATA ANALYSIS FOR DRUG UTILISATION REVIEW 
 
The dataset was retrospectively analysed using quantitative techniques.  Microsoft 
Office Access® 2003, a database program, and Microsoft Office Excel® 2003, a 
spreadsheet program, were used to analyse the data.  The following analyses were 
performed, graphically demonstrated and compared to standard treatment guidelines 
where applicable for the data from Company A for 1 January 2000 to 31 December 
2005: 
 
• Basic demographic analysis:  The demographic profiles of patients with respect 
to gender and age were established.    
 
• Overview of all diagnoses:  The most prevalent diagnoses and the number of 
different diagnoses per patient were investigated.   
 
• Overview of acne diagnoses:  The prevalence of different acne types diagnosed, 
according to ICD-10 codes and descriptions were investigated.   
 
• Specific non-acne treatment prescribing trends:  The most frequent non-acne 
active ingredients prescribed were identified.   
 
• Hormone therapy:  The prevalence of the prescription of hormone therapy in 
acne management, as well as the most frequently prescribed hormone therapy 
medications, both according to active ingredient and trade name, were 
investigated.   
 
• Antibiotic therapy:  The prevalence of prescription of topical and systemic 
antibiotic therapy in acne management, as well as the most frequently prescribed 
topical and systemic antibiotic therapy medications, both according to active 
ingredient and trade name.   
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• Systemic isotretinoin therapy:  The prevalence of prescription of systemic 
isotretinoin therapy in acne management, as well as the most frequently 
prescribed trade names and dosage strength were established.   
 
• Topical formulations:  The prevalence of prescription of topical formulations in 
acne management, as well as the most frequently prescribed topical formulation 
active ingredients, was investigated.   
 
• Summary of findings:  The frequency of prescription of hormone therapy, 
antibiotic therapy, systemic isotretinoin therapy and topical formulations in the 
management of acne were compared.   
 
3.7 DATA ANALYSIS FOR QUESTIONNAIRE SURVEY 
 
The questionnaires were retrospectively analysed using quantitative techniques.  
Microsoft Office Excel® 2003 was used to analyse the data.  The following analyses 
were performed, graphically demonstrated and compared to standard treatment 
recommendations where applicable:   
 
• Basic demographic analysis:  The demographic profiles of the patients with 
regards to age and gender were determined.  The ages at which acne started in 
the patient population were also investigated.   
 
• Overview of non-acne medications and diseases:  The prevalence of other 
medications used by the patients, as well as other disease states suffered by the 
patients, was investigated.   
 
• History of acne medication use:  The acne treatments used by patients, prior to 
initiation of systemic isotretinoin therapy, were investigated.   
 
• Systemic isotretinoin therapy:  The most frequently prescribed trade names and 
dosage strengths of systemic isotretinoin therapy were determined.  The dosage 
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instructions, duration of therapy and cumulative dosages for the patients were 
evaluated.  An investigation of the patient population’s family history of isotretinoin 
use was undertaken.    
 
• Overview of acne severity prior to isotretinoin therapy initiation:  The degree 
of acne severity was established and the extent of involvement of acne in other 
body parts, except for the face, was investigated.   
 
• Counselling and monitoring procedures:  The prevalence of counselling given 
by health care professionals to patients regarding isotretinoin was evaluated.  The 
prevalence, frequency and quality of monitoring procedures by health care 
professionals of isotretinoin patients were also investigated.   
 
• Side effects of systemic isotretinoin:  The prevalence and severity of side 
effects experienced by patients on isotretinoin were assessed.  Although there 
was a section in the questionnaire where patients were asked to provide 
information on the duration of the side effects and treatments used in alleviation of 
the side effects, this section was very poorly answered by the respondents and 
sufficient information was not obtained.  That section has been left out of the 
analysis.   
 
• Isotretinoin and pregnancy:  Contraceptive measures used by females before 
and during isotretinoin therapy were investigated.  Prevalence and quality of 
counselling given to females with regards to the danger of pregnancy in 
isotretinoin therapy were assessed.   
 
• Efficacy of isotretinoin:  The effectiveness of isotretinoin in clearing up acne and 
decreasing the number of body areas with acne involvement was evaluated.  The 
patients’ satisfaction with the effectiveness of isotretinoin and perceptions of the 
degree of acne clear up were assessed.  The patients’ perception of a decrease in 
quality of life due to the side effects of isotretinoin, as well as the patients’ 
perception of an increase in quality of life due to the benefits of isotretinoin, was 
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investigated.  The patients were also asked whether, if they could turn back time 
and choose over again, they would once again choose to use systemic 
isotretinoin.  The patients were also asked to give a reason for their answer.     
 
3.8 STATISTICAL EVALUATION OF RESULTS 
 
Microsoft Office Excel® 2003 was used for the basic differential analysis of the data.  
Numeric analysis comprised of the mean values, standard deviations, the range of 
data and minimum and maximum values that were calculated.  Where applicable, 
results were graphically represented by bar charts, pie charts or line charts.   
 
Interferential tests were employed in order to obtain statistical and practical 
significance of the results.  The significance level was α = .05.  In obtaining statistical 
significance based on frequencies, the Pearson’s Chi-square test was used, while the 
t-Test was used to obtain statistical significance where two groups based on sample 
means were compared.  The Cramér's V statistic was used to confirm practical 
significance of the Chi-square test, where the threshold values were 0.1 to 0.3 (small), 
0.3 to 0.5 (moderate) and > 0.5 (large).  The Cohen’s d statistic was employed to 
confirm the practical significance of the t-Test, where the threshold values were 0.2 to 
0.5 (small), 0.5 to 0.8 (moderate) and > 0.8 (large). 
 
3.9 DEFINITION OF TERMS 
 
• Acne:  Acne can be defined as a multifactorial, chronic (Fulton, 2002: 95), 
common disorder of the pilosebaceous unit (Mossman, 2006).  The terms “acne 
vulgaris” and “acne” can be used interchangeably to describe this overall 
condition.  It can also be referred to as “common acne” and includes all other 
subtypes of acne, for example nodulocystic acne, acne conglobata and acne 
keloidalis.  Thus, although the ICD-10 coding system utilised in Chapter 4 contains 
different codes for “acne” and “acne vulgaris”, they are the same.  The other acne 
types included in Chapter 4, namely “nodulocystic acne”, “acne conglobata”, “acne 
keloidalis” and “acne associated with polycystic ovary syndrome”, are subtypes of 
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“acne” or “acne vulgaris” due to specific causes, level of severities or affected 
areas.  These subtypes are defined in greater detail in Chapter 2.   
 
• Active ingredient, trade name and generic equivalent:  The term “active 
ingredient” has been used when describing the chemical entities contained in a 
product, for example minocycline.  The term “trade name” was used to indicate a 
branded product, for example Minotabs®.  In South Africa, there are manufacturers 
that have a patent on an active ingredient and are therefore the sole 
manufacturers of the product containing this active ingredient, for example 
Differin® gel (containing adapalene) produced by Galderma.  Other manufacturers 
are allowed to make their own formulation of the same active ingredient once the 
patent has expired.  The product produced is then known as the “generic 
equivalent” of the original product, for example Oratane® and Acnetane® are the 
generic equivalents of Roaccutane®.  A generic equivalent is a medication which is 
equivalent to a brand name medication with respect to pharmacokinetic and 
pharmacodynamic properties.   
 
• Cumulative dose of isotretinoin:  A cumulative dose is a total accumulated dose 
of a certain medication consumed by a patient during the duration of treatment 
with this medication.  The optimal cumulative dose of isotretinoin is 120 to 150 
mg/kg per patient (Acne Guideline 2005 update, 2005: 890).  In other words, after 
a course of systemic isotretinoin, a patient should have consumed a total of 120 to 
150 mg of isotretinoin for every kilogram body weight.  The cumulative dose can 
be calculated by multiplying the dose (in mg) taken per day by the number of days 
that the dose is taken.   
 
• Hormone therapy:  The term “hormone therapy” was chosen to describe the 
treatment of acne with oral contraceptives, anti-androgens and/or hormone 
replacement therapy (HRT).  HRT is different in hormonal composition from oral 
contraceptives and, although not a very prevalent treatment method for acne, was 
a relevant acne treatment prescribed for the patient population.  Anti-androgens 
can be combined with an oestrogen to form an oral contraceptive, but it can also 
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be used alone in the management of acne.  Therefore, in order to include HRT 
and anti-androgens, the term “oral contraceptives” could not be used exclusively in 
Section 4.6, and the term “hormone therapy” was used.   
 
• Quality of life:  The patients were asked in the questionnaire whether their 
“quality of life” was affected by the side effects and/or benefits of isotretinoin.  The 
term refers to the patient's ability to enjoy normal life activities. Some medical 
treatments can seriously impair quality of life without providing appreciable benefit, 
while others greatly enhance quality of life.  (MedTerms Medical Dictionary, 2007.)   
 
3.10 ETHICAL CONSIDERATIONS 
 
The Nelson Mandela Metropolitan University (NMMU) Human Ethics Committee 
approved the ethical aspects of the study as presented in the research proposal of the 
study, while the Faculty of Health Sciences Research, Technology and Innovation 
(RTI) Committee of the NMMU gave approval of the research proposal.  The letter of 
approval from the NMMU Human Ethics Committee is included as Appendix A.  The 
study adheres to the criteria of the Declaration of Helsinki (The World Medical 
Association, 1989).   
 
When considering the information received from Company A, the confidentiality of 
patient details was maintained at all times.  Company A provided each patient with a 
unique patient identification number and no names or personal details were available.   
 
A consent form or assent form had to be completed by each patient who took part in 
the questionnaire survey.  The consent forms were to be completed by participants 
aged 18 years or older (the age at which people can independently give permission) 
or by the parents or guardians of participants younger than 18 years.  By signing the 
assent forms, participants (or parents or guardians of participants) confirm that they 
were not forced in any way into completing the questionnaire, that their participation in 
the study was voluntary and that they were aware that patient confidentiality would be 
maintained at all times.  The assent forms were to be signed by participants younger 
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than 18 years of age, as proof that they give their permission to their parents or 
guardians to complete the consent forms on their behalf.  As previously explained, the 
questionnaires were handed out and returned in sealed envelopes, and in no case 
was a name or personal details of a participant requested.   
 
3.11 LIMITATIONS OF THE STUDY 
 
The most important limitations of the drug utilisation study are outlined as follows:   
 
• Discrepancies in the data provided by Company A were found.  It should also be 
noted that the data capturing errors only represented 3.2% of the total number of 
records in the original dataset and that the exclusion of these records prior to 
analysis would therefore not have had a major effect on the results of the study.   
 
• The data were captured in a way that made the analysis of the number of 
prescriptions and the number of items received per patient beyond the scope of 
this study.  Thus, instead of analysing and reporting the number of prescriptions 
per patient, the focus was aimed at the number of patients in the study population 
who received each type of acne medication.   
 
• The medication profiles analysed during the drug utilisation review contained 
records of medication authorised on the patients’ chronic medication benefit 
scheme.  Details of medications used on an acute basis or obtained on an over-
the-counter (OTC) basis were not available.  When assessing the appropriateness 
of therapy it would be optimal to include all medication used by the patient.   
 
• The sample of South African patients included in the drug utilisation review 
included only patients who chose, or could afford, to belong to a private medical 
aid scheme.  In 2005, according to a general household survey, only 14.0% of the 
South African population had medical aid coverage (Statistics South Africa1, 
2005).  In 2004, more than nine times the percentage of white people (69.2%) had 
medical aid coverage compared to the black population where only 7.2% had such 
 95
coverage (Statistics South Africa2, 2005).  Thus, the results of this study can only 
be regarded as representative of the private sector in South Africa, and not the 
public sector.   
 
• The South African Acne Guideline update was released in 2005 in the South 
African Medical Journal (Acne Guideline 2005 update, 2005; 883 – 892).  Seeing 
that the drug utilisation review included patients from 2000 to 2005, a thorough 
comparison between acne treatment regimens found in the population and the 
latest South African Acne Treatment Guidelines could not be obtained.  Therefore, 
findings were compared to these recommendations as well as to other literature 
recommendations.   
 
The most important limitations of the questionnaire survey were as follows:   
 
• The response rate to the questionnaire survey was low and thereby limited the 
validity of the statistical tests that could be performed.  The validity of the results 
would have been strengthened by a bigger patient population.  The lack of 
personal contact with the respondents, the lack of cooperation by many 
pharmacists, the complicated ethical forms that had to be completed by patients 
and the length of the questionnaire are all factors that could have contributed to 
the lack of response by patients regarding the completion of the questionnaires.   
 
• For the questionnaire survey, it would have been better to include patients who 
had already completed treatment courses with systemic isotretinoin instead of 
patients who were currently on isotretinoin.  The reason for this retrospective 
discovery was that patients who already completed their isotretinoin courses would 
have been able to give more consistent and better feedback regarding the 
outcomes of therapy.   
 
• Certain parts of the questionnaire were not completed by all the participants, for 
example alleviation methods for the side effects experienced due to isotretinoin.  
These sections, due to lack of valid information, were omitted from the analysis.   
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CHAPTER 4 
RESULTS AND DISCUSSION: 
DRUG UTILISATION REVIEW 
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4.1 INTRODUCTION 
 
A retrospective drug utilisation analysis of Population A was conducted and the results 
are displayed and discussed in this chapter.  Population A consisted of a 
representative sample of South African patients diagnosed with acne between 1 
January 2000 and 31 December 2005, and who had resultantly received medication 
(which was chronically authorised by Company A) for the treatment of acne.   
 
4.2 DEMOGRAPHICS OF POPULATION A 
 
4.2.1 GENDER DISTRIBUTION 
 
Population A consisted of 18 803 patients.  The gender distribution is outlined in Table 
4.1.   There were 2.4 females for every male in the patient population.  The difference 
between genders was significant (Chi²(1)=3 142.58, p<.0005; V=0.41 Medium).  In 
another study conducted in Canada to determine the trends of isotretinoin utilisation 
between 1984 and 2003, it was found that 50% of patients included in the study 
population were males.  (Azoulay, Oraichi & Bérard, 2006: 667.)  Thus, a more even 
gender distribution was observed from that study when compared to this study.   
 
Table 4.1:  Gender distribution of Population A 
PATIENTS GENDER NUMBER (N = 18 803) PERCENTAGE (%) 
Female 13 245 70.4 
Male 5 558 29.6 
All patients 18 803 100.0 
 
4.2.2 AGE DISTRIBUTION 
 
Patients were grouped according to their ages as outlined in Table 3.3.  Table 4.2 
represents the age distribution of Population A.   
 
The mean age of Population A was 25.5 years (Standard Deviation (SD) = 9.7 years, 
N = 18 803).  Azoulay and associates (2006: 667) found that the mean age of their 
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population was 23.9 years, thus a bit younger than in this population.  Patients aged 
13 to 18 years constituted the largest age group, accounting for 29.2% of patients.  
Patients aged 19 to 24 years and patients aged 25 to 34 years also constituted large 
percentages of the total population.  These three age groups (thus, patients aged 13 
to 34 years) made up the majority of the population, accounting for 79.0% of the total 
population.  Patients aged younger than 35 years accounted for 81.2% of Population 
A.  The age distribution of Population A is in line with literature findings which state 
that acne occurs most commonly during teenage or adolescent years (13 to 18 years) 
and during young adult years.  (Acne Guideline 2005 update, 2005: 883; Acne 
Management Guideline, 1999: 1024; Burkhart & Burkhart, 2007: 89; Buxton, 1991: 38; 
Goodman, 2006: 613.)  In 1996, a study of office-based practices in the USA (Stern, 
1996) reported that the mean age of patients seeking help for acne was 24 years and 
that the majority of these patients were females.  The results found in this study were 
therefore similar.  The elderly population (patients of 65 years or older) was the 
smallest age group.   
 
Table 4.2:  Age distribution of Population A 
PATIENTS AGE GROUPS (IN 
YEARS) NUMBER (N = 18 803) PERCENTAGE (%) CUMULATIVE PERCENTAGE (%) 
<13 402 2.1 2.1 
13 to18 5 496 29.2 31.4 
19 to 24 5 167 27.5 58.9 
25 to 34 4 198 22.3 81.2 
35 to 49 3 274 17.4 98.6 
50 to 64 251 1.3 99.9 
≥65 15 0.1 100.0 
  
The age distribution of the different genders is indicated in Figure 4.1.  The mean age 
of the female population was 26.9 years (SD = 9.7 years, n = 13 245) and the mean 
age of the male population was 22.3 years (SD = 8.6 years, n = 5 558).  The 
difference between the average ages of females and males was insignificant (t-Test(18 
801), p<.0005; d=0.05 insignificant).  The largest proportion of females was aged 
between 19 to 24 years (26.5%), while the largest proportion of males aged between 
13 to 18 years (43.9%).  It can also be observed that a larger proportion of males than 
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females were younger than 13 years.  These findings may indicate that males in 
Population A started developing acne at an earlier age than females, or that males 
started seeking acne treatment at an earlier age when compared to females.  The 
former statement, however, is in direct contrast to previous findings recorded in 
literature, where it was found that females start experiencing acne eruptions at earlier 
ages than males (Pray & Pray, 2003: 17).   
 
Figure 4.1:  Age distribution of Population A according to gender  
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There was a fairly constant decline in the number of males as age increased.  The 
same pattern did not occur within the female population, where there was a more 
even distribution of females in different age groups.  Statistical and practical 
significance were proven (Chi²(6)=1191.21, p<.0005; V=0.25 Small) for this finding.   
 
The second largest age group of the females was between the ages of 25 to 34 years 
(26.1%), while 23.1% of the females were aged between 13 to 18 years, making this 
age group the third largest female group.  The percentage of females between the 
ages 35 to 49 years (20.9%) was significantly high when compared to the 9.2% of the 
male population (Chi²(1)=320.20, p<.0005; V=0.31 Medium).   
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These findings could suggest that many males discontinue the use of acne treatment 
as they get older (past adolescence), while many females continue the use of (or even 
start with) acne treatment after their adolescent years.  The fact that oral 
contraceptives are available to women for contraceptive purposes as well as for acne 
treatment, and the fact that females often continue experiencing problems with acne 
(or may even start developing acne problems) at later stages of their lives when 
compared to males, may account for the high number of females between the ages 19 
to 49 on acne medication and the more even age distribution of females.  A literature 
source  (Pal, 1997: 15) stated that, in the USA, more males than females suffer from 
acne between the ages 18 to 28 years, while more females than males have acne 
between the ages 29 to 49 years.  This statement is in line with the result of this study.   
 
4.3    OVERVIEW OF DIAGNOSES OF POPULATION A 
 
4.3.1 DIAGNOSES OF POPULATION A 
 
A total of 356 different diagnoses types were made for Population A.  The 15 most 
prevalent diagnoses, including acne diagnoses, made for Population A are outlined in 
Table 4.3.  Due to the fact that many patients were diagnosed with more than one 
condition between 1 January 2000 and 31 December 2005, the percentage 
distribution indicated in Table 4.3 added up to more than 100.0%.  It should also be 
noted that the conditions that were diagnosed in addition to acne diagnoses could not 
be referred to as “comorbid” conditions, seeing that these conditions could have been 
diagnosed at any point during the six year study period and not necessarily during the 
time that the patient had acne.   
 
As could be expected, acne was the most frequently occurring diagnosis in Population 
A.  Allergic rhinitis was the most prevalent non-acne diagnosis, having been 
diagnosed in 10.8% of all patients.  Depression was diagnosed in 6.7% of the patient 
population, making it the second most frequently occurring non-acne diagnosis.  Any 
acne disorder is strongly associated with depression, as acne has a profound effect 
on the psychological health of many patients.  Thus, this finding strengthens the 
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previous literature findings that acne can play a role in the development of depression 
(Acne Guideline 2005 update, 2005: 883; Cooper, 2003: 97).  Eczema and asthma 
were the third and fourth most prevalent non-acne diagnoses, respectively.  It should 
be noted that allergic rhinitis, eczema and asthma (all with high incidence rates in the 
patient population) can be linked to a personal or family history of allergic 
manifestations (Terr & Stites, 1992: 624).  Questions as to a possible relationship 
between these allergy mediated disorders and acne arise, although such a 
relationship was not mentioned in any of the consulted literature sources.   
 
Table 4.3:  Most prevalent diagnoses of Population A 
PATIENTS RANK DIAGNOSIS NUMBER (N = 18 803) PERCENTAGE (%) 
1 Acne 13 740 73.1 
2 Acne vulgaris 6 586 35.0 
3 Allergic rhinitis 2 024 10.8 
4 Depression 1 253 6.7 
5 Eczema 1 041 5.5 
6 Asthma 913 4.9 
7 Nodulocystic acne 832 4.4 
8 Hypertension 794 4.2 
9 Dry eyes 325 1.7 
10 Hypothyroidism 224 1.2 
11 Hormone replacement therapy 216 1.1 
12 Diabetes type II 206 1.1 
13 Major depression (no psychosis) 186 1.0 
14 Migraine 168 0.9 
15 Menopause 152 0.8 
 
Table 4.4 indicates the most frequently occurring diagnoses in the different genders.  
Acne, acne vulgaris and allergic rhinitis (respectively) were the three most prevalent 
diagnoses amongst both the females and the males.  A higher percentage of males 
than females were diagnosed with allergic rhinitis, although not to a significant degree 
(Chi²(1)=7.81, p<.005; V=0.06 Insignificant).   
 
Depression was diagnosed in 7.9% of the female population and was the fourth most 
prevalent female diagnosis.  It was only diagnosed in 3.7% of the males and was the 
seventh most prevalent male diagnosis.  A significantly higher percentage of females 
than males were diagnosed with depression (Chi²(1)=109.40, p<.0005; V=0.30 
Medium).  Literature on depression states that the condition is nearly twice as 
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common in females as in males (Mayo Clinic Staff, 2006), as was also observed in 
this study.  Depression is one of the most common psychiatric disorders.  At any given 
moment, about five to six percent of the South African population is depressed.  
(Potter & Hollister, 2001: 498).  Therefore, it should be mentioned that the high 
prevalence of depression in the acne population is not necessarily due to acne or 
acne treatment.   
 
Table 4.4:  Most prevalent diagnoses according to gender 
FEMALES (n = 13 245) MALES (n = 5 558) 
RANK DIAGNOSIS PERCENTAGE(%) DIAGNOSIS 
PERCENTAGE 
(%) 
1 Acne 73.7 Acne 71.6 
2 Acne vulgaris 35.8 Acne vulgaris 33.2 
3 Allergic rhinitis 10.3 Allergic rhinitis 12.0 
4 Depression 7.9 Nodulocystic acne 6.8 
5 Eczema 5.9 Asthma 5.9 
6 Hypertension 4.8 Eczema 4.8 
7 Asthma 4.4 Depression 3.7 
8 Nodulocystic acne 3.4 Hypertension 2.9 
9 Hormone replacement therapy 1.6 Dry eyes 2.4 
10 Hypothyroidism 1.6 Attention deficit disorder 1.0 
11 Dry eyes 1.5 Diabetes type II 1.0 
12 Major depression – no psychosis 1.2 Epilepsy (unspecified) 0.8 
13 Diabetes type II 1.1 Hypercholesterolaemia 0.8 
14 Menopause 1.1 Thrombo-embolic prophylaxis 0.7 
15 Migraine 1.1 Acne conglobata 0.7 
 
 
Asthma was more prevalent among males, having been diagnosed in 5.9% of males 
compared with 4.4% of females, and the difference was significant (Chi²(1)=15.64, 
p<.0005; V=0.13 Small).  Dry eyes were more frequently diagnosed in males (2.4%) 
than in females (1.5%).  Significance was proven (Chi²(1)=16.00, p<.0005; V=0.22 
Small).  The occurrence of dry eyes is a prominent side effect in patients who use 
systemic isotretinoin and can occur in up to 40% of patients on isotretinoin 
(Isotretinoin (Roaccutane) usage – a South African consensus guideline, 1997: 1412).   
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Nodulocystic acne was the fourth most frequently diagnosed disorder in males (6.8%), 
but was less frequently observed amongst females, where it was eighth most 
frequently diagnosed (3.4%).   
 
Attention deficit disorder was among the 15 most prevalent diagnoses in males, but 
ranked only 57th for females.  Hormone replacement therapy and menopause were 
two diagnoses pertaining specially to females.  Both of these diagnoses were among 
the 15 most prevalent diagnoses for females.   
 
The occurrence of diagnoses in the different age groups in the patient population is 
shown in Table 4.5.  In all seven age groups, acne was the diagnosis that occurred 
most frequently.  Acne vulgaris and allergic rhinitis were second and third most 
prevalent (respectively) in all age groups up to 34 years.  Asthma was the fourth most 
prevalent diagnosis for patients up to the age of 18 years, after which depression 
became the fourth most frequently diagnosed disorder in patients aged 19 to 49 years.  
Depression was sixth most prevalent in the adolescent generation (13 to 18 years 
old).  It can be observed that there was a constant increase in the percentage of 
patients diagnosed with depression in successive age groups.  Thus, in each older 
age group, a larger proportion of the acne patients was diagnosed with depression.  
Overall, independent of acne, depressive symptoms are known to increase markedly 
between childhood and adolescence (Marcotte, 1999).  Therefore, it cannot be said 
that acne was the sole cause of the increase in depression in the older age groups.   
 
Chronic disorders such as hypertension, cardiac failure, hypercholesterolaemia, 
arthritis and osteo-arthritis became more prevalent among patients aged 50 years and 
older.  This could be expected, as chronic disorders become more prevalent as age 
increases (Carpenter, Bernabei, Hirdes, Mor & Steel, 2000: 528).   
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Table 4.5:  Most prevalent diagnoses according to age groups  
< 13 years 
(n = 402) 
13 to 18 years  
(n = 5 496) 
19 to 24 years  
(n = 5 167) 
25 to 34 years 
(n = 4 198) 
35 to 49 years 
(n = 3 274) 
50 to 64 years 
(n = 251) 
≥ 65 years 
(n = 15) RANK 
Diagnosis % Diagnosis % Diagnosis % Diagnosis % Diagnosis % Diagnosis % Diagnosis % 
1 Acne 62.2 Acne 72.2 Acne 74.9 Acne 71.3 Acne 74.6 Acne 80.9 Acne 93.3 
2 Acne vulgaris 40.8 Acne vulgaris 37.6 
Acne 
vulgaris 33.2 Acne vulgaris 37.3 Acne vulgaris 31.4 Hypertension 37.5 Hypertension 53.3 
3 Allergic rhinitis 17.4 Allergic rhinitis 12.4 
Allergic 
rhinitis 8.5 Allergic rhinitis 10.5 Hypertension 14.6 
Acne 
vulgaris 18.3 Depression 33.3 
4 Asthma 9.5 Asthma 5.9 Depression 5.2 Depression 8.6 Depression 11.5 
Hormone 
replacement 
therapy 
17.1 Hypercholes-terolaemia 26.7 
5 Eczema 6.2 Nodulocystic acne 5.8 Asthma 3.8 Eczema 6.5 Allergic rhinitis 11.0 Menopause 14.7 Menopause 20.0 
6 Nodulocystic acne 5.2 Depression 3.7 Eczema 3.8 
Nodulocystic 
acne 4.2 Eczema 10.1 Depression 12.7 
Allergic 
rhinitis 20.0 
7 
Attention 
deficit 
disorder 
1.7 Eczema 3.5 Nodulocystic acne 3.4 Asthma 4.1 Asthma 4.8 
Arthritis (not 
specific) 12.4 Asthma 20.0 
8 Depression 1.5 Dry eyes 1.6 Dry Eyes 2.3 Hypertension 3.6 
Hormone 
replacement 
therapy 
4.1 Allergic rhinitis 10.8 
Cardiac 
failure 20.0 
9 Acne conglobata 1.2 
Attention 
deficit disorder 1.0 
Major 
depression-
no psychosis 
0.8 Hypothyroidism 1.6 Nodulocystic acne 3.9 
Thrombo-
embolic 
prophylaxis 
9.2 
Thrombo-
embolic 
prophylaxis 
13.3 
10 Epilepsy (unspecified) 1.0 
Epilepsy 
(unspecified) 0.8 Hypertension 0.7 Dry eyes 1.5 
Diabetes type 
II 3.2 Eczema 8.8 
Osteo-
arthritis 13.3 
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4.3.2    NUMBER OF DIFFERENT DIAGNOSES PER PATIENT 
 
In order to determine the number of different medical conditions each patient had 
been diagnosed with between 2000 and 2005, it was decided to group all the different 
acne type diagnoses together as one overall acne diagnosis for Section 4.3.2.  These 
acne type diagnoses included acne, acne vulgaris, nodulocystic acne, acne 
conglobata, acne keloidalis and acne associated with polycystic ovarian syndrome.  
Thus, even though a patient could have been diagnosed with acne vulgaris as well as 
nodulocystic acne over the six year time period (2000 to 2005), it was counted as one 
overall acne diagnosis for the purposes of this section.  The reason for this was to shift 
the focus to the number of conditions each patient was diagnosed with, in conjunction 
to overall acne, over the study period.  Figure 4.2 indicates the percentage distribution 
of patients with regards to the number of diagnoses per patient.  The six acne type 
diagnoses are referred to as “acne” in the figure.   
 
Figure 4.2:  Percentage (%) distribution of Population A with regards to number 
of diagnoses per patient (N = 18 803) 
20.3
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The minority of the population (34.3%) was diagnosed with one or more medical 
conditions in conjunction to acne between 2000 and 2005.  Of the total population, 
20.3% had one additional diagnosis except for acne, 8.0% had two, 3.3% had three 
and 1.5% had four additional diagnoses.  Only 1.2% of the population had more than 
four diagnoses in addition to acne.  Three patients had 12 diagnoses each, which was 
the maximum number of different diagnoses per patient.  When comparing females 
and males with regards to number of diagnoses per patient, no significant difference 
could be found, and both male and female diagnoses patterns followed a similar trend 
to the overall population diagnoses pattern.  (Chi²(10)=66.90, p<.0005; V=0.03 
Insignificant.) 
 
Table 4.6 outlines the number of diagnoses per patient for the different age groups.  
Again, the six acne type diagnoses were grouped together and referred to as “acne” in 
this table.   
 
Table 4.6:  Distribution of age groups in Population A with regards to number of 
diagnoses per patient  
PERCENTAGE (%) PATIENTS 
NUMBER OF 
DIFFERENT 
DIAGNOSES 
< 13 
years 
(n = 402) 
13 to 18 
years 
(n = 5 496) 
19 to 24 
years 
(n = 5 167) 
25 to 34 
years  
(n = 4 198) 
35 to 49 
years 
(n = 3 274) 
50 to 64 
years 
(n = 251) 
≥ 65 
years 
(n = 15) 
Acne 69.7 72.7 73.3 64.5 46.9 20.7 13.3 
Acne with one 
other 21.1 18.4 18.6 20.4 25.9 21.1 0.0 
Acne with two 
others 7.2 6.4 5.4 8.8 13.1 20.7 6.7 
Acne with three 
others 1.5 1.8 1.8 3.6 6.6 17.5 26.7 
Acne with four 
others 0.2 0.5 0.7 1.5 4.4 7.6 26.7 
Acne with more 
than four others 0.2 0.1 0.3 1.1 3.3 12.4 26.7 
 
 
When observing the percentages of patients from each age group with more than four 
diagnoses in addition to at least one acne type diagnosis, it becomes apparent that 
there was an increase in the number of diagnoses per patient from the younger to the 
older age groups.  While only 0.1% of patients between the ages 13 to 18 had more 
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than five diagnoses over the six years, 26.7% of patients aged 65 years or older were 
diagnosed with more than five different disorders.  In every age group of patients 
younger than 35 years, more than 60% of patients were not diagnosed with any other 
condition except acne.  From the age of 35 years and older, however, there was a 
decrease in the percentage of patients diagnosed only with acne.  This trend could 
have been expected, taking into account the fact that chronic disease states, such as 
hypertension, hypothyroidism and diabetes, can occur more frequently as patients get 
older.   The differences between number of diagnoses for the different age groups 
were significant (Chi²(25)=1885.83, p<.0005; V=0.18 Medium).  In order to calculate the 
statistical significance, the age groups 50 to 64 years and 65 years and older were 
grouped together.   
  
4.4    ACNE DIAGNOSES FOR POPULATION A 
 
4.4.1    INTRODUCTION 
 
After the broad analysis of all the diagnoses in Section 4.3, the focus of this section 
was specifically on an overview of the different acne types diagnosed.  There were six 
types of acne diagnoses present in the population, namely acne, acne vulgaris, 
nodulocystic acne, acne conglobata, acne keloidalis and acne associated with 
polycystic ovarian syndrome.  Acne associated with polycystic ovarian syndrome will 
hereafter be referred to as APCOS.  It should be noted that the diagnosis “acne” is 
non-specific, and could have been bestowed upon patients where more specific acne 
diagnoses or acne diagnoses codes were unknown.   
 
4.4.2    ACNE TYPE DIAGNOSES FOR POPULATION A 
 
Acne was the most common acne type diagnosis, with 73.1% of all patients having 
been diagnosed with it at least once.  Acne vulgaris was second most prevalent, 
having been diagnosed in 35.0% of all patients.  These two acne type diagnoses were 
by far the most prevalent acne diagnoses, with the other acne types affecting a much 
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smaller percentage of patients.  The distribution of acne type diagnoses are shown in 
Table 4.7.  Due to the fact that some patients were diagnosed with more than one 
acne type between 1 January 2000 and 31 December 2005, the percentage 
distribution indicated in Table 4.7 was more than 100.0% in total.   
 
Table 4.7:  Occurrence of acne types diagnosed in Population A 
PATIENTS ACNE TYPES NUMBER (N = 18 803) PERCENTAGE (%) 
Acne 13740 73.1 
Acne vulgaris 6586 35.0 
Nodulocystic acne 832 4.4 
Acne conglobata 71 0.4 
Acne Keloidalis 9 0.05 
APCOS 8 0.04 
 
Figure 4.3 indicates the prevalence of the six acne type diagnoses for different 
genders.  More females were diagnosed with acne and acne vulgaris (73.7% and 
35.8%, respectively) when compared to males (71.6% and 33.2%, respectively).  The 
difference in the frequency of diagnoses of acne between the genders was 
insignificant (Chi²(1)=7.05, p<.008; V=0.02 Insignificant), as was the difference in the 
frequency of acne vulgaris diagnoses between the genders (Chi²(1)=12.43, p<.0005; 
V=0.04 Insignificant).   
 
Nodulocystic acne, acne conglobata and acne keloidalis, on the other hand, were 
diagnosed in more males (6.8%, 0.7% and 0.1%, respectively) than females (3.4%, 
0.2% and 0.0%, respectively).  The difference in frequency of nodulocystic acne 
diagnoses between females and males was significant (Chi²(1)=96.60, p<.0005; 
V=0.34 Medium), as was the difference in frequency of acne conglobata 
(Chi²(1)=27.86, p<.0005; V=0.65 Large).  It was stated by Pal (1997: 15) that milder 
forms of acne (comedonal acne) occur mostly in women.  Therefore, it is 
understandable that the more severe acne forms (nodulocystic acne, acne conglobata 
and acne keloidalis) were more prevalent in the male population than in the female 
population.  APCOS is a disease that can only be experienced by females and gender 
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distribution results regarding this condition were as expected.  It was observed that 
only a small percentage of females were diagnosed with APCOS, indicating that it was 
an infrequent acne type experienced by this population.   
 
Figure 4.3: Occurrence of acne type diagnoses according to gender  
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When looking at the incidence of the acne types in the different age groups, as 
outlined in Table 4.8, it can be seen that acne was the acne type diagnosed in the 
highest percentage of patients of all age groups.  APCOS was diagnosed only in 
females aged 19 to 24 years.  This finding was in agreement with the literature 
statement that polycystic ovary syndrome may appear in adolescent years and affects 
approximately six percent of premenopausal women (Fallon, 2002).  It is interesting to 
note that acne keloidalis was diagnosed only in patients between the ages 35 to 49 
years.  Nodulocystic acne and acne vulgaris were diagnosed in all age groups except 
in the elderly patients, and acne conglobata was diagnosed in all seven age groups.   
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Table 4.8:  Occurrence of acne type diagnoses according to age groups 
PERCENTAGE (%) PATIENTS 
ACNE TYPE <13 
years 
(n = 402) 
13 to 18 
years 
(n = 5 496) 
19 to 24 
years 
(n = 5 167) 
25 to 34 
years 
(n = 4 198) 
35 to 49 
years 
(n = 3 274) 
50 to 64 
years 
(n = 251) 
≥ 65 
years 
(n = 15) 
Acne 61.4 72.2 74.9 71.3 74.6 82.1 93.3 
Acne vulgaris 40.8 37.6 33.2 37.3 31.4 18.3 0.0 
Nodulocystic 
acne 5.2 5.8 3.4 4.2 3.9 4.4 0.0 
Acne conglobata 1.2 0.5 0.3 0.2 0.3 0.4 6.7 
Acne keloidalis 0.0 0.0 0.0 0.0 0.2 0.0 0.0 
APCOS 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
 
 
Table 4.9 gives an outline of the number of patients diagnosed with more than one 
acne type over the six years included in the study.  A total of 2 395 patients (12.7% of 
Population A) were diagnosed with two different acne types over the course of six 
years.  The majority of these patients were diagnosed with acne and acne vulgaris 
(11.3% of Population A).  A total of 24 patients (0.1% of Population A) were diagnosed 
with three different acne types over the course of six years.  Three different acne 
types were the maximum number of different acne types diagnosed per patient.   
 
Table 4.9:  Distribution of patients diagnosed with more than one acne type 
between 2000 and 2005   
PATIENTS ACNE TYPES DIAGNOSED NUMBER (N = 18803) PERCENTAGE (%) 
Acne and Acne vulgaris 2 118 11.3 
Acne and Nodulocystic acne 217 1.2 
Acne and Acne conglobata 18 0.1 
Acne and Acne keloidalis 7 0.04 
Acne and APCOS 6 0.03 
Acne vulgaris and Nodulocystic acne 27 0.1 
Acne vulgaris and Acne conglobata 2 0.01 
Acne and Acne vulgaris and Nodulocystic acne 23 0.1 
Acne and Acne vulgaris and Acne conglobata 1 0.01 
 
Figure 4.4 indicates the distribution of patients with different numbers of acne 
diagnoses within the study period.  The distribution of males and females with regards 
to one acne type diagnosed, two acne types diagnosed and three acne types 
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diagnosed were even and no significant difference could be obtained.  (Chi²(2)=2.29, 
p<.317).   
 
In both genders, the highest percentage of patients (86.9% females and 87.7% males) 
were diagnosed with only one acne type over the six years.  Two types of acne were 
diagnosed in only 13.0% of females and 12.2% of males.  A very small percentage of 
patients were diagnosed with three acne types.  This may suggest that the initial acne 
type diagnosed in patients were not frequently changed by the health care 
professionals to another acne type, whether more or less severe in nature.   
 
Figure 4.4:  Number of different acne types diagnosed per patient over six years 
according to gender 
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4.5    PRESCRIBED NON-ACNE MEDICATIONS 
 
4.5.1    INTRODUCTION 
 
In this section, an overview of all the non-acne active ingredients (chemical entities of 
medication trade names) prescribed to Population A within the study period are given.  
There were 830 different active ingredients prescribed to the patient population over 
the six year time period.  Only the non-acne active ingredients are discussed in 
Section 4.5.2, as specific acne medications prescribed to Population A are discussed 
in Sections 4.6, 4.7, 4.8, and 4.9, and a summary of these findings are given in 
Section 4.10.  In Section 4.5.3, all medications (acne and non-acne medications) were 
included.   
 
4.5.2    PRESCRIPTION OF ALL NON-ACNE MEDICATIONS 
 
Table 4.10 indicates the 10 most frequently prescribed medications other than the 
medications used in the treatment of acne.   
 
Table 4.10: Non-acne active ingredients prescribed to the highest number of 
females and males 
FEMALES (n = 13 245) MALES (n = 5 558) 
RANK 
Active ingredient Percentage (%) Active ingredient 
Percentage 
(%) 
1 Fluoxetine 20 mg 4.0 Cetirizine 10 mg 3.0 
2 Citalopram 20 mg 2.9 Fluticasone 50 mcg 2.8 
3 Cetirizine 10 mg 2.8 Salbutamol 100 mcg 2.6 
4 Fluticasone 50 mcg 2.3 Artificial tear preparations 2.5 
5 Salbutamol 100 mcg 2.1 Mometasone 50 mcg 2.2 
6 Methylprednisolone aceponate 1% m/m 2.1 Loratadine 10 mg 2.1 
7 Loratadine 10 mg 2.0 Fluoxetine 20 mg 1.9 
8 Mometasone 0.1% m/m 1.9 Budesonide 100 mcg 1.9 
9 Mometasone 50 mcg 1.6 Budesonide 200 mcg 1.8 
10 Artificial tear preparations 1.5 Mometasone 0.1% m/m 1.7 
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Eight of the 10 active ingredients in the table were similar for both females and males, 
although they occurred in different orders of prevalence.  Citalopram 20 mg and a 
topical preparation of methylprednisolone aceponate one percent were present among 
the 10 most frequently prescribed non-acne related active ingredients for females, but 
not for males.  Budesonide 100 mcg and 200 mcg were among the 10 most frequently 
prescribed non-acne medication for males and not for females.  All medications in 
Table 4.10 are indicated in the treatment of depression, allergic rhinitis, asthma, 
eczema or dry eyes.  These findings support previous findings in this study that these 
diagnoses were prevalent amongst the acne population.  Once again, it is clear that 
treatment of depression was more prevalent amongst females than males, as the two 
most frequently prescribed non-acne active ingredients for females were both anti-
depressants.  As shown in Table 4.10, fluoxetine was the seventh most frequently 
prescribed non-acne medication amongst males and was the only anti-depressant 
among the 10 most frequently prescribed non-acne medications for males.  Cetirizine 
10 mg was the most frequently prescribed non-acne active ingredient for males, 
followed by fluticasone and salbutamol.  These medications are indicated for 
treatment of allergic rhinitis and asthma.  Artificial tear preparations were prescribed to 
a higher percentage of males (2.5%) than females (1.5%), which supports previous 
findings in this study that more males were diagnosed with dry eyes than females.   
 
4.6    HORMONE THERAPY IN THE MANAGEMENT OF ACNE 
 
4.6.1    INTRODUCTION 
 
In this section, the focus is specifically on hormone therapy prescribed to females in 
order to alleviate acne.  As described in Section 3.9, hormone therapy includes oral 
contraceptive therapy, HRT and anti-androgen therapy.   
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4.6.2    PRESCRIPTION OF HORMONE THERAPY 
 
Hormone therapy was prescribed to 6 240 females (47.1% of all females) for acne 
treatment.  As shown in Figure 4.5, the highest percentage of females who received 
hormone therapy was between the ages 19 to 24 years (57.2%), while the second 
highest percentage (52.6%) of females who received hormone therapy prescriptions 
were aged between 25 to 34 years.  Thus, hormone therapy was prescribed to more 
than half of all females aged 19 to 34 years.   
 
Figure 4.5:  Percentage of females from each age group to whom hormone 
therapy was prescribed 
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Females aged 13 to 18 years constituted the third highest percentage of females on 
hormone therapy (46.5%).  The 2005 South African Acne Treatment Guideline 
recommends the prescription of hormonal therapy to females who have moderate to 
severe acne or who shows signs of androgen over-activity.  It is said to be useful in 
females with late-onset acne and in patients with prominent premenstrual acne flares.  
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It can also be considered in females with normal serum androgens if there are 
persistent inflammatory papules or nodules on the lower face.  (Acne Guideline 2005 
update, 2005: 888 – 889.)  When investigating the age groups to whom hormone 
therapy was most frequently prescribed in this population, it can be seen that it is the 
age groups with the highest associated pregnancy risk (13 to 34 years), and oral 
contraceptives may have served a convenient dual purpose.   
 
Combined oral contraceptive use is discouraged from the age 35 years and older in 
females who smoke or who are at high risk for cardiovascular disease, as oral 
contraceptives may increase cardiovascular disease risk and the risk of breast cancer.  
(South African Medicines Formulary, 2003: 223.)  In spite of this, 32.0% of females 
aged 35 years or older received prescriptions for hormone therapy.  It should be 
noted, however, that some of these females could have received HRT or anti-
androgens and not oral contraceptives.  There were only eight females who received 
hormone therapy, a very small number, and it could therefore be concluded that the 
large majority of females received either oral contraceptive therapy or anti-androgen 
therapy.  After the age of 50 years, no oral contraception should be prescribed to 
females, regardless of their smoking status or cardiovascular risk (South African 
Medicines Formulary, 2003: 223).  Despite this fact, 12.2% of females aged 50 to 64 
years, and 10.0% of females aged 65 years or older were still prescribed hormone 
therapy.  A high percentage (18.1%) of females younger than 13 years was on 
hormone therapy.  It can be assumed that hormone therapy can only be used 
effectively and safely once a female has started to menstruate.  Although the age of 
this event may differ from patient to patient, the number of females younger than 13 
years who received hormone therapy is still questionably high.   
 
 4.6.3    PRESCRIPTION OF HORMONE THERAPY TRADE NAMES 
 
There were 26 different hormone therapy trade names prescribed to females.  Of 
these 26, 19 were oral contraceptives, two were anti-androgens and five were 
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hormone replacement medications.  These trade names are indicated in Table 4.11 in 
order of prevalence.   
 
Table 4.11:  Hormone therapy trade names prescribed to females 
FEMALES (n = 6 240) 
RANK TRADE NAME TYPE# NUMBER PERCENTAGE (%) 
1 Diane-35® OC 3 684 59.0 
2 Minerva® OC 2 522 40.4 
3 Ginette® OC 1 186 19.0 
4 Androcur® AA 817 13.1 
5 Yasmin® OC 96 1.5 
6 Marvelon 150/30® OC 81 1.3 
7 Cipla-Cyproterone acetate® AA 71 1.1 
8 Melodene® OC 61 1.0 
9 Triphasil® OC 53 0.8 
10 Tricilest® OC 40 0.6 
11 Femodene ED® OC 29 0.5 
12 Mirelle® OC 10 0.2 
13 Minesse® OC 9 0.1 
13 Mercilon® OC 9 0.1 
14 Triodene ED® OC 8 0.1 
15 Minulette® OC 4 0.1 
15 Nordette 28® OC 4 0.1 
16 Climen® HRT 3 0.0 
17 Biphasil 28® OC 2 0.0 
17 Postoval 28® HRT 2 0.0 
17 Loette® OC 2 0.0 
18 Ovral 28® OC 1 0.0 
18 Primogyn®  HRT 1 0.0 
18 Duphaston® HRT 1 0.0 
18 Evra® HRT 1 0.0 
18 Microval 28® OC 1 0.0 
# TYPE:           AA = Anti-androgen OC = Oral contraceptive HRT = Hormone replacement therapy 
 
Diane-35® was the most frequently prescribed oral contraceptive, as it was prescribed 
to 59.0% of the females on hormone therapy.  Minerva® was prescribed to 40.4% of 
females on hormone therapy, making it the second most prevalent hormone therapy 
trade name.  Ginette® was prescribed to the third highest percentage of patients 
(19.0%).  The anti-androgen Androcur® was prescribed to 13.1% of females and was 
the fourth most frequently prescribed hormone therapy trade name.   
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The South African Acne Treatment Guideline recommends oral contraceptives, 
cyproterone acetate, drospirenone and spironolactone as the mainstay of hormonal 
therapy (Acne Guideline 2005 update, 2005: 889).  Although HRT was prescribed to 
only eight patients, it is not a recognised treatment option in acne management.  The 
prescription choice in these eight females can therefore represent either last resort 
efforts in acne patients older than 35 years, or inferior treatment choices by 
prescribers.   
 
4.6.4    PRESCRIPTION OF HORMONE THERAPY ACTIVE INGREDIENTS 
 
The hormone therapy active ingredients that were most frequently prescribed are 
indicated in Table 4.12.    
 
Cyproterone acetate combined with an oestrogen was prescribed to 95.2% of females 
on hormone therapy, making it by far the most popular prescribed hormone therapy.  
Cyproterone acetate without an oestrogen was the second most prevalent active 
ingredient, having been prescribed to 10.5% of all females on hormone therapy.  
Patients might have received concurrent prescriptions for a normal oral contraceptive 
with the addition of cyproterone acetate for the first 15 days of their menstrual cycle.  
Thus, cyproterone acetate-containing products played a large role in the management 
of acne amongst females.  This is in accordance with recommendations of the South 
African Acne Treatment Guideline, which recommends cyproterone acetate in 
combination, or cyproterone acetate in combination with an oral contraceptive, as first 
line hormonal therapy in acne management (Acne Guideline 2005 update, 2005: 889).  
Products containing a combination of gestodene and an oestrogen were third most 
prevalent (1.8% of females on hormone therapy).  Drospirenone in combination with 
an oestrogen, which is also an acceptable treatment according to the South African 
Acne Treatment Guideline (Acne Guideline 2005 update, 2005: 889), was prescribed 
to 1.5% of the population.  Combination therapy containing levonorgestrel, and 
levonorgestrel alone, was also prescribed for acne treatment even though it is known 
to worsen acne (Weiss, 1997: 15).    
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Table 4.12:  Most frequently prescribed hormone therapy active ingredients 
PATIENTS (n = 6 240) 
RANK ACTIVE INGREDIENT TRADE NAMES NUMBER PERCEN-TAGE (%) 
1 Ethinylestradiol; cyproterone acetate 
Diane-35®, Minerva®, 
Ginette® 5 942 95.2 
2 Cyproterone acetate Androcur
®, Cipla-
Cyproterone acetate® 658 10.5 
3 Ethinylestradiol; gestodene 
Melodene®, Femodene 
ED®, Mirelle®, Triodene®, 
Minesse®, Minulette® 
113 1.8 
4 Ethinylestradiol; drospirenone Yasmin® 96 1.5 
5 Ethinylestradiol; desogestrel Marvelon 150/30
®, 
Mercilon® 90 1.4 
6 Ethinylestradiol; levonorgestrel  Triphasil
®, Biphasil®,  
Nordette 28®, Loette® 61 1.0 
7 Ethinylestradiol; norgestimate Tricilest® 40 0.6 
8 Estradiol valerate; cyproterone acetate Climen
® 3 0.0 
8 Ethinylestradiol; norgestrel Ovral 28®, Postoval 28® 3 0.0 
9 Estradiol valerate  Primogyn® 1 0.0 
9 Dydrogesterone Duphaston® 1 0.0 
9 Ethinylestradiol; norelgestromin Evra® 1 0.01 
9 Levonorgestrel Microval 28® 1 0.01 
 
4.7    ANTIBIOTIC THERAPY IN THE MANAGEMENT OF ACNE 
 
4.7.1    INTRODUCTION 
 
The use of antibiotics in the treatment of acne is the focus of this section.  It should be 
noted that systemic as well as topical antibiotics were included in this section.   
 
4.7.2    PRESCRIPTION OF ANTIBIOTIC THERAPY 
 
A total of 8 135 patients (43.3% of Population A) received prescriptions for systemic 
antibiotic therapy to treat acne.  Of these 8 135 patients, 5 205 were female (39.3% of 
all females) and 2 930 were male (52.7% of all males).  This difference between the 
genders was significant (Chi²(1)=140.26, p<.0005; V=0.13 Small).  The reason why a 
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higher percentage of males were on systemic antibiotic therapy could be the wider 
acne therapy range available to females due to hormone therapy.  There were 985 
patients (5.2% of the population) to whom topical antibiotic therapy (alone or in 
combination with other topical active ingredients) was prescribed.  Of these 985 
patients, 697 were female (5.2% of all females) and 288 were male (5.1% of all 
males).  The prescription frequency of topical antibiotic therapy for the different 
genders was not significantly different (Chi²(1)=0.27, p<.602).  This could be due to the 
fact that the same topical agents were available for both genders.  When considering 
topical and systemic antibiotic therapy together, 8 415 patients (44.8% of the patient 
population) were on overall antibiotic therapy, of which 5 442 were females (41.1% of 
all females) and 2 973 were males (53.5% of all males).  This difference was 
significant (Chi²(1)=113.83, p<.0005; V=0.12 Small).   
 
The prescribing frequency of systemic antibiotics for all age groups of females and 
males are shown in Figure 4.6.   
 
Females younger than 13 years were the age group with the highest percentage of 
females who received systemic antibiotic prescriptions (56.0% of females younger 
than 13 years).  Thus, systemic antibiotics is a popular treatment option for females 
younger than 13 years, at which age hormone therapy or isotretinoin therapy should 
preferably not yet be administered.  It should be noted, however, that tetracycline 
derivatives are contraindicated in patients younger than eight years old and should 
preferably be avoided in patients younger than 12 years of age, and that the safety of 
cotrimoxazole in patients younger than two years old is still questioned.  (South 
African Medicines Formulary, 2003: 270, 273 – 274, 279.)  Erythromycin could be 
safely prescribed, however, and cotrimoxazole would also be safe for this population, 
as there were no patients younger than two years.  Females aged 19 to 34 years 
constituted the smallest percentage to whom antibiotics were prescribed, indicating 
that other treatment options, like hormone therapy, were more popular for this age 
group.  At the age of 35 years and older, systemic antibiotic therapy prescription 
became more prevalent again, as hormone therapy use became less prevalent.  In 
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every female age group, however, systemic antibiotic therapy was prescribed to a high 
percentage of patients.   
 
Figure 4.6: Percentage of females and males from each age group to whom 
antibiotic therapy was prescribed  
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When looking at the pattern of antibiotic prescription in the male age groups, as shown 
in Figure 4.6, it could be observed that except for the five males aged 65 years or 
older, all of whom were prescribed systemic antibiotic therapy, the highest percentage 
of males were younger than 13 years.  It could be argued that patients so young would 
probably not have had a long acne history, and therefore could have been prescribed 
antibiotics rather than isotretinoin (which should preferably be prescribed after failure 
to clear acne with systemic antibiotic therapy).  There was, as with the females, a 
small decrease in percentage in patients aged 13 to 34 years on antibiotic therapy, 
after which the percentage of patients increased with each successive age group.  
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Although this pattern is observed, systemic antibiotic therapy remained a more 
constant, continuous acne treatment option throughout all ages in the male population 
than the female population.  This difference was significant (Chi²(6)=396.14, p<.0005; 
V=0.22 Small).   
 
4.7.3   PRESCRIPTION OF SYSTEMIC AND TOPICAL ANTIBIOTIC THERAPY 
TRADE NAMES 
 
This section serves to indicate which systemic and topical antibiotic trade names were 
most frequently prescribed to the patient population.  Altogether, 72 different antibiotic 
trade names were prescribed to females and 70 different antibiotic trade names were 
prescribed to males, thus indicating that a similar variety of different antibiotic trade 
names were used by both genders.  Although different strengths of some of these 
formulations were prescribed to patients, only the different trade names, and not the 
particular strengths, were considered.   
 
The antibiotic trade names prescribed to the highest number of patients are 
represented by Table 4.13.  These 10 medications were the same for females and 
males, although their orders of prevalence differed.  The four most frequently 
prescribed trade names for both genders were Tetralysal®, Cyclimycin®, Cyclidox EC® 
and Doxycyl®.  Tetralysal® was the most frequently prescribed antibiotic trade name 
for females (prescribed to 16.2% of females on antibiotic therapy).  It was second 
most frequently prescribed for males, having been prescribed to 15.3% of males on 
antibiotic therapy.  Cyclimycin® was most frequently prescribed for males (prescribed 
to 17.6% of males on antibiotic therapy) and was the third most frequently prescribed 
for females.  Doxycyl® was the second most frequently prescribed antibiotic trade 
name for females (prescribed to 13.0% of females on antibiotic therapy).   
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Table 4.13:  Most frequently prescribed systemic and topical antibiotic trade 
names  
FEMALES (n = 5 205) 
RANK TRADE NAME ACTIVE INGREDIENT NUMBER  PERCENTAGE (%)  
1 Tetralysal® Lymecycline 879 16.2 
2 Doxycyl® Doxycycline 706 13.0 
3 Cyclimycin® Minocycline 678 12.5 
4 Cyclidox EC® Doxycycline 573 10.5 
5 Benzamycine® Erythromycin; benzoyl peroxide 516 9.5 
6 Triomin® Minocycline 461 8.5 
7 Purbac Adult® Sulfamethoxazole; trimethoprim 432 7.9 
8 Cyclidox® Doxycycline 391 7.2 
9 Purbac DS® Sulfamethoxazole; trimethoprim 366 6.7 
10 Minotabs® Minocycline 175 3.2 
MALES (n = 2 930) 
RANK TRADE NAME ACTIVE INGREDIENT NUMBER PERCENTAGE (%)  
1 Cyclimycin® Minocycline 522 17.6 
2 Tetralysal® Lymecycline 456 15.3 
3 Cyclidox EC® Doxycycline 406 13.7 
4 Doxycyl® Doxycycline 317 10.7 
5 Cyclidox® Doxycycline 258 8.7 
5 Purbac Adult® Sulfamethoxazole; trimethoprim 258 8.7 
6 Purbac DS® Sulfamethoxazole; trimethoprim 245 8.2 
7 Triomin® Minocycline 230 7.7 
8 Benzamycine® Erythromycin; benzoyl peroxide 224 7.5 
9 Minomycin® Minocycline 108 3.6 
10 Minotabs® Minocycline 92 3.1 
 
4.7.4  PRESCRIPTION OF SYSTEMIC AND TOPICAL ANTIBIOTIC THERAPY 
ACTIVE INGREDIENTS 
 
The 10 antibiotic active ingredients and active ingredient combinations that were most 
frequently prescribed to Population A are presented in Table 4.14.  Although different 
strengths of some of these formulations were prescribed to patients, only the active 
ingredients, and not the particular strengths, were taken into consideration.     
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Table 4.14: Most frequently prescribed antibiotic active ingredients  
FEMALES (n = 5 205) 
RANK ACTIVE INGREDIENT NUMBER PERCENTAGE (%)  
1 Doxycycline 1 860 34.2 
2 Minocycline 1 516 27.9 
3 Lymecycline 1 027 18.9 
4 Trimethoprim; sulfamethoxazole 810 149.4 
5 Erythromycin 571 10.5 
6 Erythromycin; benzoyl peroxide 516 9.5 
7 Clindamycin 192 3.5 
8 Oxytetracycline 154 2.8 
9 Tetracycline 14 0.3 
10 Trimethoprim 12 0.2 
MALES (n = 2 930) 
RANK ACTIVE INGREDIENT NUMBER PERCENTAGE (%) 
1 Doxycycline 1 069 36.0 
2 Minocycline 966 32.5 
3 Lymecycline 534 18.0 
4 Trimethoprim; sulfamethoxazole 529 17.8 
5 Erythromycin; benzoyl peroxide 224 7.5 
6 Erythromycin 208 0.7 
7 Oxytetracycline 84 2.8 
8 Clindamycin 67 2.3 
9 Phenoxymethylpenicillin 26 0.9 
10 Tetracycline 14 0.5 
 
Altogether, there were 16 different antibiotic active ingredients or active ingredient 
combinations prescribed to females, and 13 to males.  For both genders, the 
tetracycline derivatives (doxycycline, minocycline and lymecycline) were the antibiotics 
prescribed to the highest number of patients.  This was in accordance with the 
literature guidelines in which the tetracycline derivatives are recommended as first line 
antibiotic therapy, and are also known to be the most frequently prescribed antibiotic 
agents in acne treatment.  (Acne Guideline 2005 update, 2005: 885 – 886; Liao, 2003: 
48; Tan, 2003: 309.)  For both genders, doxycycline was the most frequently 
prescribed antibiotic active ingredient (prescribed to 34.2% of females on antibiotic 
therapy and 36.0% of males on antibiotic therapy), minocycline was the second most 
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prevalent antibiotic active ingredient and lymecycline was third most prevalent.  The 
South African Acne Treatment Guideline suggests that lymecycline should be 
considered as first choice antibiotic, while doxycycline or minocycline may be 
prescribed as second choice (Acne Guideline 2005 update, 2005: 886).  In this 
population, lymecycline was not as frequently prescribed as the other two newer 
tetracycline derivatives.   
 
Sulfamethoxazole combined with trimethoprim (cotrimoxazole) was the second most 
popular antibiotic class, followed by erythromycin and erythromycin combinations.  
These results are also in line with the South African Acne Treatment Guideline and 
with other literature sources (Acne Guideline 2005 update, 2005: 886; Presbury & 
Weiss, 2000: 5; Tan, 2003: 309.)  A significantly larger proportion of males received 
cotrimoxazole when compared to females.  (Chi²(1)=57.63, p<.0005; V=0.21 Small.)  It 
is interesting to note that oxytetracycline and tetracycline were still prescribed, 
although the newer tetracycline derivatives are equally as effective in acne treatment 
and have less resistance of P.acnes having been developed against it (Fulton, 2002: 
101; Woodard, 2002).  The South African guideline states that very little use remains 
for the first-generation tetracyclines (Acne Guideline 2005 update, 2005: 886).       
 
4.8    SYSTEMIC ISOTRETINOIN IN THE MANAGEMENT OF ACNE 
 
4.8.1    INTRODUCTION 
 
In this section, attention is given to the prescribing of systemic isotretinoin for 
Population A.  Results pertaining to topical isotretinoin are excluded from this section.  
Thus, any reference to isotretinoin in this section only includes systemic isotretinoin.   
 
4.8.2    PRESCRIPTION OF SYSTEMIC ISOTRETINOIN 
  
Of the 18 803 patients in the study, systemic isotretinoin was prescribed at least once 
to 7 915 patients (42.1% of all patients).  Of these 7 915 patients, 4 780 were females 
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(36.1% of all females) and 3 135 were males (56.4% of all males).  The proportion of 
males who received systemic isotretinoin was significantly higher than the proportion 
of females (Chi²(1)=347.96, p<.0005; V=0.21 Small).  This could be due to the 
availability of hormone therapy to females, as described earlier, but could also serve 
as an indication that more caution is taken by prescribers regarding isotretinoin 
prescription to females due to the teratogenic risk involved.   
 
The percentages of females and males from all age groups who received isotretinoin 
prescriptions are shown in Figure 4.7.  In every age group up to patients aged 49 
years, the percentage of males to whom isotretinoin was prescribed was significantly 
higher than the counterpart female percentage.  (Chi²(6)=959.37, p<.0005; V=0.34 
Medium.)  The age group where the highest percentage of females received 
isotretinoin was 35 to 49 years (40.1% of females in this age group).  Amongst 
females aged 50 to 64 years, 37.6%, the second highest percentage, received 
isotretinoin prescriptions. Although the chances of scar formation are decreased by 
early use of systemic isotretinoin (because systemic isotretinoin is the most effective 
acne treatment), the relatively low number of females younger than 35 years who 
received isotretinoin therapy suggest that isotretinoin was not a popular treatment 
option for most young females.  It could, however, also be said that the prescription of 
oral contraceptives for females older than 35 years becomes more complicated 
(Seibert, et al., 2003: 54) or that pregnancy risk decreased in these age groups, thus 
resulting in a tendency of prescribers to resort to isotretinoin therapy.   
 
It should also be noted that 37.1% of females younger than 13 years received 
isotretinoin prescriptions.  This was an unexpected finding and not in accordance with 
guidelines, as isotretinoin use is not promoted in patients younger than 12 years of 
age. (South African Medicines Formulary, 2003: 199; Layton, et al., 2006: 774.)   
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Figure 4.7:  Percentage of females and males of all age groups to whom 
systemic isotretinoin was prescribed  
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The age group with the highest proportion of males to whom isotretinoin was 
prescribed was patients aged 13 to 18 years (59.6% of males in this age group).  The 
prescription of isotretinoin to males aged 13 to 34 was popular.  The fact that 44.1% of 
males younger than 13 years received isotretinoin was, as with the females, not 
according to recommendations.     
 
4.8.3    PRESCRIPTION OF SYSTEMIC ISOTRETINOIN TRADE NAMES 
 
There were three different trade names of isotretinoin available in South Africa at the 
time of the study, namely Roaccutane®, Acnetane® and Oratane®.  Acnetane® and 
Oratane® are generic equivalents of Roaccutane®.  It should be noted that Oratane® 
was launched in South Africa during September 2003 (van Rooyen, 2007) and 
Acnetane® during October 2003 (Taggart, 2007).  All three trade names contain 
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isotretinoin in capsule form in both 10 mg and 20 mg dosage strengths.  Thus, 
altogether, three different trade names of isotretinoin, each with two different dosage 
strengths, were available to the population as of October 2003.  Only Roaccutane® 
was available from 1 January 2000 to September 2003.  This can account for the 
higher proportion of Roaccutane® prescriptions when taking the whole study period 
into consideration.  A combination of 10 mg and 20 mg capsules could have been 
prescribed to patients in order to allow for the correct dose of isotretinoin to be taken.  
It should therefore be noted that patients in Population A could have received 10 mg 
capsules and 20 mg capsules simultaneously.   
 
The different numbers of patients who received prescriptions for the different trade 
names and dosage strengths of isotretinoin are outlined in Table 4.15.   
 
Table 4.15:  Prescription of isotretinoin trade names to Population A 
PATIENTS  TRADE NAME  STRENGTH NUMBER (n = 7 915) PERCENTAGE (%) 
Acnetane®  10 mg 248 3.1 
Acnetane®  20 mg 636 8.0 
Oratane®  10 mg 411 5.2 
Oratane®  20 mg 1 057 13.4 
Roaccutane®  10 mg 2 976 37.6 
Roaccutane®  20 mg 6 191 78.2 
 
The findings were similar for females and males.  The original trade name, 
Roaccutane® was prescribed to the majority of the population.  Roaccutane® 20 mg 
was prescribed to the highest percentage of patients (78.2% of patients who received 
isotretinoin) and Roaccutane® 10 mg to the second highest percentage of patients 
(37.6% of patients who received isotretinoin).  Of the two generic isotretinoin products, 
Oratane® and Acnetane®, Oratane® was more frequently prescribed to both females 
and males.  Acnetane® was the least popular prescription choice.  The 20 mg dosage 
strength was more frequently prescribed than the 10 mg dosage strength for all three 
trade names.  This could be expected, as 10 mg capsules are usually used in 
combination with 20 mg capsules to obtain the correct dose per day (for example, 50 
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mg daily or 70 mg daily).  In many cases, however, only 20 mg capsules are needed 
in obtaining the correct dose (for example, 40 mg daily or 60 mg daily).   
 
4.9    TOPICAL FORMULATIONS IN THE MANAGEMENT OF ACNE  
 
4.9.1    INTRODUCTION 
 
This section serves to give a brief overview of the topical formulations prescribed to 
Population A in the treatment of acne.  Topical formulations included creams, gels, 
ointments, fatty ointments, lotions, swabs, applications and topical solutions.   
 
4.9.2    PRESCRIPTION OF TOPICAL ACNE FORMULATIONS 
 
There were 3 553 patients (18.9%) in Population A who received at least one 
prescription for a topical acne preparation between 2000 and 2005.  Of these 3 553 
patients, 2 557 were females (19.3% of all females) and 996 were males (17.9% of all 
males).  This difference was significant (Chi²(1)=685.82, p<.0005; V=0.44 Medium).   
 
The percentages of females and males of every age group who received prescriptions 
for topical agents are shown in Figure 4.8.  There was an increase in the percentage 
of females who received topical acne treatment as they grew older.  Females aged 50 
to 64 years were most likely to be using topical acne treatment.     
 
Amongst the males, there was a more constant pattern of topical formulation 
prescription for the age groups.  The age group in which the highest percentage of 
males received topical formulation prescriptions was 19 to 24 years.   The significant 
difference in patterns between females and males with regards to topical acne 
treatment (Chi²(6)=221.40, p<.0005; V=0.25 Small) could again be attributed to the 
high percentage of females aged 19 to 34 years who received hormone therapy 
instead of other acne treatments.   
 129
Figure 4.8:  Percentage of females and males of all age groups to whom topical 
acne formulations were prescribed  
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4.9.3 PRESCRIPTION OF TOPICAL ACNE FORMULATION ACTIVE INGREDIENTS  
 
Figure 4.9 outlines the prescription of topical agents for Population A.  Adapalene 
(Differin® gel or cream) was the topical treatment prescribed to the largest proportion 
of females (27.5% of females who received topical acne formulations).  Antibiotic 
topical formulations as a group (including clindamycin and erythromycin) was the 
second most frequently prescribed topical medicine for females, as it was prescribed 
to 27.3% of females on topical medications.  Benzoyl peroxide was the third most 
frequently prescribed, contributing to 22.8% of females’ prescriptions for acne 
treatment.  These three topical active ingredients also ranked as the most frequently 
prescribed amongst the male population, although the order of incidence was 
different.   
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Figure 4.9:  Percentage of females and males to whom topical acne formulation 
active ingredients were prescribed 
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Topical antibiotics were prescribed to the highest proportion of males (28.9% of males 
on topical acne formulations), benzoyl peroxide to the second highest proportion of 
males (24.7%) and adapalene to the third highest percentage of males (24.3%).  
Adapalene has been shown to be as effective as other topical vitamin A derivatives 
(including tazarotene, tretinoin and isotretinoin) in treating acne, but with less severe 
side effects (Acne Guideline 2005 update, 2005: 887; Ashworth, 2005: 64; Chivot, 
2005: 14; Cook-Bolden, 2006; Shalita, 2001: 45).  Therefore, the fact that adapalene 
was the most frequently prescribed topical retinoid was in accordance with literature 
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recommendations.  Topical retinoids should be the primary form of treatment for most 
forms of acne vulgaris and is also an essential part of maintenance therapy (Acne 
Guideline 2005 update, 2005: 887).  Altogether, a very small percentage of patients in 
the total population received prescriptions for adapalene, or other retinoids, and the 
prescription of adapalene should be encouraged.   
 
For both genders, the combination of erythromycin and benzoyl peroxide was the 
fourth most frequently prescribed topical treatment.  Fixed-combination products 
containing benzoyl peroxide and erythromycin are more effective for acne than their 
individual components alone.  Such combinations are not associated with the 
development of antibacterial-resistant bacteria.  (Akhavan & Bershad, 2003: 482; 
Feldman et al., 2004: 2126.)  Thus, the prescription of this combination instead of only 
antibiotic therapy or only benzoyl peroxide therapy should be encouraged.   
 
Azelaic acid, tretinoin, topical isotretinoin, topical cortisone and tazarotene were also 
agents prescribed to the population.  Sulphur, zinc, coal tar, resorcinol, calamine, 
salicylic acid, yellow paraffin, spirits of lavender, aqueous cream and emulsifying 
ointment were the ingredients present in the miscellaneous topical acne treatments 
prescribed, either in combination or alone.   
 
4.10    SUMMARY OF ALL ACNE TREATMENT OPTIONS 
 
4.10.1    INTRODUCTION 
 
This section serves as a summary of the prescription frequency of the acne treatments 
discussed in each separate section.  The treatment options included in this section are 
hormone therapy, systemic antibiotics, systemic isotretinoin and topical acne 
formulations.   
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4.10.2    PRESCRIPTION OF ALL ACNE TREATMENT OPTIONS 
 
Overall, systemic antibiotic therapy was the most frequently prescribed acne treatment 
modality in Population A.  This is in accordance with the statement of the South 
African Acne Treatment Guideline that antibiotics are the most frequently used type of 
acne medication (Acne Guideline 2005 update, 2005: 885).  Figure 4.10 gives an 
outline of the overall prevalence of the therapy methods employed in the treatment of 
acne in Population A.   
 
Figure 4.10:  Prescription of all acne treatment options to Population A  
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It can be observed from Figure 4.10 that hormone therapy was the most popular acne 
treatment method for females, having been prescribed to 47.1% of all females.  The 
second most prevalent treatment method in the female population was systemic 
antibiotic therapy, prescribed to 39.3% of females.  Systemic isotretinoin was 
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prescribed to 36.1% of females and topical acne treatment was only prescribed to 
19.3% of all females.   
 
The most prevalent acne treatment option for the males was systemic isotretinoin, as 
it was prescribed to 56.4% of males.  Systemic antibiotic therapy was the second most 
prevalent treatment, prescribed to 52.7% of males.  The impact of hormone therapy on 
the female population could be observed, as smaller percentages of females than 
males received systemic isotretinoin and antibiotic therapy.  These differences were 
significant (Chi²(1)=347.64, p<.0005; V=0.21 Small; Chi²(1)=139.87, p<.0005; V=0.13 
Small, respectively).  Topical acne medications were prescribed to only 17.9% of all 
males.      
 
After the investigation of acne therapy prescribed to Population A, it can be concluded 
that some aspects of treatment were in accordance with literature recommendations.  
However, there was a definite lack of compliance with literature recommendations 
(both the 2005 Acne Guideline 2005 update, older South African guidelines and other 
recommendations) regarding acne management by prescribers.   
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CHAPTER 5 
RESULTS AND DISCUSSION: 
QUESTIONNAIRE SURVEY 
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5.1    INTRODUCTION 
 
A retrospective analysis of data obtained through conducting a patient questionnaire 
survey was done and the results are presented and discussed in this chapter.  
Respondents to the questionnaire survey are referred to as Population B.  Population 
B consisted of patients situated in the NMM on systemic isotretinoin therapy during the 
time of the questionnaire survey conduction (thus, within the time frame of 5 August 
2006 to 20 December 2006).   
 
5.2    DEMOGRAPHICS OF POPULATION B 
 
5.2.1    GENDER DISTRIBUTION 
 
Population B consisted of 57 patients, 24 (42.1%) of whom were female and 33 who 
were male (57.9%).  There were approximately 1.4 males for every female.  The 
difference between the number of female and male respondents was insignificant 
(Chi²(1)=1.42, p<.233).   
 
5.2.2    AGE DISTRIBUTION 
 
For consistency, the same age grouping technique was used for Population B as for 
Population A (see Table 4.2).  The age distribution of Population B is indicated in 
Table 5.1, whereas Figure 5.1 indicates the gender distribution of the different age 
groups.   
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Table 5.1:  Age distribution of Population B  
PATIENTS 
AGE GROUPS (IN YEARS) NUMBER (N = 57) PERCENTAGE (%) CUMULATIVE PERCENTAGE (%)
<13 0 0.0 0.0 
13 to 18 31 54.4 54.4 
19 to 24 21 36.8 91.2 
25 to 34 2 3.5 94.7 
35 to 49 2 3.5 98.2 
50 to 64 0 0.0 98.2 
≥ 65 1 1.8 100.0 
 
Figure 5.1:  Age distribution of Population B according to gender  
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The average age of Population B was 20.2 years (SD = 7.9 years, n = 57).  The 
minimum age was 14 years and the maximum age was 65 years.  The mean age of 
females was 20.8 years (SD = 5.3 years, n = 24) and the mean age of males was 19.8 
years (SD = 9.4 years, n = 33).  The difference between these mean ages was 
insignificant (t-Test(55), p<.625).  The majority of the female patients (54.2%) were 19 
to 24 years of age, while the majority of males (66.7%) were 13 to 18 years of age.  
The second highest percentage of females was aged 13 to 18 years, while the second 
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highest percentage of males was aged 19 to 24 years.    When considering the 
significance of the difference in the distribution of females and males in the two age 
groups 13 to 18 years and 19 to 24 years, it was found to be significant (Chi²(1)=5.54, 
p<.019; V=0.33 Medium).  The youngest female was 15 years old and the oldest 
female was 41 years old, while the youngest male was aged 14 years and the oldest 
male was 65 years old.  The most prevalent age range for Population B was 13 to 24 
years, which comprised 90.9% of all males, 91.7% of all females and 91.2% of the 
total population.  There were no patients younger than 13 years or aged 50 to 64 
years, and only one male who was 65 years of age.   
 
5.2.3    AGE OF ACNE DEVELOPMENT 
 
The average age that acne started developing in Population B was 15.3 years (SD = 
4.4 years, n = 56).  The oldest acne starting age was 38 years, and the youngest 
starting age was eight years.  In the male population, the average age of acne 
development was 15.5 years (SD = 3.4 years, n = 33).  The youngest acne 
development age amongst males was 12 years, and the highest age was 29 years.  
Amongst females, the average age of acne development was 14.8 years (SD = 5.5 
years, n = 23).  The youngest starting age amongst females was eight years, and the 
highest starting age was 38 years.  These findings were in accordance with literature 
findings reported by Pray and Pray (2003: 17) that females start developing acne 
earlier in life when compared to males.  Acne can also start developing in adult 
females, due to hormonal changes associated with pregnancy, their menstrual cycles, 
or starting or stopping birth control pills (Mossman, 2006; Saljoughian, 2006).  Many 
literature sources (Goodman, 2006: 613; Presbury & Weiss, 2000: 1; Rutter, 2004: 
175) state the prevalence of acne development in females older than 30 years, 
whereas this phenomenon is not a frequent occurrence amongst males.  The 
population sample in this study was too small to effectively confirm these literature 
statements.   
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5.3  OVERVIEW OF ALL NON-ACNE DISEASE STATES AND 
MEDICATIONS IN POPULATION B 
 
5.3.1    DISEASE STATES IN POPULATION B 
 
There were few recognised comorbid conditions present in Population B.  Only 13 of 
the 57 patients (22.8%) stated that they had at least one disease in conjunction with 
acne, while 44 patients (77.2%) stated that they suffered no other disease, acute or 
chronic, except for their acne condition.  Of the 13 patients with comorbid conditions, 
eight were females and five were males.  Three of the 13 patients had two comorbid 
diseases in conjunction with acne, while the other 10 only had one comorbid disease.  
Thus, altogether there were 16 comorbid conditions present.  The prevalence of these 
diseases is shown in Table 5.2.   
 
Table 5.2:  Prevalence of diseases in the study population 
NUMBER DISEASE TYPE 
FEMALES MALES BOTH GENDERS 
Allergic rhinitis 2 1 3 
Psychological disorder 2 1 3 
Respiratory tract infection 1 2 3 
Skin disorder 2 0 2 
Low blood pressure 0 1 1 
Gastroesophageal reflux disease 1 0 1 
Asthma 1 0 1 
Neuronal disorder 0 1 1 
Hypothyroidism 1 0 1 
 
Due to the small quantity of patients who reported comorbid conditions, no specific 
classification system was used to classify the comorbid conditions.  Rather, specific 
groups were created to indicate the most prevalent conditions in a meaningful way.  
Allergic rhinitis, psychological disorders and respiratory tract infections were the most 
frequently occurring diseases in the acne patient population.  Psychological disorders 
included depression, bipolar disease and psychosis.  Respiratory tract infections 
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included sinusitis, common cold, pneumonia and bronchitis.  Skin disorders as a 
group, which included psoriasis and eczema, was another comorbid condition 
category present in the population.  It can be seen that, although the study took place 
within a much smaller patient sample, the results obtained were similar to results 
obtained in Chapter 4.  Diseases like asthma, eczema, allergic rhinitis, psychological 
disorders and even hypothyroidism were the most frequently diagnosed diseases in 
both Population A and Population B.   
 
5.3.2    MEDICATIONS USED BY POPULATION B 
 
Of the 57 patients, 46 (80.7%) claimed not to have used any medication other than 
systemic isotretinoin at the time of the study.  Thus, only 11 patients (19.3%) were on 
medication in conjunction with systemic isotretinoin.  Of these 11 patients, seven were 
females and four were males.  These medications were arranged into therapeutic 
groups according to the ATC classification system and are shown in Table 5.3.  The 
number of patients in Table 5.3 adds up to more than 11 due to the fact that some 
patients were on more than one medication.   
 
Table 5.3:  Prevalence of therapeutic groups (according to the ATC 
classification system) used by Population B 
NUMBER ATC 
CODE MEDICATION FEMALES MALES BOTH GENDERS 
N06A Anti-depressants 4 3 7 
R01B Nasal decongestants for systemic use 2 2 4 
R03B Inhaled glucocorticoids or anti-cholinergics 1 1 2 
H03A Thyroid preparations 2 0 2 
A02B Drugs for peptic ulcer and gastro-oesophageal 
reflux disease  1 0 1 
N02B Other analgesics and antipyretics 1 0 1 
 
Anti-depressants was the most frequently prescribed therapeutic group in the patients 
on systemic isotretinoin (used by seven of the 11 patients).  The medications used 
were mostly those employed in the treatment of the comorbid conditions reported by 
Population B.     
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5.4    OVERVIEW OF ACNE MEDICATION USED BY POPULATION B 
 
Table 5.4 gives an outline of the medications or alternative treatment methods that 
were used by the patient population to treat acne prior to initiation of isotretinoin 
therapy.  The use of these medications could have been during any time of the 
patient’s life and results represent an acne treatment history of the patient population.  
Altogether, 193 acne treatment methods or medications were present.   
 
As Population B comprises only of patients who were on systemic isotretinoin during 
the time of the study, 100.0% of patients used isotretinoin.  Systemic isotretinoin 
contributed to 29.5% of all acne treatment methods.  Cosmetics, which included 
commercial brands of beauty products in cream, gel and facewash formulations, were 
used by more than half of the patients (57.9%).  These products did not contain active 
ingredients proven to alleviate or treat acne effectively.  Although washing the face 
could contribute to hygiene and psychological satisfaction of the patient, it does not 
effectively clear up acne.  Many people are misled into spending money on these 
products in the hope of experiencing good results.  (Acne Guidelines 2005 update, 
2005: 891.)  The high occurrence rate of cosmetic use among Population B confirmed 
this literature finding.     
 
Benzoyl peroxide was, overall, the acne treatment used by the third largest number of 
patients.  It was also the most popular active ingredient in topical formulations (used 
by 22.8% of patients).  Topical acne formulations containing active ingredients made 
up 21.8% of all acne treatment methods used.   
 
Sulfamethoxazole combined with trimethoprim (cotrimoxazole) was the fourth most 
frequently used acne treatment, and was also the antibiotic used by the largest 
number of patients (19.3% of patients).  Altogether, antibiotic therapy contributed to 
5.7% of all acne treatment methods in the patient population.  This finding is not in 
accordance with the South African Acne Treatment Guideline (Acne Guideline 2005 
update, 2005:  890), which recommends the use of systemic isotretinoin as last resort 
 141
therapy after failure of systemic antibiotic therapy (of at least three to four months) to 
alleviate acne.  Only 19.3% of patients followed this route of treatment.  It should also 
be noted that the newer tetracycline derivates, namely minocycline, doxycycline and 
lymecycline are the preferred antibiotic medications according to the South African 
Acne Treatment Guideline (Acne Guideline 2005 update, 2005: 888).   
 
Table 5.4:  Most frequently used active ingredients and other acne treatment 
methods in Population B  
PATIENTS (N = 57) TREATMENTS (n = 193) RANK ACNE TREATMENT 
NUMBER PERCENTAGE (%) 
PERCENTAGE 
(%) 
1 Systemic isotretinoin 57 100.0 29.5 
2 Cosmetics 33 57.9 17.1 
3 Benzoyl peroxide 13 22.8 6.7 
4 Sulfamethoxazole; trimethoprim 11 19.3 5.7 
5 Adapalene 9 15.8 4.7 
5 Oral contraceptives 9 15.8 4.7 
6 Azelaic acid 6 10.5 3.1 
6 Topical cortisone 6 10.5 3.1 
6 Minocycline 6 10.5 3.1 
6 Erythromycin; zinc 6 10.5 3.1 
7 Light/laser therapy 4 7.0 2.1 
7 Zinc 4 7.0 2.1 
7 Deep cleanse facial 4 7.0 2.1 
7 Doxycycline 4 7.0 2.1 
8 Homeopathic remedies 3 5.3 1.6 
9 Topical tretinoin 2 3.5 1.0 
9 Liquid nitrogen 2 3.5 1.0 
9 White/black head extractions 2 3.5 1.0 
9 Clindamycin 2 3.5 1.0 
9 Cyclimycin 2 3.5 1.0 
9 Lymecycline 2 3.5 1.0 
10 Tazarotene 1 1.8 0.5 
10 Sand exfoliation 1 1.8 0.5 
10 Roxithromycin 1 1.8 0.5 
10 Erythromycin 1 1.8 0.5 
10 Ciprofloxacin 1 1.8 0.5 
10 Tetracycline 1 1.8 0.5 
*n3 = number of acne treatment methods or active ingredients used by Population B 
 
Although cotrimoxazole is also an acceptable treatment measure, more prescriptions 
should be for these tetracycline agents than for cotrimoxazole.  (Acne Guideline 2005 
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update, 2005: 888.)  Only 12 patients were prescribed minocycline, doxycycline or 
lymecycline (6.2% of all treatments in Population B).  Thus, as group it was only 
slightly more frequently prescribed than cotrimoxazole, and individually it was 
prescribed far less than cotrimoxazole.   
 
Oral contraceptives were used by fewer females than those that used systemic 
isotretinoin, cosmetics, benzoyl peroxide or cotrimoxazole.  It might be possible that 
many patients did not indicate their oral contraceptive pills as acne treatment as it 
could be perceived to only serve as birth control.  The South African Acne Treatment 
Guideline recommends that isotretinoin therapy be initiated if hormonal therapy (as 
well as antibiotic therapy, as explained in the previous paragraph) in females fail to 
alleviate acne (Acne Guideline 2005 update, 2005: 890).  Although nine of the 24 
females (37.5%) stated to have used oral contraceptives prior to initiation of systemic 
isotretinoin therapy, more females should have been prescribed hormone therapy 
before resorting to isotretinoin.   
 
It was interesting to note that topical therapy was used by more patients than systemic 
antibiotic therapy or hormone therapy.  The fact that these patients were all on 
systemic isotretinoin, would encourage the thought that their acne would have been 
severe or unresponsive to other systemic treatments prior to initiation of isotretinoin.  
(This would have been in accordance with guideline suggestions.)  Topical therapy is 
only indicated for mild to moderate acne, and would not have provided optimal relief of 
acne, except when prescribed in addition to systemic agents.  Systemic antibiotics or 
hormonal therapy (indicated for moderate to severe acne) should have been 
prescribed to more patients, before directly switching therapy from topical agents to 
isotretinoin therapy.  The optimal therapy option before resorting to isotretinoin 
prescription would have been a topical retinoid prescribed with a systemic antibiotic, 
specifically lymecycline (or, in case of females, an anti-androgenic preparation could 
also be used effectively).  (Acne Guideline 2005 update, 2005: 888 – 889).  Only 12 
patients used topical retinoids, and only two patients used lymecycline.   
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Alternative acne treatment methods included light therapy, laser therapy, deep 
cleanse facials, homeopathic remedies (like spirits of lavender), liquid nitrogen, white 
head or black head extractions and sand exfoliation.  Altogether, these treatments 
contributed to 8.3% of all acne treatment methods.   
 
5.5    SYSTEMIC ISOTRETINOIN THERAPY IN POPULATION B 
 
5.5.1    TRADE NAMES AND DOSAGE STRENGTHS OF ISOTRETINOIN 
 
The prescription frequency of the different isotretinoin trade names and dosage 
strengths are indicated in Figure 5.2.   
 
Figure 5.2:  Prescription frequency of isotretinoin trade names and dosage 
forms according to gender  
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The most frequently prescribed trade name of isotretinoin for Population B was 
Oratane®, as it was prescribed to 52.2% of females and 51.7% of males.  For all three 
trade names, the 20 mg dosage strength was prescribed more frequently than the 10 
mg dosage strength or the combination of 10 mg and 20 mg.  Oratane® 20 mg was the 
most frequently prescribed trade name and dosage strength for both genders, having 
been prescribed to 43.5% of females and 37.9% of males.  Acnetane® 20 mg was the 
second most frequently prescribed trade name and dosage strength in the female 
population, as it was prescribed to 21.7% of females.  Roaccutane® 20 mg was 
prescribed to 31.0% of males, and was the second most frequently prescribed trade 
name and dosage strength in the male population.   
 
5.5.2    ISOTRETINOIN DOSE TAKEN PER DAY 
 
The occurrence of different doses taken by the different genders per day is outlined in 
Figure 5.3.  The highest percentage of females (46.2%) and males (40.0%) in 
Population B were prescribed 40 mg of isotretinoin per day.  Just over 40% of patients 
used 40 mg of isotretinoin per day.  The second most frequently prescribed dose per 
day was 60 mg, prescribed to 23.1% of females, 32.0% of males and 28.9% of the 
patient population.  The average dose per day was 44.2 mg per day (SD = 16.9 mg 
per day, n = 38).   
 
5.5.3    DURATION OF ISOTRETINOIN THERAPY 
 
The prevalence of different lengths of isotretinoin courses is outlined in Figure 5.4.  
Just over 50% of patients were on an isotretinoin therapy course that would last for six 
months.  Approximately 24.0% of Population B was on a five month isotretinoin 
course.  Overall, a therapy course of four months was the third most prevalent length 
of treatment.  One male was on isotretinoin only for two months, and two females only 
for three months.   
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The average duration of therapy was 6.2 months (SD = 3.4 months, n = 50).  The 
recommended duration of therapy for isotretinoin is four to six months, depending on 
the daily dose.  It can be seen that 77.3% of females and 85.7% of males were on 
isotretinoin courses for the duration of four, five or six months.   Thus, the majority of 
Population B was on treatment courses of optimal duration.   
 
Of the three patients on treatment courses of longer than seven months, one male 
was on a 12 month course (taking 60 mg per day), one female was on an 18 month 
course (taking 30 mg per day) and one male was on a 24 month course (taking 20 mg 
per day).  Although lower doses of isotretinoin were taken by two of these three 
patients, all three would have received excessive isotretinoin doses (a cumulative 
dose of more than 150 mg/kg body weight).   
 
Figure 5.3:  Prevalence of dose taken per day according to gender 
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Figure 5.4:  Prevalence of different lengths of isotretinoin courses according to 
gender 
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5.5.4    CUMULATIVE DOSE OF ISOTRETINOIN 
 
The cumulative dosage figures for Population B are outlined in Figure 5.5.  The 
optimal cumulative dose for isotretinoin is 120 to 150 mg/kg (Acne Guideline 2005 
update, 2005: 890).   Cumulative doses could be determined for a smaller sample of 
patients (where all necessary details for the calculation were present).   Only three out 
of 13 females and four out of 21 males (thus seven out of 34 patients, 20.6%) would 
have received the optimal cumulative dose of isotretinoin.  Altogether, 10 patients 
(29.4% of the 34 patients) would have received a cumulative dose higher than 
required.  There were 17 patients who would have received suboptimal cumulative 
doses (50.0% of the 34 patients).  The latter group would be more prone to developing 
recurring acne, even if complete clearance could be observed after the initial 
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isotretinoin treatment course (Acne Guideline 2005 update, 2005: 890).  The average 
cumulative dose was 124.8 mg/kg (SD = 60.5 mg/kg, n = 34).   
 
Figure 5.5:  Distribution of cumulative doses per patient according to gender  
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5.5.5    FAMILY HISTORY OF ISOTRETINOIN USE 
 
Of the 49 patients who completed the required information for this section of the 
questionnaire, 49.0% (24 patients) had other family members who had previously 
been on isotretinoin therapy.  According to literature, acne can be hereditary and 
therefore frequently occurs in more than one member of a family prone to suffering 
acne (Fulton, 2002: 96).  The results of this study are in accordance with this 
statement.   
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5.6 OVERVIEW OF ACNE SEVERITY PRIOR TO ISOTRETINOIN 
THERAPY 
 
5.6.1    DEGREE OF SEVERITY OF ACNE  
 
The degree of acne severity of patients before and during isotretinoin therapy was 
determined by using the GAIOA scale of acne severity (Acne Guideline 2005 update, 
2005: 885).  See Section 2.1.8 for details on this grading system.  Figure 5.6 indicates 
the degree of acne severity experienced by the patient population prior to initiation of 
isotretinoin therapy.   
 
Figure 5.6:  Distribution of genders according to degree of acne severity prior to 
initiation of isotretinoin therapy  
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The majority of females (41.7%) started with isotretinoin while their acne was Grade 2 
according to severity, while the majority of males (42.4%) started with isotretinoin 
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when their acne had reached Grade 3.  Thus, the majority of females of this 
population started using isotretinoin while their acne was less severe when compared 
to the severity of the males.  The South African Acne Treatment Guideline (Acne 
Guideline 2005 update, 2005: 890) recommends the use of isotretinoin only in cases 
of: severe nodulocystic acne or its variants; inflammatory acne with scarring; moderate 
to severe acne unresponsive to treatment with other treatments; acne with severe 
psychological distress; gram-negative folliculitis; and/or frequently relapsing acne.  It 
can be seen that only 20.8% of females and 33.3% of males started using isotretinoin 
when their acne reached Grade 4 in severity (severe nodulocystic acne).  In fact, 8.3% 
of females and 3.0% of males started using isotretinoin therapy while their acne was 
only Grade 1.  The majority of patients in Population B started with isotretinoin therapy 
before their acne reached a severity of Grade 4.  Thus, except where patients 
experienced symptoms that validated isotretinoin use as described above, alternative 
treatment measures should have been recommended when acne Grades 1, 2, or 3 
were present.    
 
5.6.2    DEGREE OF INVOLVEMENT OF ACNE 
 
Before starting with isotretinoin therapy, 13 females (54.2% of all females) and 16 
males (48.5% of all males) had acne on other parts of their bodies except for their 
faces.  The areas of acne involvement are stipulated in Figure 5.7.   
 
The body part most frequently affected by acne in both genders was the torso area 
(back and chest), as experienced by 76.9% of females and 76.5% of males.  Neck and 
shoulders were affected in 23.1% of females and 23.5% of males.  Arms were affected 
in 23.1% of females and 5.9% of males.  The scalp and legs were affected in 11.8% of 
males.  No females had acne on their scalps or legs.   
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Figure 5.7:  Areas of acne involvement according to gender 
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5.7    COUNSELLING AND MONITORING PROCEDURES  
 
5.7.1    INTRODUCTION 
 
The presence and quality of the counselling and monitoring of patients on isotretinoin 
therapy by health care professionals have been researched and results are shown in 
this section.  For the purposes of this study, health care professionals included 
dermatologists, general practitioners and pharmacists.   
 
5.7.2    COUNSELLING BY HEALTH CARE PROFESSIONALS 
 
General practitioners prescribed isotretinoin to 11 of the 57 patients (19.3%) and one 
patient (who was a pharmacist) self-initiated isotretinoin therapy.  The other patients 
all received isotretinoin through prescriptions from dermatologists.  Table 5.5 
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represents the percentage of patients who received counselling by their health care 
providers regarding the use of isotretinoin, as reported by the questionnaire 
respondents.  The prescribers counselled 63.5% of their patients adequately, while the 
rest of the patients only received partial information, were not requested to sign 
consent forms or did not receive (or could not remember receiving) any counselling 
from the prescriber at all.  Of the 24 patients who did not receive (or could not 
remember receiving) adequate counselling from their prescribers, eight received 
isotretinoin prescriptions from general practitioners, one self-initiated therapy and 15 
received prescriptions from dermatologists.  Thus, it could also be said that in eight 
out of the 11 cases where general practitioners prescribed isotretinoin in this study 
(72.7%), inadequate counselling procedures were followed.  In 15 out of the 45 cases 
where dermatologists prescribed isotretinoin (33.3%), inadequate counselling took 
place.  In a study in the USA (Fleischer, Simpson, McMichael & Feldman, 2003: 662), 
it was found that dermatologists managed 83% of all isotretinoin visits.  
Dermatologists accounted for 100% of isotretinoin visits for which pregnancy 
prevention education and counselling were reported.  It can be assumed that 
dermatologists are generally better informed than general practitioners regarding 
treatment measures and operating procedures in prescription of acne treatment, 
especially isotretinoin.   
 
Table 5.5:  Presence of counselling regarding isotretinoin given to Population B 
by health care professionals 
ADEQUATE 
COUNSELLING 
RECEIVED 
PERCENTAGE (%) PATIENTS (WITH 
REGARDS TO PRESCRIBER) (n = 52) 
PERCENTAGE (%) PATIENTS (WITH 
REGARDS TO PHARMACIST) (n = 55) 
Yes 63.5 78.2 
No 36.5 21.8 
 
According to the respondents, 78.2% were counselled adequately by their 
pharmacists.  The difference between the percentages of patients adequately 
counselled by the prescriber and by the pharmacist was insignificant (Chi²(1)=1.32, 
p<.251).   
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Table 5.6 gives an outline of the frequency of counselling by prescribers and 
pharmacists on various topics with regards to systemic isotretinoin use, as reported by 
the patients.  The percentages of patients to whom the topics were not explained are 
also indicated in this table.  There was a statistically significant difference between the 
percentages of patients who received counselling regarding the various topics from 
the prescriber and from the pharmacist (Chi²(4)=10.56, p<.032; V=0.20 Small).  In 
every topic, the prescribers counselled more patients than the pharmacists.  It would 
seem that although more patients claimed to have been counselled by their 
pharmacists than by their prescribers, there was a higher percentage of counselling by 
the prescriber reported for individual topics.  These results are in opposition of each 
other, and no definite conclusion could be reached.   
 
Table 5.6:  Prevalence of counselling topics with regards to isotretinoin in 
Population B  
PERCENTAGE (%) PATIENTS (N = 57) COUNSELLING TOPICS PRESCRIBER PHARMACIST NOT EXPLAINED 
Benefits 82.5 14.0 14.0 
Diet to follow 40.4 8.8 54.4 
Dosage instructions 91.2 40.4 1.8 
Duration of therapy 89.5 12.3 8.8 
Pregnancy 47.4 14.0 38.6 
Problems for referral 71.9 12.3 22.8 
Recurrence chance 73.7 10.5 22.8 
Side effects 89.5 31.6 3.5 
 
The topic explained least by both prescribers and pharmacists was the diet that should 
be followed in conjunction with isotretinoin use (explained to 40.4% of patients by the 
prescriber and 8.8% of patients by the pharmacist).  It could be because there are few 
stipulations and recommendations with regards to diet during an isotretinoin therapy 
course.  The danger of pregnancy during treatment with isotretinoin was explained to 
only 35 patients.  Of the remaining 22 patients who did not receive any counselling 
regarding pregnancy, three were females (12.5% of all females).  The ages of these 
females were 22 years, 16 years and 17 years.  Thus, all three were of childbearing 
age.  This lack of counselling could have had detrimental effects on the lives of these 
females.   
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Dosage instructions were most thoroughly covered by prescribers and pharmacists, 
followed by side effects that could be experienced.  Other topics, including benefits of 
using isotretinoin, duration of therapy, problems that need to be addressed if they 
should occur and the chance of acne recurring after isotretinoin therapy is ceased, 
were also explained to inadequate percentages of patients by both the prescriber and 
the pharmacist.   There were seven patients who conducted self-study in obtaining 
information relevant to isotretinoin therapy.   
 
5.7.3    PREVALENCE AND QUALITY OF MONITORING PROCEDURES 
 
The following basic monitoring procedures should be performed before initiation of 
isotretinoin therapy: cholesterol tests, liver enzyme tests, pregnancy tests (when 
patients are females) and weighing the patients.  The percentages of patients for 
whom these procedures were conducted before isotretinoin therapy was initiated are 
outlined in Table 5.7.   
 
Pregnancy tests were conducted for only two of the 24 females (8.3%).  This finding is 
in direct contrast to the recommendations and guidelines regarding isotretinoin use 
and pregnancy prevention (Acne Guideline 2005 update, 2005: 889; Jones, 2007).  In 
another study conducted in Quebec in 2004 (Boucher & Beaulac-Baillargeon, 2006: 
339) to determine whether prescribing doctors advised female patients taking 
isotretinoin according to pregnancy prevention recommendations, it was found that a 
pregnancy test before isotretinoin treatment was prescribed to only 44% of the 45 
female participants.  
 
Table 5.7:  Prevalence of monitoring procedures prior to isotretinoin therapy 
initiation in Population B  
MONITORING 
PROCEDURE 
PERCENTAGE (%) FEMALES 
(n = 24) 
PERCENTAGE (%) MALES 
(n = 33) 
Weight determination 75.0 78.8 
Cholesterol test 58.3 66.7 
Liver enzyme test 62.5 69.7 
Pregnancy test 8.3 Not applicable 
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In order to ensure that the correct cumulative dose of isotretinoin will be taken by a 
patient, the patient needs to be weighed.  Even with this in mind, only 75.0% of 
females and 78.8% of males were weighed upon initiation of therapy.  This indicated 
that the remaining patients could easily have received inappropriate dosage strengths 
or durations of treatment, or both, and subsequently received inappropriate cumulative 
isotretinoin dosages.  Cholesterol tests were conducted for 63.2% of patients, and 
liver enzyme tests for 66.7% of patients, although it is recommended that all patients 
undergo these tests before initiation of isotretinoin therapy (Acne Guideline 2005 
update, 2005: 889).   
 
The initial use of systemic prednisone in a dose of 0.5 to 1 mg/kg daily for two to three 
weeks in addition to isotretinoin is recommended to prevent severe acne flares on 
initiation of isotretinoin (Acne Management Guideline, 1999: 1031).  Only 14 patients 
(24.6% of all patients) received prednisone on isotretinoin therapy initiation.  Of these 
14 patients, four were females and 10 were males.  Treatments for the side effects 
that might be experienced due to isotretinoin were prescribed, or recommended, to 29 
patients (50.9% of all patients).  The maximum relief of the side effects of isotretinoin 
should be made possible to the patient by the health care provider, and prescribers 
should always recommend side effect alleviators to their patients (Isotretinoin 
(Roaccutane) usage – a South African consensus guideline, 1997: 1412).   
 
Table 5.8 indicates the frequency of appointments with, and all monitoring procedures 
done by, the prescriber since isotretinoin therapy commenced.  The results are 
discussed below.   
 
• Appointments 
 
Of the 56 patients who responded in this section of the questionnaire (regarding 
number of appointments with prescribers), 23.2% had two appointments with the 
prescriber during their isotretinoin course; one at the start of therapy and one after one 
month of therapy.  This was the most popular appointment pattern.  Patients who only 
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had one appointment at the commencement of therapy constituted 14.3% of the 
population, as did patients who only had one appointment one month after therapy 
has commenced.  Patients who had monthly appointments with the prescriber 
constituted 12.5% of the population.  It was interesting to note that 8.9% of patients 
(five patients) claimed to have never had an appointment with the prescriber.   
 
• Pregnancy tests 
 
When considering frequency of pregnancy tests performed, it was found that 22 out of 
the 24 females (91.7%) never had a pregnancy test while on isotretinoin therapy, nor 
did they expect to have one done for the remainder of the therapy course.  Two 
females (8.3%) had prescribers who conducted pregnancy tests on them at the 
commencement of therapy.  One female (4.2%) was unsure as to whether a 
pregnancy test had been performed.  Negative pregnancy tests upon initiation of 
isotretinoin therapy together with monthly negative pregnancy tests are recommended 
in South Africa (Acne Guideline 2005 update, 2005: 889) and compulsory in the USA 
(Jones, 2007).  The majority of practitioners in this study did not follow these 
recommendations.     
 
• Cholesterol tests 
 
Cholesterol tests usually include an analysis of high density lipoproteins (HDL), low 
density lipoproteins (LDL) and triglyceride levels.  It is important to monitor cholesterol 
and triglycerides in isotretinoin patients.  When considering cholesterol test 
frequencies in the population, it was found that the highest percentage of patients 
(35.2%) did not have cholesterol tests done.  Cholesterol tests were conducted on 12 
patients (22.2%) on isotretinoin initiation.  In 10 patients, cholesterol was monitored on 
initiation and one month after initiation.  Three monthly cholesterol check-ups were 
done in 5.6% of patients.  The South African Acne Treatment Guideline (Acne 
Guideline 2005 update, 2005: 890) recommends that a cholesterol test be conducted 
upon isotretinoin initiation and again after one month.  If the baseline and one month 
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results are both normal, no further tests are required for the remainder of the course.  
If there was a significant increase in cholesterol, re-evaluation must take place on a 
frequent basis as decided by the health care provider. It would seem that there was a 
lack of compliance to or knowledge of guidelines by the health care providers.  From 
all the monitoring procedures in Table 5.9, cholesterol testing is the one most likely to 
be conducted by pharmacists.  Thus, pharmacists could have contributed in 
ascertaining optimal timing of cholesterol tests in isotretinoin patients, as well as in 
conducting cholesterol tests.   
 
• Liver enzyme tests 
 
The same recommendations as above are also valid for liver enzyme monitoring 
(Acne Guideline 2005 update, 2005: 890).  The liver enzymes that should be 
monitored for changes include aspartate aminotransferase and alanine 
aminotransferase (Isotretinoin (Roaccutane) usage – a South African consensus 
guideline, 1999: 1412).  The highest percentage of patients (26.8%) claimed to have 
had a liver enzyme test once on initiation of therapy.  Again, a high percentage of 
patients (23.2%) also claimed not to have had a liver enzyme test done at all.  In 10 
patients (17.9%), these tests were conducted on initiation of therapy and one month 
after initiation.  Liver enzyme tests were performed on eight patients (14.3%) after a 
month on isotretinoin therapy.  As with cholesterol monitoring, a lack of compliance 
with and knowledge of the guidelines was present amongst the health care providers.   
  
• Side effect monitoring 
 
Side effects were monitored (meaning that the prescriber enquired about the type and 
severity of side effects experienced by the patient) in 16.1% of patients at the start of 
therapy and one month after starting.  There were 10.7% of patients who claimed that 
their side effects were monitored monthly.  This is possible as monitoring could have 
happened either telephonically or during an appointment.  There were 33.9% of 
patients who claimed that their side effects were never monitored.  It is important for 
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patients to inform their prescribers of the occurrence of certain side effects, like nightly 
or early-morning headaches (Acne Guideline 2005 update, 2005: 890).  Patients need 
the assurance from their health care providers that they are still experiencing normal 
side effects and they should be advised on the treatment of these side effects.  
Therefore, the counselling of patients with regards to these aspects is mandatory 
during visits with the prescriber or pharmacist.   There was a lack of follow-up and 
counselling of side effects from the health care providers in Population B.   
 
• Weighing 
 
Although inquiry into the frequency of weighing was conducted, results obtained were 
in contrast with results obtained in Table 5.7, where more than 70% of females and 
males claimed to have been weighed prior to initiation of isotretinoin therapy.  Only 
40.4% of patients, in this section of the questionnaire, claimed to have been weighed 
at the start of isotretinoin therapy.  Thus, results regarding weighing frequency were 
inconclusive and omitted from the study.   
 
Table 5.8:  Monitoring procedure and appointment frequency (in percentage) in 
Population B  
FREQUENCY 
Appoint-
ments 
(n = 56) 
Pregnancy 
tests 
(n = 24) 
Cholesterol 
tests 
(n = 54) 
Liver enzyme 
tests 
(n = 56) 
Monitor side 
effects 
(n = 55) 
Start of isotretinoin 14.3 8.3 22.2 26.8 3.6 
Start and one month after 
start 23.2 0.0 18.5 17.9 16.1 
Start, one month after 
start and three months 
after that 
3.6 0.0 1.9 1.8 8.9 
One month after start 3.6 0.0 3.7 14.3 0.0 
Monthly 12.5 0.0 1.9 3.6 10.7 
Two monthly 8.9 0.0 1.9 3.6 8.9 
Three monthly 14.3 0.0 5.6 5.4 8.9 
Never 8.9 87.5 35.2 23.2 33.9 
Unsure 3.6 4.2 5.6 3.6 3.6 
Other 7.1 0.0 3.7 0.0 1.8 
 
Table 5.9 gives an overview of the results of patients’ cholesterol tests, liver enzyme 
tests and weight changes, and of the incidence of unbearable side effects experienced 
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by patients.  Unbearable side effects can be defined as side effects due to isotretinoin 
that were experienced to such a severe degree that the patient’s day-to-day activities 
were greatly affected.  It can be seen that, in all four monitoring aspects, the majority 
did not experience any noticeable change or any unbearable side effects.   
 
There were 19 patients who were unsure whether or not their cholesterol levels had 
increased, and 18 patients who were unsure of changes in their liver enzymes.  This 
indicates a lack of counselling by the health care professionals who were involved in 
these monitoring procedures.  There were five patients with reported increased 
cholesterol (8.9% of patients), four with reported liver enzyme changes (7.3% of 
patients), 10 with reported noticeable weight changes (17.5% of patients) and 12 
patients (21.4% of patients) who claimed to have suffered unbearable side effects.   
Alcalay (2003) reported a study conducted in 1985, wherein 60 patients treated with 
isotretinoin were studied.  Of these patients, 17% showed elevations of triglycerides, 
cholesterol and LDL cholesterol.  They concluded that if the changes in plasma lipids 
persisted over a long period of time, it might increase the risk of cardiac disease 
(Alcalay, 2003).   
 
In 2001, Alcalay and associates (Alcalay, et al., 2001: 9 – 10) identified 876 patients 
who were prescribed isotretinoin between 1992 and 1999 and analysed the available 
computerised data of these patients.  Data included complete blood counts, liver 
function tests and blood lipids.  Serum creatine kinase (SCK) levels were measured in 
patients undergoing strenuous physical activity during the treatment.  None of the 
patients stopped the medication because of disturbance in physical activity, including 
high-intensity physical training or weight-lifting.  Slightly elevated cholesterol levels 
were seen in 54 patients (6.2% of patients) while only five patients (0.6%) presented 
with more severe elevated cholesterol.  Treatment was continued in all patients with 
elevated serum lipids.  No clinical evidence of pancreatitis was noted in any of the 
patients with elevated triglycerides.  Liver enzymes were moderately elevated in a 
minority of the patients.  All abnormal values returned to normal despite continuation 
of isotretinoin.  (Alcalay, et al., 2001: 9 – 10.)  Barnes and Osborne (2000: 80) stated 
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that about one percent of all patients receiving isotretinoin experienced severe liver 
enzyme elevations, including hepatitis and liver insufficiency.   
 
Table 5.9:  Prevalence of change in monitoring factors in Population B 
EXPERIENCED INCREASE IN CHOLESTEROL 
CHANGE IN 
LIVER ENZYMES 
NOTICEABLE 
WEIGHT CHANGE 
UNBEARABLE 
SIDE EFFECTS 
Yes 5 4 10 12 
No 32 34 36 42 
Unsure 19 18 3 2 
Total 56 56 49 56 
 
Table 5.10 reports the isotretinoin dosage changes made by the prescribers resulting 
from increased cholesterol levels, changes in liver enzymes, weight changes or the 
presence of unbearable side effects.   
 
Table 5.10:  Occurrence of dosage changes in patients who experienced change 
in monitoring factors 
ISOTRETINOIN 
DOSAGE CHANGE CHOLESTEROL
LIVER 
ENZYMES WEIGHT 
UNBEARABLE SIDE 
EFFECTS 
Decrease dose 1 1 2 2 
Increase dose 0 0 0 1 
Stop isotretinoin 1 2 0 0 
No change in dose 2 1 5 7 
Unsure of change in dose 1 0 3 2 
Total 5 4 10 12 
 
• Cholesterol 
 
In two of the five patients who experienced increased cholesterol since isotretinoin 
commencement, there was no change in the dose of isotretinoin.  Isotretinoin was 
stopped for a while in one patient, and the dose was lowered for another patient.  The 
other patient was unsure if a dosage change was made.   
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• Liver enzymes 
 
In two of the four patients who had liver enzyme changes, isotretinoin use was ceased 
for a short period of time.  One patient received a decreased isotretinoin dose, and 
there was no dosage change for the other patient.  During research conducted by 
Cunliffe and his associates in 1997 (Cunliffe, van de Kerkhof, Caputo, Cavicchini, 
Cooper, Fyrand, Gollnick, Layton, Leyden, Mascaro, Ortonne & Shalita, 1997), it was 
found that mild elevation of fasting lipids or liver enzymes did not result in a change of 
dose or cessation of therapy in any of the patients in the study.   
 
• Weight 
 
Of the 10 patients who had weight changes, there were five who did not have any 
change of isotretinoin dose.  The dose was lowered for two patients, and three 
patients did not know if the prescriber had lowered their isotretinoin dose.   
 
• Unbearable side effects 
 
For seven of the 12 patients who claimed to have experienced unbearable side 
effects, there was no change in dose.  Two patients claimed to have received 
decreased doses of isotretinoin, while one claimed to have received an increased 
dose.  Two patients were unsure whether or not dosage changes were initiated.   
 
It can be seen, after observation of the above findings, that there was a lack of follow- 
up monitoring and adjustment of doses in the patients.  For example, one patient had 
lost 10 kg with no accompanying isotretinoin dosage decrease, thus leading to a 
cumulative dose that may have been too high.  Although the latest South African Acne 
Treatment Guideline (Acne Guideline 2005 update, 2005; 883 - 892) gives indications 
as to when monitoring tests should be performed, there are no recommendations on 
how isotretinoin dosage should be adjusted in cases of abnormal test results, weight 
increase or decrease, or unbearable side effects.   
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5.8    SIDE EFFECTS DUE TO SYSTEMIC ISOTRETINOIN 
 
5.8.1    INTRODUCTION 
 
The focus of this section is on the side effects experienced during isotretinoin use 
reported by the patient population.  Section 5.8.2 outlines the most frequently reported 
side effects, regardless of the experienced severity.  Section 5.8.3 gives more detail 
on the severity of the side effects as perceived by the respondents.   
 
5.8.2    MOST FREQUENTLY REPORTED SIDE EFFECTS 
 
There were 36 identified side effects due to isotretinoin reported by Population B.  
Table 5.11 is a representation of the order of the prevalence of the side effects in the 
patient population.  The most frequently occurring side effect, experienced by 98.2% 
of patients, was dryness of lips (cheilitis).  Only one patient did not have dry lips as a 
side effect.  This side effect is also the most prevalent according to the Acne 
Management Guideline (1999: 1032), where it is stated that more than 90% of patients 
on isotretinoin experience cheilitis.  Dry skin was present in 87.7% of patients.  
Altogether, seven patients did not complain of dry skin.  The Acne Management 
Guideline (1999: 1032) also claims that dry skin is the second most frequently 
occurring side effect (present in more than 80% of patients on isotretinoin).  Thus, 
these results are in line with the findings of the Acne Management Guideline (1999: 
1032).   
 
There were 36 patients (63.2%) who claimed that they had experienced an initial 
worsening and inflammation of acne on commencement of isotretinoin therapy.  This 
side effect was the third most prevalent of all side effects.  The Acne Management 
Guideline (1999: 1031) stated that an initial acne flare could be anticipated in six 
percent of patients.  There was a much greater percentage of Population A with an 
initial flare than that which is stated in this literature source.  The recommended short 
course of prednisone which serves to counter this side effect was prescribed to only 
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11 of these 36 patients (30.6%).  The lack of prednisone use on initiation of 
isotretinoin could therefore contribute greatly to the high percentage of patients who 
experienced acne flare-ups.  The fourth most frequently occurring side effect in this 
population, dryness of eyes, was present in 56.1% of patients.  Dry eyes or 
conjunctivitis could be expected in approximately 40% of patients according to the 
Acne Management Guideline (1999: 1032).  According to these guidelines, dry eyes or 
conjunctivitis is the fourth most frequently occurring side effect of isotretinoin, as was 
proven to be true for Population B as well.  Nose bleeding and sunburn were present 
in more than half (52.6%) of patients.   
 
There were 43.9% of patients who reported backache, making it the seventh most 
frequently occurring side effect.  Depression and fatigue were both experienced by 24 
patients (42.1% of patients) and both side effects rated as eighth most frequently 
occurring.  There were eight patients who admitted to have had suicidal thoughts while 
using isotretinoin.  Eight patients complained about a feeling of anxiety.  One patient 
mentioned specifically that he suffered from severe mood swings.    
 
Case reports in the literature describe depression that developed in conjunction with 
isotretinoin treatment, resolved with discontinuation of the medication, and in some 
cases returned when the medication was restarted.  Other reports have noted suicidal 
tendency, behavioral disturbances, and psychotic-type symptoms with isotretinoin 
treatment in addition to the typical symptoms of depression.  (Bremner, et al., 2005: 
983.)  A pilot study conducted in Turkey in 2004 to evaluate anxiety and depressive 
scores in acne patients treated with isotretinoin found that anxiety levels decreased 
significantly in patients after a 16 week isotretinoin course, while no statistically 
significant change in depression scores could be obtained.  None of the 23 patients 
committed or attempted suicide.  (Ferahbas, et al., 2004: 153.)  Consensus has not 
been reached on the issue of depression and suicide resulting from isotretinoin use.  
Statistically, there is a lower incidence of suicide in patients who are on treatment with 
this drug compared with a similar population not exposed to it (Acne Guideline 2005 
update, 2005: 889).  A study conducted in 2001 where two population-based 
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databases were assessed to determine the relative risks of depression, suicide, or 
neurotic and psychotic symptoms.  It was found that the relative risks of all of these 
disorders were no different for acne patients who took isotretinoin than for those who 
did not.  The databases included 7 195 isotretinoin users and 13 700 antibiotic users, 
and 340 isotretinoin users and 676 antibiotic users, respectively.  (Kubetin, 2001.)   
 
Muscle pain (myalgia) was experienced by 23 patients (40.4%).  The Acne 
Management Guideline (1999: 1032) states that joint and muscle pains may 
accompany isotretinoin use in approximately 16% of patients, noticeably less than the 
percentage of patients in Population B who experienced myalgia.  Dizziness, 
headache, delay in time of wound healing and joint pains were each experienced by 
22 patients (38.6% of patients).  Headache is mentioned as a rare side effect in the 
Acne Management Guideline (1999: 1032).  It should be noted that the prevalence of 
headaches in Population B was quite high.     
 
Neck stiffness was experienced by 18 patients, and 17 patients had sudden urges to 
fall asleep.  There were also 17 patients who were constipated during the time of 
isotretinoin use.  Sudden urges to fall asleep are not listed as a specific side effect in 
any of the three isotretinoin trade name package inserts (Acnetane® Package Insert, 
2004; Oratane® Package Insert, 2003; Roaccutane® Package Insert, 2003).  It is also 
not a side effect acknowledged through literature, although a high percentage of this 
population had experienced it while on isotretinoin therapy.  It was included in the 
questionnaire as a side effect option to challenge a case of narcolepsy that might have 
been associated with concurrent isotretinoin use that was reported by a patient in the 
questionnaire pilot study population.  Constipation is also not recognised specifically 
as a frequently occurring side effect, although gastrointestinal side effects are 
reported.  There were four patients who complained of diarrhoea, and six patients 
experienced nausea and/or vomiting during isotretinoin therapy.  Three patients 
claimed to have had appendicitis during isotretinoin therapy.  Azón-Masoliver and 
Grau (2000: 233 – 234) found four cases of acute appendicitis associated with 
isotretinoin use.  They stated that no similar cases had been published, and that it 
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could be due to the high frequency of appendicitis in the younger population overall 
and the fact that in isolated cases they would be considered as coincidental.   
 
Table 5.11:  Prevalence of side effects in Population B 
PATIENTS RANK SIDE EFFECTS NUMBER (N = 57) PERCENTAGE (%) 
1 Dry lips 56 98.2 
2 Dry skin 50 87.7 
3 Initial acne flare-up 36 63.2 
4 Dry eyes 32 56.1 
5 Nose bleeding 31 54.4 
6 Sunburn 30 52.6 
7 Backache 25 43.9 
8 Depression 24 42.1 
8 Fatigue 24 42.1 
9 Muscle pains 23 40.4 
10 Dizziness 22 38.6 
10 Headache 22 38.6 
10 Slow healing wounds 22 38.6 
10 Joint pains 22 38.6 
11 Neck stiffness 18 31.6 
12 Sudden urges to fall asleep 17 29.8 
12 Constipation 17 29.8 
13 Loss of appetite 14 24.6 
14 Blurred vision 13 22.8 
14 Hair loss 13 22.8 
15 Anxiety 11 19.3 
16 Ingrown nails 10 17.5 
16 Weight loss 10 17.5 
17 Weight gain 9 15.8 
18 Suicidal thoughts 8 14.0 
19 Irregular menstruation 6 10.5 
19 Rectal bleeding 6 10.5 
19 Nausea and vomiting 6 10.5 
20 Blood in urine 4 7.0 
20 Diarrhoea 4 7.0 
21 Vaginitis 3 5.3 
21 Appendicitis 3 5.3 
22 Nose sores 2 3.5 
23 Skin thinning 1 1.8 
23 Mood swings 1 1.8 
23 Dandruff 1 1.8 
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There were 14 patients who had a decreased appetite while on isotretinoin therapy, 
and weight loss occurred in 10 patients.  In contradiction to these findings, there were 
also nine patients who experienced noticeable weight gain.  These side effects may 
also be linked to the high occurrence rate of depression in the population, seeing that 
depression may be associated with changes in eating habits and appetite.   
 
Other side effects commonly associated with isotretinoin use that were present in the 
patient population were blurred vision, ingrown toe- and/or fingernails, hair loss, 
irregular menses, rectal bleeding, blood in urine, vaginitis, nose sores, thinning or 
peeling of skin and dandruff.   
 
5.8.3    SEVERITY OF REPORTED SIDE EFFECTS 
 
The patients were asked to express the severity to which they experienced each side 
effect.  The severity scores were “1” to “5”, “5” being the most severe and “2” being 
least severe.  If a patient gave “1” to a side effect, it means that this side effect was 
not experienced at all.  The explanation of each score is given in the questionnaire 
(See Appendix G).  Therefore, it was also possible to determine which side effects 
were experienced more severely than others.  The number of patients who 
experienced each side effect differed to a great extent as shown in Table 5.11.  
Therefore, the percentage distribution of the severity levels of each side effect could 
not effectively be compared to each other.  (For example, if five out of the 10 patients 
who had ingrown nails claimed to have experienced it at severity level 5, it was 
experienced as very severe by 50.0% of these patients.  But, if the one patient who 
had dandruff claimed to have experienced it at severity level 5, 100.0% of patients 
with dandruff experienced it as very severe.)  It was therefore decided to take both 
prevalence and severity of side effects into account when calculating a final severity 
score for each side effect.  This was done by multiplying the severity level with the 
number of patients who experienced that severity level of the side effect and adding 
up the total severity number scores for each side effect to obtain a final severity score. 
The results are indicated in Table 5.12.   
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Example of calculation: 
Final severity score for hair loss = number of patients with severity level 2 hair loss x 2 
+ number of patients with severity level 3 hair loss x 3 + number of patients with 
severity level 4 hair loss x 4 + number of patients with severity level 5 hair loss x 5 
 
Thus:  
Final severity score for hair loss = (4x2) + (7x3) + (1x4) + (1x5) 
                                                    = 38 
 
Thus, when taking the severity of the experienced side effects into account, dry lips 
were still the most frequently occurring and most severely experienced side effect by 
far.  This was followed by dry skin, dry eyes and sunburn.  The initial flare-up of acne 
was not taken into account for this section, as severity levels were not obtained and 
could not be calculated.  The order of prevalence for the side effects did not change 
dramatically, although small differences between Table 5.11 and Table 5.12 can be 
found.  For example, backache, dizziness and blurred vision rate lower when taking 
both prevalence and severity into account than when taking only prevalence into 
account, and therefore it can be seen that these side effects were experienced to a 
milder degree.  On the other hand, joint pains and ingrown nails were not as frequently 
experienced as some of the other side effects, but were experienced to a severe 
degree by many of the affected patients.   
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Table 5.12:  Frequency and severity of side effects in Population B 
NUMBER OF PATIENTS (N = 57) 
SEVERITY LEVEL 
RANK 
SIDE EFFECT OVERALL 2 3 4 5 
FINAL 
SEVERITY 
SCORE 
1 Dry lips 56 1 18 19 18 222 
2 Dry skin 50 10 20 10 10 170 
3 Dry eyes 32 9 12 9 2 100 
4 Sunburn 30 14 6 4 6 92 
5 Nose bleeding 31 12 15 3 1 86 
6 Fatigue 24 6 7 7 4 81 
7 Depression 24 8 9 1 6 77 
8 Backache 25 7 13 3 2 75 
9 Joint pains 22 5 11 2 4 71 
10 Muscle pains 23 7 12 1 3 69 
11 Headache 22 10 8 0 4 64 
12 Slow healing wounds 22 11 6 3 2 62 
13 Dizziness 22 14 5 2 1 56 
14 Constipation 17 7 6 1 3 51 
15 Sudden urges to fall asleep 17 7 6 2 2 50 
16 Neck stiffness 18 12 2 2 2 48 
17 Ingrown nails 10 2 1 3 4 39 
18 Loss of appetite 14 7 4 3 0 38 
18 Hair loss 13 4 7 1 1 38 
19 Anxiety 11 3 4 2 2 36 
20 Blurred vision 13 8 3 2 0 33 
21 Weight gain 9 4 1 2 2 29 
21 Suicidal thoughts 8 1 2 4 1 29 
22 Weight loss 10 6 2 2 0 26 
23 Nausea and vomiting 6 3 1 1 1 18 
23 Rectal bleeding 6 2 2 2 0 18 
24 Irregular menstruation 6 4 1 1 0 15 
25 Blood in urine 4 2 1 1 0 11 
25 Diarrhoea 4 1 3 0 0 11 
26 Appendicitis 3 1 1 1 0 9 
27 Vaginitis 3 1 2 0 0 8 
28 Nose sores 2 0 1 1 0 7 
29 Skin thinning 1 0 0 0 1 5 
29 Dandruff 1 0 0 0 1 5 
30 Moodswings 1 1 0 0 0 2 
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5.9    ISOTRETINOIN AND PREGNANCY 
 
5.9.1    INTRODUCTION 
 
The following section serves to report on the presence and quality of measures taken 
by health care providers to prevent pregnancy in females on isotretinoin.  There are 
very specific guidelines available in South Africa for the prevention of pregnancy in 
females on isotretinoin (Acne Guidelines 2005 update, 2005: 889), and findings of this 
study are compared to these recommendations in this section.   
 
5.9.2    CONTRACEPTION AND COUNSELLING IN THE FEMALE POPULATION 
 
Of the 24 females in Population B, 16 stated that they were, according to their 
knowledge, able to fall pregnant while three stated that they were not able to fall 
pregnant.  There were five females who did not answer whether or not they are able to 
fall pregnant.  Some females might have felt that the information required (regarding 
contraception and pregnancy) in the questionnaire was of a private nature.  Of the 16 
females who claimed that they were able to fall pregnant, 12 were between 19 and 24 
years old, three were between 13 and 18 years old and one was aged between 25 
and 34 years.  Of the three females who claimed that they could not fall pregnant, one 
was aged between 13 and 18 years, one was aged between 19 and 24 years and one 
was aged between 35 and 49 years.   
Figure 5.8 indicates the contraceptive measures taken by the patients before and 
during isotretinoin therapy.  Of the 14 females who completed this section of the 
questionnaire, five were on oral contraceptives, four practised abstinence, one was on 
an oral contraceptive and practised abstinence, one received an injectable 
contraceptive, one’s husband had a vasectomy, one had a hysterectomy and one 
patient had no contraceptive method before isotretinoin therapy commenced.   
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Figure 5.8:  Contraceptive measures taken by females before and during 
isotretinoin therapy 
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After commencement of isotretinoin therapy, no changes were made in these 
contraceptive methods, except that one patient stopped using an oral contraceptive 
and started to practise abstinence.  The South African Acne Treatment Guideline 
recommends the use of effective contraceptive measures for one month prior to 
isotretinoin therapy, during isotretinoin therapy and for one month after isotretinoin 
therapy has been stopped (Acne Guideline 2005 update, 2005: 889).  In the USA, the 
use of two effective contraceptive measures is required for females on isotretinoin 
(Jones, 2007).  In the UK, two complementary contraceptive methods are 
recommended (Layton, et al., 2006: 774).  Of the 14 respondents, only one female 
used two contraceptive measures.  In a study conducted in South Africa in 1994, it 
was found that only 48.25% of females on isotretinoin were practicing some form of 
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contraception.  The study population consisted of 728 patients on isotretinoin, of 
whom more than half were females.  (Smart & Walters, 1994: 497.)  It could be 
observed that there is a lack of counselling regarding the importance of contraception 
whilst using isotretinoin.   
Contraception was recommended by the prescriber to only six out of 19 females 
(31.6%) who completed this section of the questionnaire.  This is in direct contrast to 
recommendations that females of child-bearing age should not receive isotretinoin 
therapy unless they are using effective contraceptive measures (Acne Guideline 2005 
update, 2005: 889).  Of the 16 patients who claimed that they were able to fall 
pregnant, only five received a recommendation for contraceptives.  Among patients 
aged 13 to 18 years, there was not one patient who received a recommendation for 
contraceptive therapy.  Five patients aged between 19 and 24 years received a 
recommendation, and contraceptives were also recommended to one patient aged 
between 35 and 49 years.   
 
The procedure that should be followed, should a female fall pregnant while on 
isotretinoin therapy, was explained correctly to only four out of 19 females (21.1%) by 
their health care professionals.  Three out of four of these females received 
isotretinoin prescriptions from dermatologists and one from a general practitioner.  Of 
the 19 patients, 12 (63.2%) did not receive any instructions or explanation and three 
(15.8%) received wrong information.  Two of the patients who did not receive 
instructions were unable to fall pregnant.  The South African Acne Treatment 
Guideline states that a patient should be fully aware of the risks, and should sign 
written consent for isotretinoin use and indicating her understanding that a therapeutic 
abortion would be compulsory should she fall pregnant while on isotretinoin therapy 
(Acne Guideline 2005 update, 2005: 889).   
 
Even though there was a clear lack of counselling and monitoring procedures from 
health care professionals, 100.0% (out of 20 females who answered this question in 
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the questionnaire) claimed that they had never fallen pregnant while on isotretinoin 
therapy.   
 
5.10    EFFICACY OF ISOTRETINOIN 
 
5.10.1    INTRODUCTION 
 
The effectiveness of isotretinoin in treating acne in Population B is reported in this 
section.  The results include the change in the grade of acne since the start of 
isotretinoin, and the change in the number of body parts affected by acne since the 
start of isotretinoin.  The history of isotretinoin use (prior to this isotretinoin course) 
was obtained to investigate the recurrence of acne after isotretinoin use in Population 
B.  The perceived acne clearance and patient satisfaction are also reported.  The 
extent to which the patients’ quality of life had been affected by the side effects as well 
as the benefits of isotretinoin are shown.  Patients were asked whether or not, if they 
were figuratively able to return in time, they would again have chosen to start 
isotretinoin therapy.  Their responses, together with reasons, are indicated in this 
section.  It should be noted that patients were on varying stages of their isotretinoin 
therapy courses, and this could have affected the results of this section to a great 
extent.   
 
5.10.2    EFFICACY IN ACNE CLEAR UP 
 
Before isotretinoin therapy, there were no patients without acne.  After initiation of 
isotretinoin therapy, 23 patients claimed that their acne had been cleared up 
completely.  Three patients had acne Grade 1 prior to isotretinoin therapy, but after 
isotretinoin therapy had been started, 14 patients claimed to have Grade 1 (or mild) 
acne.  Thus, there was a noticeable improvement in the patients’ acne severity since 
initiation of isotretinoin therapy.  This is confirmed by the lower number of patients 
suffering Grades 2, 3 and 4 acne after starting with isotretinoin when compared to 
prior to isotretinoin therapy initiation.  The difference between severity of acne before 
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and during isotretinoin therapy was significant (Chi²(4)=46.67, p<.0005; V=0.64 Large).  
These results are represented by Figure 5.9.  In a study of 188 patients on isotretinoin 
over a nine year period, it was found that immediate, long-term, stable remissions 
were present in 111 patients following one single course of isotretinoin, while stable 
remissions after two or three isotretinoin courses were obtained in 54 patients.  The 
remaining 23 patients continued to present with at least Grade 3 acne.  (Lehucher-
Ceyrac & Weber-Buisset, 1993: 123.)  Ng and Schweitzer (2003: 78) stated that 
isotretinoin has been used by over eight million people worldwide and has an efficacy 
rate of more than 75%, often with complete remission.   
 
Figure 5.9:  Distribution of severity of acne in Population B prior to and during 
isotretinoin therapy 
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Figure 5.10 represents the patients who had acne on other body parts, except for the 
face, prior to and while on isotretinoin therapy.  There were 38 patients with acne on 
other body parts before isotretinoin therapy had begun, and only 11 patients with acne 
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on other body parts after the initiation of isotretinoin.  A significantly lower number of 
patients had acne on the torso area, neck, shoulders, arms, scalp and legs after the 
initiation of isotretinoin therapy (Chi²(1)=14.88, p<.0005; V=0.55 Large).   
 
Figure 5.10:  Distribution of body areas affected by acne in Population B prior to 
and during isotretinoin therapy  
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5.10.3    REPETITIVE ISOTRETINOIN THERAPY COURSES IN POPULATION B 
 
Although every patient in Population B was on isotretinoin during the time of the study, 
it was not the first isotretinoin course for all patients.  There were 12 patients (21.1% 
of all patients) who had been on previous isotretinoin courses.  Of the 12 patients, 
eight were females (25.0% of all females) and four were males (12.1% of all males).  
Nine patients (five females and four males) were on one previous isotretinoin course, 
and three females were on two previous isotretinoin courses.  Thus, the isotretinoin 
course the patients were on was the first course for 45 patients (78.9%), the second 
course for nine patients (15.8%) and the third course for three patients (5.3%).  It was 
calculated that, altogether, there were 15 previous isotretinoin courses in the history of 
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the patient population.  The duration of therapy for each of these 15 isotretinoin 
courses are outlined in Table 5.13.   
 
Table 5.13: Duration of therapy for previous isotretinoin therapy courses 
COURSES DURATION (IN MONTHS) NUMBER (n = 15) PERCENTAGE (%) 
1 1 6.7 
3 2 13.3 
4 2 13.3 
5 3 20.0 
6 6 40.0 
8 1 6.7 
*n8 = number of previous isotretinoin therapy courses in Population B 
 
The highest percentage of the courses endured for six months (40.0%).  Three of the 
15 therapy courses (20.0%) were for five months.  There was one therapy course that 
lasted for eight months.  Two therapy courses lasted for four months, two lasted for 
three months and one lasted for one month.  It can be seen that the majority of the 
previous isotretinoin courses had an appropriate duration to achieve the correct 
cumulative dose (between four to six months).  However, three of the 15 courses were 
too short and could have contributed to the need of repeat isotretinoin courses due to 
a cumulative dose below the recommended range.  It should also be noted, however, 
that dose per day and weight of the patient should also be taken into consideration in 
determining if the optimal cumulative dose was taken, and no definite conclusions 
could be made from investigating only the duration of previous isotretinoin courses.   
 
5.10.4    PERSONAL SATISFACTION OF POPULATION B WITH EFFICACY OF 
ISOTRETINOIN 
 
The satisfaction of the patients regarding the effectiveness of isotretinoin in clearing 
up their acne was investigated.  The results are given in Figure 5.11.  The highest 
percentage of patients (42.1%) claimed that they were satisfied, while the second 
highest percentage of patients (38.6%) claimed that they were very satisfied.  There 
was a feeling of dissatisfaction among five patients (8.8%), and three patients (7.7%) 
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had neutral feelings in this regard.  There were two patients who were very dissatisfied 
with the efficacy of isotretinoin in clearing up their acne.  Altogether, there was a 
greater feeling of satisfaction in the female population, as 83.4% of females felt either 
very satisfied or satisfied, while 78.8% of males felt either very satisfied or satisfied.  
The two patients who were very dissatisfied were both males.  It should be taken into 
account that patients were at random stages of their individual isotretinoin courses 
and that the level of satisfaction, degree of acne clear up and severity of side effects 
could have been influenced greatly by the duration of time each patient had already 
been on isotretinoin when answering these questions.   
 
Figure 5.11:  Level of satisfaction of both genders with isotretinoin effectiveness 
in acne clearance  
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The perception of the degree to which acne had cleared up in each patient since 
initiation of isotretinoin was also investigated.  The results are shown in Figure 5.12.  
The highest percentage of patients perceived that their acne had cleared up very well.  
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There were 47.4% of the total population, 50% of females and 45.5% of males with 
this perception.  The second highest percentage of patients (24.6%) stated that their 
acne had resolved to a satisfactory degree.  The improvement was just noticeable in 
21.1% of patients, while two males perceived no change and one male perceived a 
worsening in his acne condition.   
 
Figure 5.12:  Degree of resolution of acne perceived by both genders at time of 
survey conduction 
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The degree to which patients experienced a decrease in quality of their life (QOL) due 
to the impact of the side effects of isotretinoin is indicated in Figure 5.13.  The highest 
percentage of patients (45.6%) felt that their QOL was negatively affected to a small 
degree.  The second highest percentage of patients (26.3%) felt that their QOL was 
not negatively affected at all.  There were 17.5% of patients who perceived a 
noticeable decrease in their QOL, and 10.5% of perceived a great decrease in QOL.  
Although many patients complained about side effects, the majority of the population 
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(71.9% of all patients) felt that these side effects did not affect their QOL or only 
affected it to a small degree.   
 
Figure 5.13:  Degree of decrease in quality of life experienced by both genders 
due to side effects experienced during isotretinoin therapy 
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The degree to which patients experienced an increase in QOL due to the benefits of 
isotretinoin is outlined in Figure 5.14.  The highest percentage of patients (45.6%) 
experienced a noticeable increase in QOL.  A small increase in QOL was experienced 
by 24.6% of the patient population, and a great increase in QOL was perceived by 
21.1% of patients.  Only 8.8% of the population did not experience an increase in their 
QOL.  Altogether, 66.7% of the patient population experienced a great or noticeable 
increase in their QOL, and 33.4% of the patients experienced little or no increase in 
their QOL.   
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Figure 5.14:  Degree of increase in quality of life experienced by both genders 
due to benefits of isotretinoin therapy 
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In a study conducted in Australia between 1998 and 2000, where 174 patients on 
isotretinoin and 41 patients on antibiotics were included, researchers utilised the WHO 
Quality of Life 100 item questionnaire in order to assess the change in quality of life of 
these patients before and during isotretinoin or antibiotic use.  The quality of life 
measures in this study were not better with improving acne.  The researchers stated 
that the physical side effects of isotretinoin may have contributed to a worsening in 
quality of life during treatment.  It was also said that it is possible that improved quality 
of life may become evident with the resolution of side effects and further clinical 
improvement after completion of treatment at six months.  (Ng, et al., 2002: 266.)   
 
Patients were asked to take both the decrease in QOL due to side effects and the 
increase in QOL due to benefits of isotretinoin into consideration, and to then decide 
whether or not they would have chosen to use isotretinoin again if they were able to 
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return to the moment when the doctor prescribed isotretinoin to them.  The results are 
indicated in Table 5.14.   
 
Table 5.14:  Gender distribution of Population B with regards to choice of use of 
isotretinoin 
FEMALES (n = 24) MALES (n = 33) BOTH GENDERS  (N = 57) CHOICE 
Number Percentage (%) Number
Percentage 
(%) Number 
Percentage 
(%) 
Use again 21 87.5 28 84.8 49 86.0 
Not use again 3 12.5 5 15.2 8 14.0 
 
The majority of patients (86.0% of patients) declared that they would indeed make the 
same decision if they were to choose again.  There were eight patients (14.0%) who 
would have chosen not to use isotretinoin.  There were a greater percentage of 
females (87.5%) than males (84.8%) who would have chosen to use isotretinoin 
again.   
 
Reasons pertaining to the patients who stated that they would make the same choice 
again (in Table 5.14) are presented in Table 5.15.  The most frequently stated reason 
for the use of isotretinoin was that patients experienced that their acne cleared up.  
This reason was given by 55.1% of the population, 47.6% of females and 60.7% of 
males.  Thus, more males than females gave this reason.  The second most popular 
reason was that the use of isotretinoin had improved the patient’s self-confidence, 
self-perception and/or social acceptability.  There were 35.7% of patients, 42.9% of 
females and 32.1% of males (thus more females than males) who gave this reason.  
Isotretinoin would have been chosen again by 14.3% of the patient population due to 
the fact that it has been the only successful treatment for these patients.  There were 
8.2% of patients (four patients) who stated that they would once again choose to use 
isotretinoin because the benefits outweigh the side effects.  No severe side effects 
were experienced by three patients, leading to them choosing isotretinoin again, and 
two patients claimed that they would choose to use isotretinoin again due to the quick 
results obtained from it.  One patient, that had not yet experienced any improvement 
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in his acne condition, would choose to use it because he believed that improvement 
would soon follow.   
 
Table 5.15:  Reasons why patients would choose to use isotretinoin according 
to gender 
FEMALES (n = 21) MALES (n = 28) BOTH GENDERS  (N = 49) POSITIVE REASON 
Number Percentage (%) Number 
Percentage 
(%) Number 
Percentage 
(%) 
Clearing up of acne 10 47.6 17 60.7 27 55.1 
Improved self 
confidence 9 42.9 9 32.1 18 36.7 
Only successful 
treatment 2 9.5 5 17.9 7 14.3 
Benefits were more 
than side effects 1 4.8 3 10.7 4 8.2 
No severe side 
effects experienced 1 4.8 2 7.1 3 6.1 
Quick results 1 4.8 1 3.6 2 4.1 
Believed that 
improvement will 
follow 
0 0.0 1 3.6 1 2.0 
 
As outlined in Table 5.14, there were eight patients who would not make the same 
choice of taking isotretinoin if they had to make the choice again.  Table 5.16 presents 
the reasons for this negative response.  Five of the eight patients felt that the side 
effects of isotretinoin outweighed the benefits.  One patient felt that isotretinoin 
therapy was too expensive.  There was one patient who would not choose to use 
isotretinoin again due to the fact that he did not experience any noticeable acne 
improvement.  One female stated that she did perceive improvement of her acne 
whilst on isotretinoin, but once therapy stops her acne returns.  Thus, she would not 
make the same decision again.  It was interesting to note that the cumulative dose for 
this patient’s current isotretinoin course would have been 92.1 mg/kg, and can be 
classified as suboptimal.  The chances of recurrence of acne after a suboptimal 
cumulative dose was reached are increased.  This patient was on two previous 
isotretinoin courses before the course under discussion.  One patient felt that 
isotretinoin had not completely cleared up his acne, although there was some 
improvement.  There was also one patient who felt that it would have been better for 
 181
him to first try some of the other acne treatment methods before resorting to 
isotretinoin therapy.   
 
Table 5.16:  Reasons why patients would not choose to use isotretinoin 
according to gender 
FEMALES (n = 3) MALES (n = 5) BOTH GENDERS (n = 8) NEGATIVE 
REASON Number Percentage (%) Number
Percentage 
(%) Number 
Percentage 
(%) 
Side effects are more 
than benefits 2 66.7 3 60.0 5 62.5 
Too expensive 0 0.0 1 20.0 1 12.5 
No noticeable results 0 0.0 1 20.0 1 12.5 
Return of acne once 
treatment course is 
over 
1 33.3 0 0.0 1 12.5 
No complete acne 
clear up 0 0.0 1 20.0 1 12.5 
Choose other 
effective agents 
before resorting to 
isotretinoin 
0 0.0 1 20.0 1 12.5 
 
After taking all of these opinions into consideration, it can be concluded that the 
majority of patients were satisfied with the efficacy of isotretinoin and would have 
made the same decision to use it if they had to choose again.  The majority of patients 
had an increase in QOL due to the benefits of isotretinoin, and the majority of patients 
did not experience a big decrease in QOL due to the side effects of isotretinoin.  There 
were, however, a few patients who were unhappy with the efficacy of isotretinoin and 
a few patients would not have chosen to use it if they had to choose again.  There 
were also patients who experienced a great decrease in the quality of life due to side 
effects of isotretinoin and patients who did not gain any quality of life from the benefits 
of isotretinoin.  Although a majority of patients seemed happy with the isotretinoin, it 
can be clearly observed that the extent of satisfaction and the extent of the benefit 
versus risk ratio differed considerably from one individual to another.   
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6.1 STUDY IN REVIEW 
 
A drug utilisation study and a patient questionnaire survey was conducted in order to 
investigate the appropriateness of medications prescribed in the treatment of acne in 
South Africa, and to evaluate the safety and efficacy of systemic isotretinoin utilised by 
acne patients in the NMM.  The drug utilisation review included a representative 
sample of South African patients from the private medical sector who were diagnosed 
with acne between 1 January 2000 and 31 December 2005, while only a sample of 
patients in the NMM who were on systemic isotretinoin therapy were included for the 
questionnaire survey.   
 
In order to accomplish the primary aim of the study, the objectives set out in Chapter 
one needed to be realised.   
 
Firstly, the prescription of acne medications in South Africa was investigated by the 
conduction of a drug utilisation study.  The results were compared to relevant literature 
recommendations and to recommendations of the South African Acne Treatment 
Guideline (Acne Guideline 2005 update, 2005: 883 – 892).   
 
The questionnaire survey served to realise the other objectives of the study.  The 
appropriateness of systemic isotretinoin prescription in the NMM was investigated by 
determining the following factors:   
 
• The history of acne medication use (prior to the use of systemic isotretinoin) by the 
questionnaire respondents.     
 
• The severity of acne of the isotretinoin patients, prior to the initiation of systemic 
isotretinoin therapy.   
 
• The appropriateness of the dosages of isotretinoin prescribed to patients by 
determination of total cumulative doses.   
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• The counselling of isotretinoin patients by the involved health care professionals.  
(This involved investigating the presence, quality, appropriateness and frequency 
of counselling received by isotretinoin patients.)   
 
• The presence, frequency and appropriateness of recommended monitoring 
procedures among the isotretinoin patients.  The South African Acne Treatment 
Guideline (Acne Guideline 2005 update, 2005: 883 – 892) includes specific 
monitoring procedures that should be executed in patients treated with systemic 
isotretinoin. 
 
The side effects experienced by the isotretinoin patients and the severity with which 
these side effects were experienced were investigated.  Lastly, the overall satisfaction 
of isotretinoin patients regarding the outcomes of therapy was investigated.  The 
patients’ perceived decrease in quality of life due to side effects of isotretinoin and 
perceived increase in quality of life due to benefits of isotretinoin were assessed.   
 
The next three sections include a summary of the findings of this study, conclusions 
that could be drawn, and recommendations based on these conclusions.   
 
6.2 SUMMARY OF FINDINGS 
 
A brief report on the most important findings of the drug utilisation study and the 
patient questionnaire survey are discussed separately in this section.   
 
6.2.1 DRUG UTILISATION REVIEW 
 
There were 18 803 patients in Population A, of whom 13 245 (70.4%) were females.  
The mean age of the population was 25.5 years (SD = 9.7 years, n = 18 803).  Of the 
seven age groups into which patients were divided, the highest percentage of patients 
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(29.2%) was between 13 to 18 years of age.  Just over 80% of the population was 
younger than 35 years of age.   
 
Diagnoses unrelated to acne were present in only 34.4% of patients.  Of these 
diagnoses, allergic rhinitis was the most frequently occurring and was diagnosed in 
10.8% of all patients.  Depression was the second most frequently occurring, as 6.7% 
of patients were diagnosed with this condition.  A significantly higher percentage of 
females than males were diagnosed with depression (Chi²(1)=109.40, p<.0005; 
V=0.30 Medium).  It was also found that each successive age group had a larger 
proportion of patients diagnosed with depression.  Eczema and asthma were the third 
and fourth most prevalent diagnoses unrelated to acne, respectively.  The 10 most 
frequently prescribed medications (other than medications for the treatment of acne) 
for both females and males were all indicated in the treatment of these four conditions, 
namely allergic rhinitis, depression, eczema and asthma.  Thus, the non-acne 
medications were in accordance to the non-acne diagnoses.  Therefore, as expected, 
a larger proportion of females were prescribed anti-depressants, while anti-histamines 
and topical corticosteroids were prescribed to a larger proportion of males.   
 
Hormone therapy (for acne treatment) was prescribed to 47.1% of females.  Patients 
aged between 19 to 34 years constituted the largest age group to whom hormone 
therapy was prescribed.  Over 30% of females aged 35 years or older and over 12% 
of females aged 50 years or older received prescriptions for hormone therapy, 
although discrepancies regarding the safety of prescription of oral contraceptives in 
these age groups were found in literature.  (It should be noted, however, that hormone 
therapy also included HRT, which, when prescribed to these age groups, would have 
been acceptable, although not recommended for acne treatment.)  Although 
menstruation might not have commenced in many females in the age group of 12 
years and younger, over 18% of these females received hormone therapy 
prescriptions.  A large majority of females (95.2% of the 6 240 females to whom 
hormone therapy was prescribed) received prescriptions for a combination of 
ethinylestradiol and cyproterone acetate.  This finding was in accordance with the 
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recommendations of the Acne Guideline 2005 update (Acne Guideline 2005 update, 
2005: 890).   
 
Systemic antibiotics were prescribed to 43.3% of Population A.  Almost 40% of 
females and more than 50% of males received prescriptions for systemic antibiotics.  
Systemic antibiotic therapy was prescribed to a high percentage of patients aged 
younger than 13 years.  Tetracycline derivatives should preferably be avoided in 
patients younger than 12 years of age (South African Medicines Formulary, 2003: 
273), although the prescription of these specific active ingredients to the age groups 
was not investigated.  Doxycycline was the most frequently prescribed antibiotic active 
ingredient for both genders, followed by minocycline and lymecycline.  Cotrimoxazole 
was the fourth most frequently prescribed antibiotic agent.  These findings were not in 
accordance with the latest South African recommendations (Acne Guideline 2005 
update), as lymecycline is recommended as first-line systemic antibiotic therapy, 
followed by the other tetracycline derivatives and then cotrimoxazole.     
 
Systemic isotretinoin was prescribed to 42.1% of Population A.  There were 36.1% of 
females and 56.4% of males who received isotretinoin prescriptions.  This difference 
was significant (Chi²(1)=347.96, p<.0005; V=0.21 Small), and could be due to the fact 
that females had the option of hormone therapy for acne treatment and/or that more 
caution was taken by prescribers when prescribing isotretinoin to females, possibly 
due to the teratogenic risk involved.  The female age group with the highest 
percentage of patients who received systemic isotretinoin prescriptions was 35 to 64 
years.  This was a surprising finding, but could be due to the decreased risk of 
pregnancy in this age group or the complications that the initiation of hormone therapy 
might entail in this age group.  In contrast, the highest proportion of males to whom 
isotretinoin was prescribed were aged between 13 to 24 years.  Isotretinoin was also 
frequently prescribed to females and males younger than 13 years of age.  According 
to the South African Medicines Formulary (2003: 199) and Layton and associates 
(2006: 774), caution regarding the use of systemic isotretinoin by patients younger 
than 12 years of age is advised.   
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Almost 19% of Population A received prescriptions for topical acne medication.  
Topical therapy was only prescribed to 17.9% of males and 19.3% of females.  
Adapalene was the topical agent prescribed to the highest percentage of females, 
followed by topical antibiotic therapy as a group.  The highest proportion of males was 
prescribed topical antibiotics (as a group), followed by benzoyl peroxide and thirdly, 
adapalene.   
 
Overall, systemic antibiotics were the acne treatment prescribed to the highest 
percentage (43.3%) of patients in Population A, while 42.1% of patients received 
systemic isotretinoin prescriptions.  Just over 33% of patients received hormone 
therapy prescriptions, while only 18.9% of patients were prescribed topical acne 
therapy.   
 
6.2.2 PATIENT QUESTIONNAIRE SURVEY 
 
Population B consisted of 57 patients, of whom 24 (42.1%) were females.  The 
average age of Population B was 20.2 years (SD = 7.9 years, n = 57), with an age 
range of 14 to 65 years.  The average age of initial acne development in Population B 
was 15.3 years (SD = 4.4 years, n = 56), with an age range of eight to 38 years.   
 
Only 22.8% of patients reported to have experienced disease conditions in addition to 
acne (comorbid conditions), and 19.3% of patients were on non-acne medication, 
during the time of the study.  Allergic rhinitis, psychological disorders and respiratory 
tract infections were the most frequently reported comorbid conditions.  The most 
frequently used therapeutic group was anti-depressants.  These findings were similar 
to findings for Population A, although for a much smaller population size.    
 
When investigating the use of acne medications or treatments by patients prior to 
isotretinoin therapy initiation, almost 58% of patients reported the use of cosmetic 
agents.  Only 21.8% of patients had tried topical acne therapy to alleviate acne before 
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isotretinoin therapy was prescribed, while systemic antibiotic therapy was prescribed 
to only 19.3% of patients prior to isotretinoin therapy prescription.  The most frequently 
prescribed systemic antibiotic agent was cotrimoxazole.  There were 37.5% of females 
who reported the use of hormone therapy prior to isotretinoin therapy.  Topical 
retinoids were prescribed to only 21.1% of patients.   
 
In Population B, Oratane® was the most frequently prescribed systemic isotretinoin 
trade name.  There were 34 patients who reported adequately in the questionnaire to 
allow for the determination of their cumulative isotretinoin dosages.  Only seven 
(20.6%) of these patients would have received the optimal cumulative dose of 
between 120 to 150 mg/kg, while 29.4% would have received a cumulative dose 
higher than 150 mg/kg and 50.0% would have received a cumulative dose below 120 
mg/kg.  The latter group would be more prone to developing recurring acne, even if 
complete clearance was to be observed after the initial isotretinoin treatment course 
(Acne Guideline 2005 update, 2005: 890).   
 
Only 16 of the 57 patients reported Grade 4 acne prior to isotretinoin therapy initiation, 
while 21 patients reported Grade 3 acne.  There were 17 patients with Grade 2 acne 
and 3 patients with Grade 1 acne on isotretinoin therapy initiation.  These findings 
could indicate inappropriate isotretinoin prescription, as it is usually reserved for the 
treatment of Grade 4 acne, except if patients who experienced Grades 1, 2 or 3 acne 
met the criteria for isotretinoin therapy through additional indications (which includes 
acne unresponsive to systemic antibiotic therapy for four months or unresponsive to 
four cycles of hormone therapy, scarring acne, acne with severe psychological stress 
or frequently relapsing acne) (Acne Guideline 2005 update, 2005: 890).   
 
General practitioners prescribed isotretinoin in 19.3% of cases, one patient (who was 
a pharmacist) self-initiated therapy and all other patients received prescriptions for 
isotretinoin from dermatologists.  Approximately 46% of patients did not receive 
adequate counselling regarding isotretinoin therapy from their prescribers.  It was 
found that inadequate counselling was given in eight of the 11 cases (72.7%) where 
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isotretinoin was prescribed by general practitioners and in 15 out of 45 cases (33.3%) 
where it was prescribed by dermatologists.  Just over 78% of respondents stated to 
have received adequate counselling from their pharmacists.  However, when the 
counselling of patients by prescribers and dispensers for specific topics was 
investigated, it was found that patients were counselled more by prescribers than by 
dispensers.  However, there was an overall lack of counselling by health care 
providers in all topics that should have been discussed when isotretinoin therapy 
commenced.   
 
Prednisone (as an adjunct to isotretinoin for a short period of time upon start of the 
isotretinoin course) was prescribed to only 24.6% of patients, although its prescription 
is recommended to prevent the flare of acne that might occur on initiation of 
isotretinoin.  In addition, it should be noted that acne flares were reported in over 63% 
of the population.  Just over half of the patients received recommendations or 
prescriptions from their prescribers regarding treatment agents that can be used to 
alleviate or prevent the side effects of isotretinoin (for example, lip balm or sunscreen).   
 
There was a lack of the conduction of cholesterol tests in 35.2% of patients, while 
correct cholesterol monitoring procedures (entailing tests upon isotretinoin initiation 
and one month after initiation) were conducted in only 18.5% of patients.  When 
considering the adherence of prescribers to the guidelines with regards to the 
monitoring of liver enzyme levels, it was found that liver enzyme tests were conducted 
according to guideline recommendations (once upon initiation of isotretinoin and once 
one month after initiation) in only 17.9% of patients.  Just over 23% of patients 
reported not to have had a liver enzyme test done at all.   
 
The most frequently reported side effect of isotretinoin in the population was dryness 
of lips (reported by 98.2% of patients).  Almost 88% of patients experienced dry skin, 
while 56.1% of patients reported dry eyes.  Mucocutaneous side effects were 
therefore the most frequently reported side effects in Population B.  The prevalence of 
backache and myalgia was high, as each was experienced by more than 40% of 
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patients.  It should be noted that overall, the backache reported was mostly to a mild 
degree.  The occurrence of depression and fatigue were each reported by 42.1% of 
respondents.  Eight patients admitted having suicidal thoughts while on isotretinoin 
therapy.  Headache (which could have been a sign of raised intracranial pressure) 
was reported by 38.6% of patients.  Almost nine percent of patients reported to have 
experienced increased cholesterol levels and 7.3% of patients reported liver enzyme 
changes.      
 
Of the 24 females, 66.6% claimed that they possessed childbearing potential.  There 
were 14 females willing to report on their contraception use prior to and during 
isotretinoin therapy.  Of these 14 females, 35.7% were on oral contraceptives and 
42.9% practised abstinence during the time of isotretinoin therapy.  One patient did 
not take any contraceptive precautions during this time.  No changes in the usage 
pattern of contraceptives before and after initiation of isotretinoin could be observed, 
except for one patient who reported to have stopped the use of her oral contraceptive 
prior to isotretinoin initiation and started practicing abstinence.  Thus, no health care 
provider intervention at the time of isotretinoin therapy initiation could be found.  Only 
31.6% of respondents reported that the use of contraception during isotretinoin 
therapy was recommended to them, whilst none of the females between the ages of 
13 to 18 years received a recommendation for the use of a contraceptive measure.  
There were three females (all of childbearing age) who did not receive any counselling 
regarding the teratogenic effects of isotretinoin, and only four females were counselled 
appropriately regarding the procedures that one should follow if pregnancy should 
occur during an isotretinoin therapy course.  Pregnancy tests were conducted before 
isotretinoin therapy initiation in only two of the 24 (8.3%) females.  Although there was 
a clear lack of the counselling and monitoring of females regarding pregnancy 
prevention, 100% of females reported that they had not fallen pregnant while on 
isotretinoin therapy.   
 
Just over 40% of patients reported a complete clearance of acne lesions during their 
isotretinoin therapy course.  The difference between severity of acne before and 
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during isotretinoin therapy was significant (Chi²(4)=46.67, p<.0005; V=0.64 Large).  It 
was also found that a significantly lower number of patients had acne on the torso 
area, neck, shoulders, arms, scalp and legs after the initiation of isotretinoin therapy 
(Chi²(1)=14.88, p<.0005; V=0.55 Large).  Over 83% of females and almost 80% of 
males felt either very satisfied or satisfied with the perceived efficacy of isotretinoin.  
Although many side effects were reported, the majority of the population (71.9% of 
patients) felt that these side effects did not negatively affect their QOL or only affected 
it negatively to a small degree.  A great or noticeable increase in the QOL of patients 
due to the clearing up of acne was reported by 66.7% of the patients.   
 
6.3 CONCLUSIONS 
 
After evaluating the most relevant findings of both the drug utilisation review and the 
patient questionnaire survey, conclusions could be drawn.  These conclusions are 
stipulated in this section.   
 
Depression occurred frequently among acne patients of both populations.  Literature 
states that acne is a condition that may lead to depression and/or social and emotional 
dysfunction (Isotretinoin (Roaccutane) usage – a South African consensus guideline, 
1997: 1410; O’Reilly, et al., 2006: 1925).  Therefore, specific caution should be taken 
when prescribing isotretinoin to acne patients who may already be prone to 
depression.  It was not assessed whether depression occurred prior to, during or after 
the use of isotretinoin (or in patients who did not use isotretinoin) in Population A.   
 
Although the acne medication prescription that was investigated for Population A 
occurred prior to the release of the 2005 guidelines, similarities with guideline 
recommendations and other literature recommendations could be found.  Hormone 
therapy, specifically cyproterone acetate–containing hormone regimens (as 
recommended in Acne Guideline 2005 update, 2005: 889), were prescribed to a high 
percentage of females.  It should, however also be noted that many females older 
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than 35 years and younger than 13 years also received prescriptions for hormone 
therapy, although the safety and efficacy in these age groups could be questioned.   
 
Systemic antibiotics were prescribed to a high percentage of Population A, and 
although the use of systemic antibiotics in acne treatment is promoted, caution against 
overuse of antibiotics is also advised.  Lymecycline, which is the first-choice antibiotic 
according to the Acne Guideline 2005 update (2005: 886), was not prescribed as 
frequently as it should have been for either Population A or Population B.  The 
prescription and use of topical antibiotic agents for both populations were not a highly 
prevalent treatment method.  This finding was positive, as resistant strains of bacteria 
are promoted by the overuse of topical antibiotic agents.  For optimal results and in 
order to prevent bacterial resistance from developing, topical antibiotic agents should 
be combined with a topical anti-resistance agent like benzoyl peroxide.  In both 
populations, the prescription of topical antibiotics alone was more prevalent than the 
prescription of a combination of a topical antibiotic with benzoyl peroxide.   
 
The underutilisation of topical acne formulations, especially topical retinoid therapy, 
has come to light in both populations of this study.  Topical retinoids can be prescribed 
for Grades 1 and 2 acne, and can be prescribed in addition to systemic therapy in 
Grades 3 and 4 acne.  It may serve as acute and preventative therapy (Acne 
Guideline 2005 update, 2005: 887).  Therefore, if guideline recommendations were 
followed, a much greater percentage of both populations would have received topical 
retinoid therapy.   
 
Systemic isotretinoin was prescribed to a high percentage of patients in Population A, 
especially to a high percentage of males.  It is apparent that there is a high incidence 
of systemic isotretinoin use amongst acne patients in the private medical aid sector of 
South Africa.  The high incidence of systemic isotretinoin use in patients younger than 
13 years is worthy of note, as its use is not promoted in children.  (Layton, et al., 2006: 
774; South African Medicines Formulary, 2003: 199.)  When looking at isotretinoin 
prescription in Population B, it could be concluded that many prescribers did not follow 
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the recommendations for isotretinoin prescription in the Acne Guideline 2005 update.  
Isotretinoin was prescribed to many patients who did not have Grade 4 acne and who 
had not received previous prescriptions for systemic antibiotic therapy or hormone 
therapy, which might have been effective if tried before resorting to isotretinoin 
prescription.  However, the psychological aspects and scarring potential of the 
patients were not investigated in this study and could have contributed to the 
prescribers’ decision to prescribe isotretinoin.  It is important to note that in Grades 1, 
2 or 3 acne (except in the special circumstances which render isotretinoin therapy 
appropriate), systemic antibiotics in combination with topical retinoid therapy, or 
hormonal therapy in combination with retinoid therapy, should have been prescribed 
before resorting to isotretinoin.  These effective acne treatments, for example topical 
retinoids and systemic antibiotics, were prescribed only to small percentages of 
patients in Population B before they received isotretinoin prescriptions.   
 
A majority of patients received inappropriate cumulative doses, which, if too low, could 
lead to the return of acne at later stages of their lives, or if too high, could have led to 
severe (unnecessary) side effects.  The side effects experienced by Population B 
were in accordance with prevalent side effects reported in the literature, although the 
incidence of many side effects was higher in the population than that which was 
reported for other studies.  This could be due to the small population size and did not 
lead to any definite conclusion.  The high occurrence of depression and suicidal 
thoughts, however, was noteworthy.  Although patients in Population B were still on 
their isotretinoin courses, just over 40% reported to have experienced a complete 
clearing of acne.  This, together with the fact that over 80% of the patients felt satisfied 
or very satisfied with the perceived efficacy of isotretinoin, once again proves how 
effective isotretinoin therapy is in noticeably clearing acne within a few months.   
 
Counselling of patients regarding isotretinoin therapy was substandard by all health 
care professionals, including dermatologists, pharmacists, and especially general 
practitioners.  Monitoring procedures as recommended in Acne Guideline 2005 update 
(2005: 889 - 890), were largely insufficient and not done in accordance to 
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recommendations.  Special emphasis is placed on the unacceptable lack of 
compliance of health care providers in implementing pregnancy prevention measures 
amongst female isotretinoin users and counselling females in this regard.   
 
6.4 RECOMMENDATIONS 
 
Based on the conclusions reached from the study, the following recommendations are 
made:  
 
•  Many acne treatments are contraindicated (or cautioned) in children.  Therefore, a 
special set of acne treatment guidelines for children should be prepared and 
implemented.   
 
• The value of topical retinoid therapy in acne management should not be 
underestimated.  It could be of great value in all grades of acne, and could provide 
optimal preventative therapy.   
 
• The prescription of systemic isotretinoin should be limited to dermatologists only, 
and general practitioners should not be allowed to prescribe it.   
 
• On initiation of isotretinoin therapy, patients should receive a “clinic card” that they 
can keep with them, designed for the collection of dosage, monitoring and 
counselling information.  Dosage indications, together with a calculation of an 
optimal cumulative dose for the patient, should be recorded on the card.  The 
dates of conduction and the results of all monitoring procedures should be also 
recorded in this card, as well as the counselling given to the patient.  Any 
problematic side effects as well as questions could also be written in the card by 
the patient and presented to the health care provider during appointment sessions.  
The health care provider should also keep a copy of the card in order to keep 
record of all the information.  Any changes in dose, weight of patient or monitoring 
results could be recorded and followed up.  This tool will allow for better patient 
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compliance and understanding, better communication between the prescriber and 
the dispenser with regards to the health of the patient, and more organised health 
care provision according to guideline recommendations.   
 
• Special care should be taken in patients prone to depression to whom systemic 
isotretinoin therapy is prescribed.  At least one counselling session with a 
psychologist during the course of treatment should be compulsory in order to 
recognise possible depressive symptoms and/or suicidal inclinations.   
 
• As in the USA and in the UK, a national Pregnancy Prevention Program must be 
instituted in South Africa.  The implementation of this program should be 
compulsory for all females on isotretinoin therapy and all health care providers 
involved in care of females on isotretinoin therapy.  This program should include a 
regulation that two effective contraceptive measures (and not just one) must be 
implemented by all females of childbearing age for one month prior to isotretinoin 
initiation, during isotretinoin therapy and for one month after therapy cessation.  A 
negative pregnancy test result must be provided by the female prior to initiation of 
isotretinoin therapy, and also every month upon receiving her month’s supply of 
isotretinoin.  It should be compulsory for all females to sign a consent form 
regarding their understanding of the teratogenic risks of isotretinoin and their 
willingness to partake in a program to prevent pregnancy while on isotretinoin 
therapy.   
 
• Although there are guidelines for isotretinoin prescription available from all three 
isotretinoin therapy trade name manufacturers in South Africa and in the Acne 
guideline 2005 update, a national consensus flowchart or protocol for the 
prescription of isotretinoin therapy should be designed and implemented.  An 
example of such a flowchart is shown in Figure 6.1.  This is only an example and 
great care and effort should be exercised in order to make this protocol specific for 
different genders and age groups of patients.   
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Figure 6.1:  Example of a flowchart that may be implemented in the prescription of systemic isotretinoin therapy 
Grade of acne:    
 
 
 
 
 
 
 
 
 
 
1 
Comedones only 
2 
Inflammatory papules 
present in addition to 
comedones 
3 
Pustules present in 
addition to any lesions 
in Grade 1 or 2 
4 
Nodules, cysts, conglobate 
lesions or ulcers present in 
addition to any lesions in 
Grade 1, 2 or 3
Has patient unsuccessfully used a 
topical treatment regimen 
including a topical retinoid alone or 
in combination with benzoyl 
peroxide for at least four months? 
YES
YES
Use topical retinoid in 
combination with 
benzoyl peroxide for 
at least four months.   
NO
YES
*Has patient un-
successfully used at 
least one four month 
systemic antibiotic 
therapy course in 
combination with a 
topical retinoid? 
FEMALES ONLY:  
Has patient 
unsuccessfully used 
at least one four 
month systemic 
course of 
cyproterone acetate 
combined with 
ethinylestradiol? 
YES 
(if female) 
YES to both (if female), 
YES to * (if male) 
Systemic 
isotretinoin 
therapy 
YES YES
Use systemic 
antibiotic combined 
with topical retinoid 
for three to four 
months. 
NO
FEMALES ONLY:  Use 
systemic cyproterone acetate 
combined with ethinylestradiol 
for at least four months.  
Topical retinoid may be added.   
NO (if female) 
Is the patient 
severely 
psychologically 
stressed or prone to 
scarring? 
Is the patient 
severely 
psychologically 
stressed or prone to 
scarring? 
NO
NO
YES YES
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APPENDIX C:  EXTRACT FROM DATA RECEIVED FROM COMPANY A (part 1) 
 
BenID 
Gen-
der BirDte 
Postal 
Code 
Active 
Flag Modified_ Date Comm Date Term Date 
ICD10 
Code Diagnosis 
Drug 
Form Drug Name 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20000818 20000818 F32.9 Depression TAB LUVOX 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20000818 20010409 F32.9 Depression TAB LUVOX 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20050517 20051102 L23.9 
Dermatitis 
(allergic) CRE ELOCON 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20020412 20020627 L70.9 Acne JEL 
PANOXYL ACNE 
10 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20010409 20011010 G43.9 Migraine CAP SIBELIUM 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20010409 20011010 F32.9 Depression TAB ZOLOFT 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20021021 20030403 L70.9 Acne CAP CYCLIDOX 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20031128 20040128 F32.9 Depression TAB AURORIX 
100182 F 
1979-03-01 
00:00:00.000 1867 1 
2005-05-22 
00:00:10.447 20050517   J30.4 Allergic rhinitis AQS 
RHINOCORT 
AQUA 64MCG 120 
DOSE 
100258 F 
1963-03-17 
00:00:00.000 1940 0 
2003-05-18 
00:00:38.530 20011203 20020509 L70.9 Acne CAP ROACCUTANE 
100258 F 
1963-03-17 
00:00:00.000 1940 0 
2003-05-18 
00:00:38.530 20000313 20000804 L70.9 Acne CAP ROACCUTANE 
100258 F 
1963-03-17 
00:00:00.000 1940 0 
2003-05-18 
00:00:38.530 20000313 20000804 L70.9 Acne CAP ROACCUTANE 
100258 F 
1963-03-17 
00:00:00.000 1940 0 
2003-05-18 
00:00:38.530 20011203 20020509 L70.9 Acne CAP ROACCUTANE 
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APPENDIX C:  EXTRACT FROM DATA RECEIVED FROM COMPANY A (part 2) 
 
Strength Nappi RetPrc 
Pac 
Sze 
Direc-
tions Jan Feb mar Apr May Jun Jul Aug Sep Oct Nov Dec 
ATC_ 
Description ATC _Code 
100MG 805203 275.79 30 1 daily 30 30 30 30 30 30 30 30 30 30 30 30 Fluvoxamine N06AB08 
100MG 805203 275.79 30 1 daily 30 30 30 30 30 30 30 30 30 30 30 30 Fluvoxamine N06AB08 
1MG/1g 782017 95.59 20 mdu 0 0 0 0 20 20 20 20 20 20 0 0 Mometasone D07AC13 
10G/100
G 835358 86.06 40 
APPLY 
BD 0 0 0 40 40 40 0 0 0 0 0 0 
Benzoyl 
peroxide D10AE01 
5MG 763780 378.16 60 2 nocte 0 0 0 60 60 60 60 60 60 0 0 0 Flunarizine N07CA03 
50MG 868833 203.21 30 1 daily 0 0 0 30 30 30 30 30 30 0 0 0 Sertraline N06AB06 
100MG 716944 19.32 30 1 daily 30 30 30 0 0 0 0 0 0 30 30 30 Doxycycline J01AA02 
150MG 788775 325.55 60 1 bd 60 60 60 60 0 0 0 0 0 0 60 60 Moclobemide N06AG02 
64MCG 703203 120.51 1 
1 puff 
daily 1 0 1 0 1 0 1 0 1 0 1 0 Budesonide R01AD05 
20MG 761133 484.82 60 2 daily 60 60 60 60 0 0 0 0 0 0 0 60 Isotretinoin D10BA01 
20MG 761133 484.82 60 2 daily 0 0 60 60 60 60 60 0 0 0 0 0 Isotretinoin D10BA01 
10MG 761125 266.53 60 1 daily 0 0 30 30 30 30 30 0 0 0 0 0 Isotretinoin D10BA01 
10MG 761125 266.53 60 1 daily 30 30 30 30 0 0 0 0 0 0 0 30 Isotretinoin D10BA01 
219
 
 
 219
 
 
 
 
 
 
 
 
 
 
APPENDIX D 
LETTER OF INFORMATION TO 
PARTICIPANTS IN QUESTIONNAIRE 
SURVEY 
 
 
 
 
 
 
 
 220
                            Faculty of Health Sciences 
                                                                           NMMU 
                                                                                            Tel: 041 504-2128   
                                                                                             Fax: 041-504-2744 
                                                                                                                          E-mail Researcher: 
                                                                                                                                  soleburger@yahoo.com  
                                                                                                                         Tel Researcher: 083 6025281 
                                                                                             19 September 2006 
 
Dear Isotretinoin Patient and/or Parent or Guardian of Isotretinoin patient 
 
A research study is currently being undertaken in which the use of acne medications, especially with 
regards to isotretinoin, is investigated.  As a patient who is currently taking isotretinoin for the treatment 
of your acne, your participation in this study will be greatly valued.  This letter will provide all the 
necessary information to explain to you what would be expected of you (the participant).  The letter will 
also assist you in understanding the study.  Please feel free to ask the researcher or pharmacist to 
clarify anything that is not clear to you.   
 
BACKGROUND 
Acne is a common disease worldwide, and there are many medications and treatment options 
available for the treatment of acne.  Isotretinoin is one of these available options, and is usually 
reserved for more severe cases of acne, or acne in which scarring may be prominent.  Isotretinoin is 
the active ingredient in Roaccutane®, Acnetane® and Oratane®.  You are currently taking one of these 
three medicines to treat your acne.   
 
AIM OF THE STUDY 
The primary aim of this study is to investigate the patterns and appropriateness of medications used for 
the treatment of acne in the Nelson Mandela Metropole (NMM), and to evaluate the safety and 
effectiveness of isotretinoin used by acne patients.   
 
WHAT IS EXPECTED OF YOU 
Your pharmacist will provide you with three documents, in an envelope, namely: 
• this patient information letter; 
• a patient consent form with an attached patient assent form; and 
• a patient questionnaire.   
 
Should you choose to participate, please complete the following steps: 
 
1. You will be required to provide written consent by completing the patient consent (and/or 
assent) form.  This must please be done according to the participants AGE.    
 
Participants younger than 21 years:  
? are not allowed to give consent themselves according to law, and consent by a parent 
or guardian is therefore required.   
? Thus a PARENT OR GUARDIAN must sign the CONSENT form.   
? In this case, the ASSENT form attached to the front of the CONSENT form MUST be 
completed and signed by the PARTICIPANT younger than 21 years of age in order to 
give his/her permission to the parent/guardian to complete the CONSENT form on 
his/her behalf.   
 
Participants older than 21 years:  
? must sign the CONSENT form; and  
? does NOT need to sign the ASSENT form as well.   
 
!!! Please note that in order for the researcher to use any information provided by you, your 
consent is compulsory.  If the consent and assent forms are not filled in correctly, none of 
your information in the questionnaire can be used for the study.   
 
2. You will then have to complete the enclosed patient questionnaire.  Please note that this 
questionnaire must be filled in as accurately and completely as possible, seeing that every 
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question will render valuable information to the researcher.  The questionnaire is one of the 
most important and critical parts of the study.  Patients younger than 18 years are required 
to complete the questionnaire with the aid of a parent, guardian or pharmacist as far as 
possible.   
 
3. After completion of the questionnaire and the consent form, which can take place either at 
home or at your pharmacy, please return the completed forms in an envelope to the pharmacy 
where you received the forms before the 10th of November 2006.   
 
YOUR RIGHTS AS PARTICIPANT 
 
You have the right to query concerns regarding the study at any time. Immediately report any new 
problems during the study, to the researcher.  Telephone numbers of the researcher are provided.  
Please feel free to call these numbers.    
 
Furthermore, it is important that you are aware of the fact that the study has to be approved by the 
Research Ethics Committee (Human) of the university. The RECH consist of a group of independent 
experts that has the responsibility to ensure that the rights and welfare of participants, in research are 
protected and that studies are conducted in an ethical manner.  Studies cannot be conducted without 
RECH’s approval.  Queries with regard to your rights as a research subject can be directed to the 
Research Ethics Committee (Human) you can call the Director: Research Management at (041) 504-
4536.  If no one could assist you, you may write to: The Chairperson of the Research, Technology and 
Innovation Committee, PO Box 77000, Nelson Mandela Metropolitan University, Port Elizabeth, 6031. 
 
Participation in research is completely voluntary.  You are not obliged to take part in any research.  If 
you choose not to participate, your present and/or future medical care will not be affected in any way 
and you will incur no penalty and/or loss of benefits to which you may otherwise be entitled. 
 
Although your identity will at all times remain confidential, the results of the research study may be 
presented at scientific conferences or in specialist publications.  
 
This informed consent statement has been prepared in compliance with current statutory guidelines. 
 
Yours sincerely 
 
Solé Burger 
RESEARCHER 
Telephone number: 083 60252 81 
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SUMMARY OF ACNE GUIDELINE 2005 UPDATE 
 
The most recent South African Acne Treatment Guideline was published in 2005 in 
the South African Medical Journal (Acne Guideline 2005 update, 2005: 883 – 892).  It 
was based on a consensus document of the Global Alliance to Improve Outcomes in 
Acne (GAIOA).  The GAIOA was created in 2001 as a worldwide effort to assemble a 
group of recognised experts in the field of acne treatment.  (Acne Guideline 2005 
update, 2005:  883.)  In addition to a detailed layout of findings and information, the 
Acne Guideline 2005 update also includes short summaries of the main findings and 
recommendations of the Global Alliance.  These short summaries are spread over 
many of the pages of the guideline, which make the document easy to read and to 
understand.  The summaries in the document are named “Recommendations of the 
Global Alliance” and “Consensus of the Global Alliance”.  This Appendix is a 
compilation of the various short summaries in the Acne Guideline 2005 update.  The 
two main headings in this document will therefore also be “Recommendations of the 
Global Alliance” and “Consensus of the Global Alliance”.  The words used in this 
summary are directly quoted from the short summaries in the Acne Guideline 2005 
update.  (Acne Guideline 2005 update, 2005: 883 – 892.)   
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1. CONSENSUS OF THE GLOBAL ALLIANCE 
 
• Acne has very significant impact on patients 
 
o Negative effect on emotions and social functioning 
o Associated with anxiety, depression, unemployment 
o Impact not always easy to assess clinically 
 
• Knowledge of pathophysiology should influence treatment 
 
o Primary pathophysiological factors in acne: 
 
? Androgen production 
? Excessive sebum production 
? Abnormal desquamation of the follicular epithelium 
? P.acnes proliferation 
? Inflammation and immune response 
 
o Treatment should target as many factors as possible 
 
• Topical retinoids have multiple anti-acne actions 
 
o Inhibits / reduces number of microcomedones 
o Reduces mature comedones 
o Reduces inflammatory lesions 
o Promotes normal desquamation of follicular epithelium 
o Anti-inflammatory 
o Enhances penetration of other drugs 
o Maintains remission by inhibiting microcomedones 
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• Benzoyl peroxide is a useful adjunctive treatment 
 
o Potent antimicrobial effects 
o Slower-acting than systemic antibiotics 
o No resistance reported to date 
o Useful in patients with mild to moderate acne 
 
• Combination therapy is now standard of care for mild to moderate acne 
 
o Antimicrobial therapy plus topical retinoids is significantly better than 
antimicrobials alone 
o Clearance of both inflammatory lesions and comedones is faster 
o Combination therapy allows targeting of different pathophysiological factors 
o Topical retinoids are likely to enhance penetration of antimicrobials, and to 
speed up action of antibiotics 
o Topical retinoids added early, at start of treatment, give fastest results 
o Antibiotic can be discontinued when inflammatory lesions resolve (3 – 4 
months) 
o If this is not possible, benzoyl peroxide of benzoyl peroxide / antibiotic 
combination can be used 
o Success can be maintained with topical retinoids 
 
• Maintenance therapy 
 
o The microcomedo is the precursor of all acne lesions 
o The process of microcomedo formation is permanent and persists after 
acne is cleared 
o Avoiding microcomedo formation has a preventive effect in acne 
o Microcomedones are the main target of topical retinoids 
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• Hormonal therapy is useful in androgen-driven acne 
 
o Excellent choice for women who need oral contraception for gynaecological 
reasons 
o Should be used early for patients with moderate or severe acne or with 
SAHA signs 
o Useful in combination treatment 
o Useful in women with late-onset acne 
 
• Oral isotretinoin is standard of care for severe acne 
 
o Targets all the pathophysiological factors 
o May achieve dramatic results even in severe disease 
o May be used more frequently in moderate and unresponsive disease 
o Side-effects common but manageable 
o Variable rate of recurrence; retreatment may be needed 
 
• General acne management strategies form useful part of therapy 
 
o Patient understanding of therapy (use, expected results, the risk of 
worsening acne) 
o Skin care regimens 
o Office procedures: comedo extraction, chemical peels, and intralesional 
corticosteroids 
 
RECOMMENDATIONS OF THE GLOBAL ALLIANCE 
 
• Quality of life 
 
o Effective treatment dramatically improves a patient’s quality of life (QOL) 
o Use of a simple QOL assessment tool can help clinicians optimise therapy 
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• Oral antibiotics for acne 
 
o Oral cyclines should be considered as a first choice when treating acne 
o Lymecycline should be considered as a first-choice antibiotic when treating 
moderate to severe inflammatory acne 
o Doxycycline or minocycline can be prescribed as second choice 
o First-generation tetracyclines should be considered a third choice 
o Erythromycin can be used in children under 12 years old or during 
pregnancy 
o Co-trimoxazole can be considered in selected cases 
 
• Optimal dosage for antibiotics in acne 
 
o 300 – 600 mg per day for lymecycline 
o 100 – 200 mg per day for doxycycline and minocycline 
o One gram per day for oxytetracycline 
o Topical antibiotics should never be used as monotherapy 
 
• Duration of antibiotic treatment 
 
o Oral antibiotics should be prescribed for 3 months 
o An additional month can be considered if a steady improvement has been 
seen over the previous 3 months, but total clearance has not been achieved 
o Compliance should be checked in patients who do not respond well 
 
• Topical retinoids in acne treatment 
 
o Should be the primary form of treatment for most forms of acne vulgaris 
o Use early for best results 
o Add antimicrobial therapy for inflammatory lesions when present 
o Should be applied to the entire affected area 
o Essential part of maintenance therapy 
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• Benzoyl peroxide 
 
o Use in patients with mild to moderate acne 
o Apply once or twice daily to entire affected area 
o Use lower strengths in persons with: 
 
? Sensitive skin 
? Very young or anxious patients 
 
o Higher concentrations and washes for: 
 
? Chest, shoulders, back 
 
• Combination therapy 
 
o Oral antibiotics should not be used alone 
o Oral antibiotics should not be combined with topical antibiotics (increases 
the risk of bacterial resistance and provides no additive action) 
o Oral antibiotics should always be combined with a topical retinoid from the 
start (3 pathogenic factors addressed) 
o Benzoyl peroxide can be added to topical retinoids and oral antibiotics in 
order to lower the incidence of bacterial resistance 
o Benzoyl peroxide should be added when longer courses of antibiotics are 
used 
o Topical retinoids and benzoyl peroxide can be used in combination, either 
on alternate days or one in the morning and the other at night 
 
• Maintenance therapy 
 
o After the acute phase of acne treatment (> 90% improvement), maintenance 
therapy should always be considered to limit relapse 
o Topical retinoids are the treatment of choice for maintenance therapy 
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o Suggested duration of maintenance therapy is 6 – 12 months 
o Benzoyl peroxide can be added to topical retinoids to lower bacterial 
resistance after antibiotic treatment 
o Second choices for maintenance therapy are azelaic acid and salicylic acid 
 
• Hormonal therapy 
 
o Use early in female patients with clinical signs of hyperandrogenism 
(endocrine evaluation – dehydroepiandrosterone (DHEAS), testosterone, 
luteinizing hormone / follicle-stimulating hormone (LH / FSH) ratio) 
o Consider in women with normal serum androgens: 
 
? Persistent inflammatory papules, nodules on lower face 
? Prominent acne flare at menstruation 
 
o Mainstay of hormonal therapy: oral contraceptives, cyproterone acetate, 
drospirenone, spironolactone 
 
• Oral isotretinoin 
 
o Indications: 
 
? Severe nodulocystic acne and its variants 
? Inflammatory acne with scarring 
? Moderate to severe acne unresponsive to treatment with: 
 
- Three months of combination treatment including systemic 
cyclines 
- Four cycles of anti-androgen containing hormonal treatment 
 
? Acne with severe psychological distress (dysmorphophobic patients) 
? Gram-negative folliculitis 
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? Frequently relapsing acne where repeated or prolonged courses of 
systemic antibiotics are needed 
 
o Patient counselling is critical (side-effects, teratogenicity, monitoring) 
o Typical dosage: 0.5 – 1 mg/kg/day, cumulative dosage 120 – 150 mg/kg.   
o Pulse-dosing permitted for relapse cases or older patients with chronic, 
indolent acne 
o Recurrence is common; a topical retinoid should be used as maintenance 
treatment after isotretinoin treatment 
 
• General management principles 
 
o Take careful patient history 
o Teach patients about gentle skin cleansing 
o Show appropriate application techniques for topical therapies 
o Help patients to have realistic expectations of therapy 
o Show empathy for patient’s distress due to acne 
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APPENDIX I 
GLOSSARY 
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AERS Adverse Effects Reporting System 
ANA Anti-Nuclear Antibody 
APCOS Acne associated with Polycystic Ovarian Syndrome 
ATC Anatomical-Therapeutic-Chemical 
CNS Central Nervous System 
EDL Essential Drugs List 
FDA Food and Drug Administration 
GAIOA Global Alliance to Improve Outcomes in Acne 
HRT Hormone Replacement Therapy 
IBS Irritable Bowel Syndrome 
ICD-10 International Classification of Disorders tenth revision 
NAPPI A unique code designated to every proprietary medication or product in 
South Africa 
NMM Nelson Mandela Metropole 
P. acnes Propionibacterium acnes 
PUVA Psoralen and Ultra Violet A 
QOL Quality Of Life 
SD Standard Deviation 
SMART System to Manage Accutane Related Teratogenicity 
UK United Kingdom 
USA United States of America 
UVA Ultra Violet A 
WHO World Health Organization 
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